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EXPERIMENTAL AND COMPUTATIONAL ANLALYSIS OF THE 
SYNUCLEINS PROTEINS
Sr. Agatha Munyanyi 
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Director: Dr. Lesley Greene
The synuclein proteins a. (3 and y which are located in the brain, have been a 
subject o f intense research. O f particular interest is a-synuclein, which is found in 
misfolded forms in Lewy bodies that are associated with Parkinson’s disease. Despite the 
efforts o f researchers across the w orld, the physiological structure and function o f  the 
synucleins remains elusive. In recent years, highly controversial reports by some 
investigators indicate that in its natural form, a-synuclein exists as a tetramer instead o f 
as an intrinsically unstructured monomer. This dissertation presents results o f  the 
experimental and computational analysis o f  the synucleins. First, we investigated 
methods o f destroying protein fibrils from a-synuclein. We report that low temperature 
plasma can disrupt synuclein fibrils and proposed that neuronal macrophages can 
eliminate the resulting structures via phagocytosis. We also conducted inhibition studies 
to investigate the mechanism by which p-synuclein inhibits a-synuclein fibrillation. 
Using our experimental conditions, |3-synuclein readily formed fibrils while a-synuclein 
inhibited p-synuclein fibrillation. We show, for the first time, that two fibril forming 
proteins when incubated together have an inhibitory effect on each other. This important 
information can be employed in the future development o f inhibitors o f formation. In 
order to determine the native structure o f  the synucleins, we expressed and isolated 
multimeric forms o f the synuclein proteins. We found that expression o f P-synuclein in
which we did not boil the bacterial lysate, yielded a high molecular weight multimeric P- 
synuclein form. This study has established the basis for further research with the ultimate 
aim o f forming a well-diffracting crystal that w ill lead to solving a high resolution X-ray 
crystallographic structure o f  the native state. Finally, computational approaches involving 
bioinformatics and molecular modeling were employed to establish a superfamily for the 
synucleins. The hypothesis is based on the fact that the structure and function o f  the 
synucleins could be inferred from that o f  their related proteins, whose structure and 
function have been resolved. Our computational results indicated that the synucleins 
seem to be orphans in the animal kingdom but share sequence similarity w ith an 
endoglucanase enzyme from Acetobacter pom orum  bacterium, a CRE-DUR-1 protein 
from a nematode, a cytochrome c protein from a spiral bacterium and a protein from the 
Tasmanian Devil. This study led to the development o f a proposed evolutionary model 
for the synucleins, which hypothesized that P-synuclein, encoded by seven exons, is the 
oldest o f  the synucleins. a-Synuclein, encoded by 6  exons, evolved to contain amino acid 
sequences to prevent fibril formation such as the change from threonine 53 to alanine. 
Together, these results further our understanding o f  the synuclein proteins from a myriad 
of experimental and computational vantage points.
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When amino acids are joined by covalent peptide bonds in a specific order, they 
produce a polypeptide. The specific amino acids, the order in which the am ino acids are 
linked as well as the size o f  a chain are termed the primary structure o f  a polypeptide. 
The information for the correct folding o f a particular polypeptide chain is contained in 
its sequence (Anfinsen, 1973). After a polypeptide chain is synthesized on the 
ribosomes, it forms secondary structures including a-helices and P-sheets, which are 
stabilized by hydrogen bonds between the carbonyl oxygen and the amide hydrogen o f 
the polypeptide backbone. The a-helices, P-sheet structures and turns constitute the 
secondary structures o f  a protein.
It is a common view that for a protein to function, it must fold into a three- 
dimensional structure (3D) or tertiary structure. When the secondary structures o f  a 
polypeptide chain interact in space via noncovalent bonds including hydrogen bonds, 
van der Waal forces, non-polar hydrophobic interactions, acid/base ionic interactions 
and cysteine covalent disulfide bonds, a globular or tertiary structure is generated. 
Globular proteins are composed o f either all a-helices, all P-sheets or mixed a/p 
secondary structures which interact in space to form a tertiary structure (Figure 1). A 
protein can be composed o f one or more polypeptide chains. In the case o f  a multimeric
The journal for this dissertation is Cell
protein, different polypeptide chains associate through noncovalent bonds, disulfide 
bonds or cofactors to form a quaternary structure (Rodrigues et al.. 2012; Sanchez - 
Romero et al.. 2013).
All a  a /p  All p
Figure 1. Examples of globular monomeric protein structures based on class
The rainbow color scheme indicates the flow o f  the polypeptide with the N-term inus in 
blue and the C-terminus o f  the polypeptide in red. The proteins from left to right are the 
all a-helical myoglobin protein (pdb code: la 6 n), the mixed a/p protein GB1 (pdb code: 
lpgb) and the all p-sheet titin, (pdb code: ltit). These structures are visualized with 
Rasmol (version 2.7.1).
In general, there are three types o f  fundamental protein forms: globular such as 
myoglobin, transmembrane such as bacteriorodopsin and fibrous structures such as 
collagen (Garrett and Grisham, 2013). The proteins in these three categories carry out 
the overwhelming majority o f biological functions in an organism, from metabolism , to
cell structure, cell-cell adhesion, cell-cell communication, intracellular signaling, 
replication, transcription, translation and immunity. As the scientific community makes 
advances in protein research, it is now becoming understood that the traditional viewr o f 
protein structure also extends to partially unfolded proteins (also known as intrinsically 
unstructured proteins) and protein fibrils (Soto, 2003: Tompa et al.. 2005).
Intrinsically unstructured proteins
Contrary to conventional thinking that a defined 3D structure is necessary for 
protein function, experimental studies have shown that function can arise from 
unstructured proteins (Wiltzius et al., 2009). Their persistence in nature implies that they 
have a pivotal role to play in the biological activities o f the cell. As a matter o f  fact, it 
has been proposed that over time, proteins have been evolving to lose their high degree 
o f hydrophobic character in the core. The absence o f a hydrophobic core has led the way 
for intrinsically unstructured proteins to evolve and come into existence (M annige et al.,
2012). For a protein to be described as intrinsically unstructured or unfolded, it must 
lack a hydrophobic core and have high densities o f  charged amino acids including 
lysine, glutamate and arginine (Nelson and Cox, 2013). The hormone amylin is a good 
example o f an unstructured protein with metabolic function. Amylin, also known as islet 
amyloid polypeptide, is secreted in the beta-islet cells o f  the pancreas along with insulin 
(Westermark et al., 1987; Westermark et al., 2007). It regulates blood glucose levels in 
the body (Wiltzius et al., 2009) (Figure 2). As in the case o f  amylin, it appears at present 
that the majority o f  the functions o f intrinsically unstructured proteins are involved in 
regulating cellular processes including transcription, translation, signal transduction and 
the cell cycle (Tompa. 2002). Apparently, the conformational flexibility o f  intrinsically
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unstructured proteins allows them to interact with a wide range of different proteins 
(Wright and Dyson. 1999). Their unstructured state helps them to overcome steric 
hindrances and also enables them to make contact over a larger surface area o f  the 
substrate than could be achieved by a rigid structure (Figure 3) (Dunker et al.. 2001).
Figure 2. Model structure of amylin peptide hormone (pdb code: lkuw)
The structure represented is conformer six in the ensemble which is the best 
representative o f  the peptide hormone in the pdb file. The model shows the peptide 
backbone o f the amylin hormone. The black color indicates the N-terminus and the dark 
grey the C-terminus o f the peptide. This structure is visualized with Rasmol (version 
2.7.1).
Figure 3. Intrinsically unstructured proteins interacting with globular proteins
Unstructured proteins depicted in red or yellow wrap around their respective protein 
substrates which are shown in blue (A-D). Their unfolded conformations allow them to 
cover a long stretch o f  their targets. Because intrinsically unstructured proteins contain 
more a-helix forming amino acid residues than (3-sheet formers, they have a tendency to 
form a-helices (Tompa, 2005). Figure reproduced from Tompa (Tompa, 2005).
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There must be a special feature in the amino acid sequence o f  intrinsically 
unstructured proteins that keeps them in the partially unfolded state at physiological 
conditions. Researchers observed that intrinsically unstructured proteins are rich in 
amino acids that have a high net charge and low hydrophobicity (Dunker et al., 2001; 
Williams et al.. 2001; Tompa. 2002). Amino acids that keep the polypeptide in an 
extended or unstructured form include proline, arginine, glutamate, lysine, serine and 
glutamine (Maikov et al.. 2009). The high net charge provided by lysine, glutamate and 
arginine promotes electrostatic repulsion which in turn prevents hydrophobic core 
formation (Kuznetsov and Rackovsky, 2003). The lack o f cysteine residues avoids intra- 
or intermolecular disulfide bonds which otherwise are important stabilizing factors. The 
composition o f amino acids in an intrinsically unstructured protein demonstrates that 
their structure has been evolutionarily selected (Tompa, 2002).
There are other factors that support the selection o f  a particular sequence by 
evolution. High net charge, low hydrophobicity and low p-sheet propensity help the 
intrinsically unstructured proteins to avoid P-aggregation (Linding et al., 2004). Some o f 
the factors that enhance p-aggregation include a low net charge and the presence o f 
amino acid residues including valine, isoleucine, tryptophan and phenylalanine which 
have side chains at the P-C position (Linding et al., 2003). In addition, high 
concentrations o f proline and glutamine in an intrinsically unstructured protein prevent 
the polypeptide from forming P-strands because both residues do not promote P-sheet 
conformation which may result in fibril formation. The presence o f many prolines at 
either the N- or the C-terminus o f an intrinsically unstructured protein, results in the 
formation o f polyproline II helices (W illiamson. 1994; Adzhubei et al.. 2013). The
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polvproline II helices provide hydrophobic surfaces and carbonyl oxygens for protein- 
protein interactions between the intrinsically unstructured protein and its protein ligand 
(Williamson. 1994). Furthermore, the amino acid composition of intrinsically 
unstructured proteins is not as complex or variable as compared to that o f  a globular 
protein (Wootton. 1994). The low complexity is characterized by repeats o f  one or more 
amino acid residues, for example, the KTKEGV repeat sequences in the N-terminal 
regions o f  the synuclein proteins (Uversky et al.. 2002).
Observations indicate that intrinsically unstructured proteins have a tendency to 
form local 1-4 hydrogen bonds leading to the formation o f a-helices (Fuxreiter et al.. 
2004). Consequently, a-helical structures are observed more often than p-sheets since 
intrinsically unfolded proteins contain m ore a-helix forming amino acid residues than 
the P-sheet formers (Kuznetsov and Rackovsky, 2003).
Normally, unfolded proteins easily undergo protease digestion in the cell 
cytoplasm (Glickman and Ciechanover, 2002). Flowever, there are m echanisms that 
protect disordered proteins from proteolytic enzymes. For example, some disordered 
segments are not accessible to proteases due to steric hindrance while other disordered 
segments lack protease susceptible amino acid residues (Dunker et al., 2002). In 
addition, some unfolded regions o f proteins are protected by chaperones (Dunker et al., 
2001). Also, association with another protein can protect the disordered region from 
protease digestion. However, when the protein substrate is removed, the disordered 
protein is susceptible to protease digestion (Dunker et al.. 2002).
Experimental studies have shown that when intrinsically unstructured proteins 
were subjected to high temperatures, heat-induced secondary structures were formed
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(Uverskv et al.. 2001a). For example, when the unfolded a-synuclein protein was heated, 
its circular dichroism spectrum changed from one o f a random coil to that o f  a partially 
folded protein (Uversky et al.. 2001a). In this case, heat induced the unstructured protein 
to partially fold. This finding is contrary to what would be expected in the case o f  a 
folded protein. It has been suggested that the partial folding upon heating may be due to 
increased hydrophobic interactions at higher temperatures (Uversky et al., 2001a). 
Similarly, at low pH. when the net charge was decreased, hydrophobic interactions also 
promoted a-synuclein protein to transition from a random coil to a partially folded 
conformation (Uversky et al.. 1999; Uversky et al.. 2001a).
When some unfolded proteins bind divalent or trivalent metal ions or lipids, they 
are transformed from a random coil to a conformation which contains secondary 
structures (Uversky et al., 2001b). The water soluble m yelin basic protein (major 
component o f myelin sheath), for example, has been reported to be transform ed from a 
random coil to a partially folded conformation with secondary structures after binding 
lipids (Polverini et al., 1999). Ribosomal proteins involved in the assembly o f the 
subunits 50S and SOS are unfolded in solution, but acquire a 3D structure after binding 
the ribosome subunits (Yusupov et al., 2001; Timsit et al., 2009).
During their protein-protein interaction, the unstructured proteins employ 
specific side chains to interact with the binding site or groove of the protein substrate 
(Rajamani et al., 2004). They bind their protein substrates with high specificity but with 
low affinity which enables them to dissociate easily from their substrates when the 
function is accomplished. The anchor side chains themselves are eventually buried in the 
groove after the formation o f the complex. The segments o f  the unfolded protein which
9
are in an appropriate conformation for interacting with a protein substrate make the first 
contact. The recognition o f binding sites on the substrate is followed by the organization 
o f the flexible region and the stabilization o f the protein-protein complex. Table 1 
indicates several examples o f intrinsically unstructured functional proteins. In solution, 
intrinsically unstructured proteins exist as a mixture o f fluctuation conformational 
structures (Fuxreiter et al., 2004).
Protein fibrils
A protein fibril is a long and insoluble fibrous polymer which can arise from 
misfolded and normal monomeric protein molecules or peptides. The P-strands form p- 
sheets which then stack on each other to form a fibril and run perpendicular to the long 
axis o f  the fiber (Sunde and Blake, 1997) (Figures. 4-5). Generally protein fibrils are 10 
nm in diameter but can vary in length. The distance between the P-strands is 0.48 nm 
while the p-sheet layers are 1.0 to 1.3 nm apart (Dobson, 1999; Serpell et al., 2000). The 
mechanism o f protein fibrillation is not yet clearly understood. Interestingly, the protein 
fibril appears to be a unique protein fold that can be formed by all proteins under a 
specific set o f conditions for a given protein (Collins and Greene, 2012). This hypothesis 
was proposed by Professor Christopher Dobson (University o f  Cambridge. UK)
(Dobson, 1999). Details on protein fibrillation will be discussed in another section.
10




(Uversky et al.. 2 0 0 0 )
SRY Assembly o f transcription 
initiation complex
(Zhao and Koopman. 
2 0 1 2 )
Prion protein Copper binding (Dunker et al., 2002)
Synaptobrevin Protein-protein binding 
(membrane fusion)
(Fasshauer et al.. 1997)
SNAP-25 Protein-lipid binding 
(membrane fusion)
(Fasshauer et al., 1997)
Topoisomerase I Protein-protein and protein- 
DNA binding
(Stewart et al., 1996)
Topoisomerase 11 Protein-protein binding, 
phosphorylation
(Shaiu et al., 1999)
Hi stone 5 Protein-DNA binding (Ramakrishnan et al., 
1993)
Hi stone 3 Protein-DNA binding (Lambert et al., 1999)
Small heat shock 
chaperones
Protein-protein binding (Kim et al., 1998)
50s ribosomal proteins Protein-protein and protein- 
DNA binding
(B anet al., 1999)
30s ribosomal proteins Protein-protein and protein- 
DNA binding
(B anet al., 1999)
Amylin peptide Regulates blood glucose (Wiltzius et al., 2009)
Figure 4. Early structural model of a fibril based on solid-state nuclear magnetic 
resonance spectroscopy
The structure shows a proposed model o f  the AP 1.40 protein fibril. The Ap peptide 
contributes P-strands that form p-sheets (red and blue). The loops that link together the 
p-strands are indicated in green. Then the P-sheets stack on each other to form a fibril. 
Figure reproduced from Petkova (Petkova et al., 2006).
Figure 5. Most recent and accurate structure of the Ap fibril based on solid-state 
nuclear magnetic resonance spectroscopy
The rainbow color scheme indicates the flow o f  the polypeptide with the N-terminus in 
blue and the C-terminus o f the polypeptide in red. Several P-strands make a p-sheet. 
Then three P-sheets assemble to make a fibril. During the elongation o f  the fibril, triplet 
P-sheets stack on each other. Figure reproduced from Tycko (Tycko and W ickner,
2013).
BIOPHYSICAL TECHNIQUES TO STUDY THE STRUCTURE OF PROTEINS
Nuclear magnetic resonance (NM R) spectroscopy and X-ray crystallography are 
the two experimental methods presently in use to study protein structure (Clore and 
Gronenbom, 1998; Acharya and Lloyd, 2005). The solved structures o f  proteins are 
stored in the Protein Data Bank (PDB). In X-ray crystallography, the 3D structure o f  a 
protein is determined from a crystal o f  the protein. One o f the challenges o f  the X-ray 
crystallographic technique is to find suitable conditions that enable the researcher to
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grow single crystals o f sufficient size to be used for determining structure (Smyth and 
Martin. 2000). The determination o f the structure o f a protein in its crystal form may not 
give an accurate evaluation o f  the true structure o f  a protein compared to what one 
would obtain when the protein is in solution. The NM R method has an advantage over 
X-ray crystallography in that the protein is analyzed in solution almost under 
physiological conditions but its applicability is limited by size unlike crystallography 
(Clore and Gronenbom. 1998).
Near- and far-ultraviolet circular dichroism
Circular dichroism (CD) is a biophysical technique employed to determine 
secondary and tertiary structure of a globular protein (Sreerama and W oody, 2004). The 
molecule under investigation must have a chiral center, or must be covalently linked to a 
chiral center or be in an asymmetric environment (Kelly and Price, 2000). An optically 
active molecule may absorb equal or unequal amounts o f  left- and right-circularly 
polarized light at a given wavelength. The difference in the absorption between the left- 
and right-circularly polarized light by the molecule is w hat is termed CD (Greenfield,
2006). When at a given wavelength, the chiral molecule absorbs equal left- and right- 
circularly polarized light, the resultant component is plane polarized light. However, 
when one of the components is absorbed more than the other, the result is an elliptically 
polarized light. The CD instrument displays dichroism either as the difference in 
absorption between the left- and right-circularly polarized light or as ellipticity in 
degrees (Kelly and Price, 2000).
In order for the polarized light to be absorbed, a protein must contain a 
chromophore which include the C = 0  o f the peptide bond and the C=C bonds in the
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aromatic rings tryptophan, tyrosine and phenylalanine (Kelly and Price. 2000). A 
chromophore is a group o f atoms in a molecule that absorbs ultra-violet (UV) and visible 
radiation at specific wavelengths. The absorbed energy will cause either an n-a* or a n- 
n transition in the chromophore (Chen et al.. 1972). In the case o f a protein molecule, 
the far-UV CD signals are generated when the C = 0  chromophore o f  the peptide bond 
absorbs the radiation in the 240 nm -180 nm range. The chiral a-Cs o f  the amino acid 
residues provide an optically active environment for the C = 0  chromophores. In the 
near-UV, the CD signals are produced by the radiation absorbed by any one o f  the 
aromatic amino acid side chains depending on the asymmetry of their environments. 
These aromatic rings absorb radiation in the 260 nm - 320 nm range (Kelly and Price, 
2000).
The far-UV CD provides the content o f  secondary structures in a natively folded 
or fibril protein structure, while the near-UV CD provides a signature o f  the tertiary 
structure. a-Helices show negative molar ellipticities at 208 nm and 222 nm and positive 
molar ellipticity 193 nm. Anti-parallel p-sheets show a negative molar ellipticity at 218 
nm and a positive molar ellipticity at 195 nm. A random coil has a negative molar 
ellipticity at 195 nm. These basic patterns in ellipticities can be found in the work by 
Greenfield, Whitmore and Wallace (Greenfield, 2006; Whitmore and Wallace, 2008). 
Bioinformatics
Bioinformatics, which is a combination o f biology, biochemistry, computer 
science and mathematics, is increasingly being employed to complement the 
experimental methods used to investigate protein structure and function (Todd et al.,
2001; Greene and Grant, 2012). Bioinformatics techniques use computer programs to
analyze protein or gene sequences in order to elucidate the relationship between them 
(Kinch and Grishin. 2002). One o f the algorithms used to identify to which family or 
superfamily a protein belongs is the position-specific iterated basic local alignment 
search tool (PSI-BLAST) (Altschul et al.. 1997). Proteins related to a common ancestor 
can be identified by a consensual sequence signature, a common 3D structure and may 
have a similar function (Greene and Higman, 2003). The structure and function o f  an 
uncharacterized protein can be inferred from that o f  its relatives (proteins which share 
sequence identity with the query protein) whose 3D structure and function have been 
determined. Despite the fact that there may be some sequence and structural changes 
over time as an ancestor protein evolves, those regions o f  the ancestral protein that are 
responsible for its structural stability and function remain largely preserved in the 
offspring protein (Kinch and Grishin, 2002; Alexander and Zhulin, 2007). This has great 
value when trying to understand the nature o f a protein whose structure and function is 
not known. This is particularly important when it can take several years to solve the 
structure and function o f a protein experimentally if  at all as some proteins are not well 
behaved.
PROTEIN FOLDING
Protein folding is a process in which linear polypeptide chains are converted into 
their 3D structures that give proteins their functional properties. During the folding 
process, the polypeptide does not try out all possible conformations in order to find the 
native conformation. Instead, interactions between amino acid residues that lead to a 
stable native fold are chosen over those that lead to unstable conformations, thus, the 
process o f  folding is directed and nonrandom (Levinthal. 1968; Dinner et al.. 2000).
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The three most prominent mechanisms by which a polypeptide chain folds are: 
the hydrophobic collapse model, the framework model and the nucleation-condensation 
model. Early proposed protein folding pathways (Figure 6). include the framework and 
the hydrophobic collapse as well as the spontaneous refolding model, the nucleation 
growth model and the jigsaw model. In the framework model, some segm ents o f  the 
polypeptide chain may form helices and P-strand structures. The native conform ation of 
the protein is then formed by diffusion and collision o f the pre-formed secondary 
structures (Karplus and Weaver, 1994; Dinner et al., 2000). In the hydrophobic collapse 
model, nonpolar amino acid residues associate with each other and form a hydrophobic 
core in order to keep away from an aqueous environment. The remainder o f  the 
polypeptide chain folds around the hydrophobic core into a 3D structure (Cheung et al., 
2002). Anfmsen proposed that a polypeptide chain can spontaneously fold (Anfinsen, 
1973). The nucleation growth model suggests that a diffuse nucleus containing 
secondary structures is formed by specific amino acids, then the tertiary structure grows 
from this nucleus (Fersht, 2000; Vendruscolo et al., 2001). In the jigsaw  model, 
individual polypeptide molecules can fold by any o f the pathways into intermediates 
which then associate with one another to produce the native structure o f  the protein 
(Kim and Baldwin, 1982).
After the early protein folding models, another folding pathway, the nucleation- 
condensation model was proposed (Fersht, 2000; Vendruscolo et al., 2001) (Figure 7). In 
this model, the folding process begins via the formation o f a nucleus which contains 
some secondary and tertiary structures (Daggett and Fersht, 2003). Then, the remainder 
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Figure 6. Early protein folding models
In the hydrophobic collapse model, hydrophobic side chains o f amino acid residues 
associate to form a core in order to avoid the aqueous environment. The rem ainder o f  the 
polypeptide chain folds around the core into a 3D structure (Cheung et al., 2002). In the 
framework model, some segments o f  the polypeptide chain form secondary structures. 
The native fold is formed by diffusion and collision o f the pre-formed secondary 
structures (Dobson, 2004). Anfinsen model suggests that the polypeptide chain can 
spontaneously fold (Anfinsen, 1973). The nucleation growth model proposes that 
specific amino acid residues associate to form a diffuse nucleus with secondary 
structure. Then, the tertiary structures develop from this nucleus to produce a 3D fold 
(Fersht, 2000; Vendruscolo et al.. 2001). In the jigsaw  model, individual polypeptide 
molecules may fold by any of the pathways into intermediates which then associate to 
form one 3D native structure o f  the protein (Kim and Baldwin, 1982). Figure reproduced 
from Radford (Radford, 2000).
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nucleus limits the alternative pathways by which the polypeptide chain can fold (Fersht. 
1995). Note, this model is different from the nucleation growth because its transition 
state contains some characteristics o f  the native state. The folding nucleus also termed 
the ‘fold-determining core* by Greene et al. is proposed to be evolutionarily conserved 
(Greene et al.. 2003).
Unfolded state Nucleus Folded conformation
Figure 7. The nucleation-condensation protein folding model
The unfolded polypeptide chain first forms a nucleus which contains some secondary 
and tertiary structures. The remainder o f  the polypeptide chain folds around the nucleus 
to form the native conformation of the protein (Fersht, 1995). Figure reproduced from 
Nolting (Nolting and Andert, 2000).
Protein folding is now recognized to occur on a funnel shaped energy landscape; 
irrespective o f the model (Figure 8) (Dill and Chan, 1997; Miao et al., 2014; W oodside 
and Block. 2014). The energy landscape describes the energy levels o f  different
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conformations which a polypeptide can assume as it moves from a high energy level 
unfolded structure towards a low energy level native structure (Wolynes. 1997;
Weinkam et al.. 2010). Small proteins, such as chymotrypsin inhibitor 2 (64 residues), 
have one transition from the unfolded to the native state while large proteins (>100 
residues) can involve intermediates (Jackson and Fersht. 1991; Walters et al.. 2013). 
These intermediates may or may not contain structures similar to those in the native state 
o f the protein (Brockwell et al., 2000). The polypeptide intermediates that contain 
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Figure 8. The protein folding funnel
Unfolded protein molecules at the top o f  the energy landscape fold to their native 
conformation using any o f the folding models. Small proteins fold smoothly dow n the 
funnel to their native structure (Jackson. 1998). The folding o f large proteins may 
involve few or many intermediates. The molten globule is one of the intermediates into
2 0
Figure 8 Continued
which a polypeptide can be trapped during the folding process (Schultz. 2000). Some 
protein molecules achieve their native fold at the bottom o f the funnel w hile others fail 
to fold correctly and assume a misfolded conformation. Figure reproduced from Radford 
(Radford. 2000).
structures are described as off-pathway (Brockwell et al.. 2000). Conformers on the off- 
pathway are trapped at certain energy levels o f  the folding funnel. Chaperones can assist 
the trapped intermediates to form native-like secondary structures which culminate in 
the native state (Radford, 2000; Kim et al., 2013).
Chaperones and in vivo folding
Under normal circumstances a cell employs molecular chaperones to deal with 
the problem of proteins that tend to misfold and/or aggregate. These chaperones 
maintain the normal levels and integrity o f  these proteins (Takalo et al., 2013). A 
molecular chaperone recognizes and binds the exposed hydrophobic segments o f  the 
newly synthesized polypeptide chains or misfolded proteins, assists them to fold 
correctly into their native conformations, prevents their aggregation and assists in the 
repair o f damaged proteins (Hartl, 2011; Vabulas et al., 2010).
Chris Anfinsen used ribonuclease to show that a pure denatured protein can 
refold spontaneously in vitro to its functional native state when the denaturant is 
removed. This earned him a Nobel prize in 1972 (Anfinsen. 1973). However, the ideal 
conditions in vitro are different from those in the cell cytoplasm where there are many
other nascent polypeptide chains (Fink. 1999). A mechanism that prevents the newly 
synthesized polypeptides from interacting with each other is necessary'. The exposed 
hydrophobic regions o f linear polypeptide chains have the tendency to associate with 
each other resulting in flawed and premature folding (Srinivasan. 2012). In a folded 
protein, such hydrophobic patches are buried in the core o f  the protein or in the lipid 
bilayers in the case o f membrane proteins (Bross, 2011). Chaperones are able to identify 
and bind these hydrophobic segments o f  the polypeptide chains and prevent 
inappropriate interactions within the chain or between the chains (Chaudhuri and Gupta, 
2005). Chaperones do not determine how a protein will fold to its native conformation, 
but prevent ineffective intra- and intermolecular contacts and assist the linear 
polypeptide chain to reach its 3D structure determined by its amino acid sequence (Hartl 
and Martin, 1995; Dahiya and Chaudhuri, 2014). Some polypeptide chains do not 
require chaperones and fold as they emerge from the ribosomes or fold after they are 
released into the cytoplasm (Figure 9) or into the lumen o f the endoplasmic reticulum 
(Hardesty et al., 1999).
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Figure 9. Chaperones assist the newly synthesized polypeptide chains to fold
The figure depicts the folding process in a prokaryotic cell. Approximately seventy 
percent o f  small polypeptide chains fold spontaneously to their native structure with the 
help of the trigger factor (TF). About twenty percent o f  larger polypeptides require the 
assistance o f  Hsp70 (DnaK) and Hsp40 (DnaJ) chaperones to fold correctly as they 
emerge from the ribosomes. Ten percent o f  the larger polypeptide chains will enter the 
GroeEL-GroES complex where they will fold and then be released into the cytoplasm 
(Hartl and Hayer-Hartl, 2002; Vabulas et al., 2010; Dahiya and Chaudhuri, 2014). 
Figure reproduced from Hartl.
The molecular chaperones found in eukaryotic cells include heat shock proteins 
(Hsp) Hsp40. Hsp60. Hsp70 and Hsp90 (Hartl and Haver-HartL 2002). The Hsp are 
synthesized when a cell experiences stress due to environmental changes including 
increased temperatures above the physiological level (Schlesinger et al.. 1997). The heat 
shock proteins are able to distinguish between native and non-native conformations o f  
proteins (McClellan and Frydman. 2001). The activities o f  the Hsp60 and Hsp70 are 
regulated by the binding and hydrolysis o f  ATP. The Hsp60 chaperones, which are 
GroEL-like proteins, have a central cavity. In a prokaryotic cell, the GroEL and its 
cochaperone the GroES isolate a nascent or a misfolded protein from the cytoplasm and 
allow it to fold in a protected environment and then release it again into the cytoplasm 
after it has folded correctly (Hartl, 2011). The Hsp70 chaperones do not only assist the 
newly synthesized polypeptides to fold but also protect the hydrophobic patches o f  the 
polypeptide chains as they translocate from the cytoplasm into the endoplasmic 
reticulum (Fink, 1999). Another group o f  chaperones are the small heat shock proteins 
which are not ATP regulated. These chaperones form spherical structures to which 
unfolded proteins can bind during unfavorable conditions until chaperones that assist the 
proteins to fold are available (Bross, 2011).
PROTEIN MISFOLDING
When a polypeptide folds into a conformation which is different from the native 
state, it is considered to be misfolded. Often misfolded proteins can refold properly with 
the help o f  chaperones (Hartl, 2011; De Los Rios and Barducci, 2014). Misfolded 
proteins that cannot be rescued by molecular chaperones are destroyed by the cell 
through mechanisms discussed in the next section. However, a small group o f proteins
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can misfold into an alternative, stable conformation that eventually leads to fibrils. As 
mentioned previously, most fibrils are stacked p-sheets which elongate into an insoluble 
polymer. Some peptides naturally form P-sheet polymers, for example, the conversion of 
fibrinogen to fibrin during the formation o f a blood clot. Studies have shown that 
proteins and peptides associated with neurodegenerative diseases including 
Huntington's, Parkinson's. A lzheim er's and Dementia with Lewy bodies are misfolded 
and have a p-sheet conformation, which is prone to aggregation and fibrillation (Soto. 
2003; Ross and Poirier, 2004; Suzuki, 2014; Valastyan and Lindquist, 2014). The fate o f 
a newly synthesized polypeptide chain is determined by the physiological conditions in 
the cell cytoplasm which may enhance or prevent it from folding to its native 



















Figure 10. The fate of a polypeptide chain coming off the ribosome
The nascent polypeptide chain can, through an intermediate, fold to a monomeric native 
structure, or form a  protein fiber, a functional oligomer or a  crystal in vitro. The 
polypeptide intermediate can form disordered aggregates or prefibrillar species which 
assemble into amyloid fibrils. The unfolded polypeptide chain can also form disordered 
aggregates and/or amyloid fibrils or it can be degraded into fragments. The degraded 
fragments can assemble into disordered aggregates or amyloid fibrils (Dobson, 2003). 
Figure reproduced from Dobson.
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Certain conditions, such as inflammation, oxidative stress and aging have a 
tendency to enhance protein oxidation, phosphorylation, nitration and protease 
truncation (Haigis and Yankner. 2010; Tarawneh and Galvin. 2010). These can result in 
protein misfolding and aggregation. Reactive oxygen species (ROS) including 
superoxide anion (O2 ). hydrogen peroxide (H2O2 ) and peroxynitrite (ONOO') are 
produced during cell respiration and by the oxidative burst o f  macrophages during 
inflammation (Sultana et al., 2006; Slauch. 2011). The reactive species can generate free 
radicals which react with and damage nucleic acids, lipids and proteins. The resulting 
oxidation at the cysteine and methionine residues increases protein susceptibility to 
aggregation (Slauch, 2011). In individuals with A lzheim er's disease, 
hyperphosphorylation of the tau protein enhances tau aggregation (M andelkow and 
Mandelkow, 2012). Furthermore, increased cleavage o f the Ap precursor protein by P- 
and y-secretase enzymes increases the levels o f  P-amyloid peptide resulting in its 
accumulation and aggregation (Haass et al., 2012).
Other examples o f unfavorable conditions in a cell that trigger protein 
conformational changes include high concentrations o f free fatty acids due to obesity 
(Boden, 2008) and the presence o f numerous unfolded newly synthesized polypeptide 
chains (Goldberg, 2003). The hydrophobic regions o f fatty acids act as micelles which 
denature proteins by binding their hydrophobic regions. Denatured proteins whose 
hydrophobic cores are exposed to the aqueous solvent have the propensity to aggregate 
before they are destroyed by the proteasome system (Sherman and Goldberg, 2001).
Another cause of protein misfolding problems is from mutations in the sequence 
that are prone to form P-sheets and fibrils (Bross. 2011). The mutations either impair
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correct folding or decrease the stability o f  the native conformation (Valentini. 2013). 
Thus, energy o f the folding funnel is affected such that misfolded proteins have a greater 
chance o f forming.
Neurodegenerative diseases are generally related to a combination o f aging and 
mutations (Migliore and Coppede. 2009). During aging, the protein quality control 
system declines and fails to efficiently sustain protein homeostasis (Haigis and Yankner,
2010). Increased accumulation o f  misfolded and aggregated proteins may overwhelm 
the protein quality control and the clearance systems (Cuervo et al., 2010).
Protein misfolding and degradation
A cell has two mechanisms by which it maintains protein quality (Bross, 2011). 
The first mechanism, already discussed, involves chaperones which assist in folding and 
refolding nascent polypeptides and denatured proteins, respectively (Hartl, 2011). In the 
case o f proteins beyond rescue, chaperones will interact with the ubiquitination system 
to mark them for degradation by the ubiquitin-proteasome system (UPS) or by the 
autophagosome-lysosome pathway (ALP) (Ciechanover et al., 2000; Dikic et al., 2009; 
Amm et al., 2014). The UPS involves the 26S proteasome system (Figure 11) which 
eliminates proteins no longer required by the cell and those incapable o f folding to their 
native structure. The 26S protease complex consists o f  a central 20S cavity and a 
regulatory 19S particle at both ends o f  the cavity (Voges et al., 1999; Glickman and 
Ciechanover, 2002). Most cell proteins are degraded by the 26S proteasome (Glickman 
and Ciechanover, 2002). The ubiquitinated proteins enter the proteasome system through 
the 19S regulatory particle, which contains ATPases that bind the proteins and use ATP 
hydrolysis to unfold them and then transfer the linear polypeptides to the 20S particle
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(Benaroudj et al.. 2003). The 19S particle also contains enzymes which dissociate 
ubiquitin molecules from the proteins (Glickman and Ciechanover. 2002). The 
peptidases o f  the 20S particle digest the polypeptides into small peptides (Kisselev et al..
1999). The peptides released into the cytoplasm are rapidly broken down to amino acids 
by cytosolic endopeptidases and aminopeptidases (Saric et al.. 2004).
Ubiquitin
Figure 11. The ubiquitin-proteasome system
Three ligase enzymes E l , E2 and E3; the ubiquitin protein and the barrel shaped 26S 
proteasome complex make up the ubiquitin-proteasome system. Enzyme E 1 activates 
the ubiquitin molecule. The activated ubiquitin molecule is transferred to E2 (the 
ubiquitin conjugating enzyme).The ubiquitin can either be transferred to a protein 
substrate already bound to E3 enzyme or it is transferred first to an E3 enzyme and
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Figure 11 Continued
then transferred to the E3 bound substrate. In a similar manner, additional molecules o f 
ubiquitin are successively added to the already conjugated ubiquitin strand. The protein 
substrate enters the 26S proteasome complex where it is broken down to small peptides. 
The deubiquitination enzymes free the ubiquitin strand from the protein substrate for 
reuse. Figure reproduced from Ciechanover (Ciechanover and Brundin, 2003).
The second pathway for protein degradation involves the ALP. A constitutively 
expressed cytoplasm Hsp70 chaperone directs proteins intended for degradation to the 
surface o f lysosomes (Pan et al., 2008). The proteins are then transferred into the 
lysosomes and are degraded (Mijaljica et al., 2010). When a misfolded protein fails to 
refold and is not degraded by either the UPS or ALP, it is isolated in a specific location 
in the cell, where it forms an intracellular inclusion body (Kopito, 2000; Olzm ann et al., 
2008). Inclusion bodies in the surviving neurons, are believed to be a defense scheme by 
the cell against misfolded proteins and aggregates (Kopito, 2000). The sequestration o f  
misfolded proteins into inclusions reduces the accumulation o f misfolded proteins and 
toxic species and prevents them from interacting with other proteins and cell organelles 
(Chen et al., 2011). Protein folding, refolding, degradation and isolation into inclusion 
bodies all require the action o f different types o f  chaperones (Takalo et al., 2013). 
Protein misfolding and fibril formation
Under certain unfavorable conditions, a natively folded protein may unfold 
partially or completely and expose its hydrophobic patches, which are normally buried
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in the protein core, to the aqueous environment. These hydrophobic segments o f a 
polypeptide have the tendency to associate with one another and form soluble oligomers 
that are stabilized by P-sheet structures (Hilbich et al.. 1992). The soluble oligomers can 
be formed by a few' or several residues o f  the polypeptide chain (Chamberlain et al..
2000). These oligomers can act as a nucleus and incorporate additional monomers to 
form larger polymers called protofibrils, which are the precursors o f  protein fibrils 
(W alsh et al., 1997; W alsh et al.. 1999; Alexander and Zhulin, 2007). The fibrils are 
characterized by an interior cross p-sheet structure which resists protease digestion, 
binds to Congo red and thioflavin T dyes and appears as rod-like structures under 
transmission electron microscopy and atomic force microscopy (Soto, 2003).
Protein fibrils can arise from proteins with a folded native state and from 
intrinsically unstructured proteins. The ability to form fibrils is not restricted to proteins 
associated with diseases and is an intrinsic property o f  polypeptide chains (Chiti et al., 
1999). In fact the general overall basic morphology is similar for large and small 
proteins as well as peptides (Lopez De La Paz et al., 2002). The core o f  the fibril is held 
together by hydrogen bonds involving the polypeptide backbone (Dobson, 2004). Since 
the polypeptide backbone is common to all proteins; it explains why protein fibrils 
formed by proteins o f different native conformations have certain common 
morphological features. However, each protein and even the same proteins forming 
fibrils under different conditions have unique structural characteristics (Collins and 
Greene. 2014).
In a folded protein, the polypeptide backbone is buried in the interior o f  the 
protein. The polypeptide backbone must be exposed before fibrillation process can take
place. Consequently, globular proteins must fully or partially unfold before they refold 
into fibrils (Kelly. 1998). Protein fibrillation in vitro has a lag phase that is followed by a 
rapid growth o f fibrils (Harper and Lansbury. 1997). The lag phase is the period when 
the fibril nucleus is formed and the rapid growth or elongation period occurs when the 
nucleus incorporates monomers or oligomers. The nucleation phase can be by passed by 
adding preformed exogenous fibrils or oligomers to fresh protein solution (Harper and 
Lansbury, 1997).
The mechanism o f protein fibrillation is not yet fully understood. One proposed 
pathway for amyloid fibril formation suggests that a natively folded protein is 
destabilized and unfolds (Figure 12). Then the m isfolded intermediates aggregate into 
soluble oligomers which are stabilized by a cross (3-sheet structure (Soto, 2003). These 
soluble oligomers then incorporate additional misfolded monomers to form protofibrils. 
The protofibrils then stack up to form mature, insoluble fibrils. The fibrils can also serve 
as nuclei to which monomers, soluble oligomers and protofibrils are incorporated. 
Factors including pH, temperature, ionic strength, protein concentration and agitation 
have an effect on the length o f the lag phase in vitro. Each protein has its own unique 
conditions under which it unfolds and then forms fibrils (Soto, 2003). The factors in 
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Figure 12. Model of protein fibril formation
The native protein is destabilized and unfolds, the misfolded intermediates form soluble 
oligomers which incorporate more m isfolded intermediates to form protofibrils. 
Protofibrils interact through hydrogen bonds to form fibrils. The p-strands are 
perpendicular to the long axis o f the fibril. Figure adapted from Soto (Soto, 2003).
Protein misfolding and potential disease states
Neurodegenerative disorders including A lzheim er's, Parkinson's, H untington's, 
Amyotrophic Lateral Sclerosis and Dementia with Lewy bodies are characterized by a 
gradual loss o f neurons in certain regions o f  the brain resulting in abnormal synapses 
and clinical symptoms (Martin, 1999). In addition, intracellular or extracellular protein
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fibrils are found in the affected regions o f  the brain (Dobson. 2001). The cytoplasmic 
inclusions that are detected in surviving neurons contain ubiquitin tagged misfolded 
proteins that have transformed into an amyloidogenic or fibril conformation (Soto. 2003; 
Ross and Pickart. 2004). The loss o f neurons occurs by programmed cell death (Mattson. 
2000; Simon et al.. 2012). Cell death can occur because the function o f  a specific protein 
associated with the disease has been lost due to the protein having a misfolded or fibril 
conformation. The regions o f the brain and the type o f neurons affected by the protein 
fibrils determine the clinical symptoms associated with each disease (Soto. 2003).
Protein fibrils, particularly those deposited outside the cell may interact with 
surface receptors and activate signal transduction pathways leading to apoptosis 
(Bamberger et al., 2003). When protein aggregates bind transcription factors and 
chaperones, they interfere with the production o f mRNA and the protein folding process 
respectively (Soto, 2003). Soluble protein oligomers may form ion channels which are 
large and nonselective (Lashuel et al., 2002). These channels disrupt membrane potential 
and allow an influx o f calcium ions which initiates apoptosis (Lin et al., 1997). Protein 
aggregates may also stimulate oxidative stress by producing ROS resulting in protein 
and lipid oxidation. For example, when a-synuclein located at the inner mitochondrial 
membrane aggregates, it potentially inhibits complex I which can disrupt the electron 
transport chain system (Schapira, 2007, 2008). Consequently ATP production is 
reduced. An acidic cytosolic environment created by the ROS activates cytochrome c 
and an apoptotic pathway can then be initiated resulting in cell death. (Mounsey and 
Teismann, 2010).
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Additionally, brain inflammation may be triggered by the accumulation o f 
protein aggregates or by signals from injured neurons. A large number o f  activated 
microglia and astrocytes are usually found in the areas around protein deposits (Zhang et 
al.. 2005). Activated microglia cells produce superoxide anions resulting in oxidative 
stress in the affected neurons (Colton et al.. 1989).
Two types o f  fibrils are observed for those with Alzheim er's disease. The 
amyloid plaques are deposited outside the cell and the main component o f  the plaque is 
a 40 or 42 residue Ap peptide fibril (Glenner and Wong, 1984). However, these plaques 
do not necessarily correlate with the severity o f the disease. The fibrillar tangles (tau 
protein fibrils), whose main constituent is tau protein, are deposited in the cytoplasm 
(Grundke-Iqbal et al., 1986) and are potentially one o f the contributing factors in this 
disease. It is presently under intensive investigation. In Alzheimer’s disease the loss o f  
hippocampus and neocortex neurons result in dementia.
Patients with Parkinson’s disease have inclusions called Lewy bodies and Lewy 
neurites in the cytoplasm o f the substantia nigra neurons. The major protein in the Lewy 
body and Lewy neurite inclusions is a-synuclein fibrils (Spillantini et al„ 1997). Rigidity 
and tremor in Parkinson’s are caused by the lack o f the neurotransmitter dopamine due 
to the death o f  the dopamine producing neurons in the substantia nigra region (Wu,
2011). The presence o f Lewy bodies is not directly linked as a cause to these motor 
problems.
Huntington’s disease is characterized by the aggregated huntingtin protein which 
is deposited in the nucleus o f the cell (Kaltenbach et al., 2007). Depleted levels o f  
huntingtin protein (an anti-apoptotic protein) due to its aggregation result in the death of
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the striatum and cortex neurons (Cattaneo et al.. 2001). The loss o f brain cells o f  the 
cerebral cortex and striatum in Huntington's disease results in uncontrolled movements 
and dementia.
Individuals with Amyotrophic Lateral Sclerosis have aggregates composed o f 
superoxide dismutase which are deposited in the cell bodies and axons o f  motor neurons 
(Turner et al., 2005). The enzyme superoxide dismutase, which catalyzes the conversion 
of superoxide anions to hydrogen peroxide, is depleted by misfolding and aggregation 
(Murakami et al.. 2011). The loss o f superoxide dismutase activity results in the 
accumulation o f superoxide anions which initiate lipid peroxidation. Lipid peroxidation 
causes neuronal membrane damage which results in cell death (Mattson, 2000; W ang et 
al., 2012). In this disease, neuronal cell death occurs in the spinal cord, the brain stem 
and the motor cortex causing progressive paralysis (Soto, 2003).
Functional protein fibrils
Although protein fibrils are more often associated with select neurodegenerative 
diseases, functional fibrils have been identified in bacteria, fungi, insects, invertebrates 
and humans. The fibril structure is now described as a quaternary structure formed by 
hydrogen bonded (3-sheets (Chiti and Dobson, 2006). E. coli and Salmonella  species 
employ curli fibrils (from protein curli) to attach themselves to surfaces to form colonies 
and invade host cells (Cherny et al., 2005; Gebbink et al., 2005; Fowler and Kelly,
2012). Insects and fish use chorion protein fibrils as a structural component and for 
protection o f their eggshells (Hamodrakas et al., 2004). The electron micrographs o f a- 
synuclein and chorion protein fibrils are shown in Figure 13. There appears to be no 
significant difference in structure between functional and disease state fibrils.
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Figure 13. Fibril structures of a-synuclein and silkmoth chorion proteins
(A) Transmission electron microscopy micrograph o f a-synuclein fibrils.
(B) Transmission electron microscopy micrograph o f silkmoth protein fibrils.
Figures reproduced from Bousset, Panel A (Bousset et al., 2013) and Hamodrakas, Panel 
B (Hamodrakas et al., 2004).
Fibrin fibrils are also employed in clot formation. Factor XII initiates the 
cleavage o f fibrinogen into fibrin. The fibrin polymerizes and contributes to the 
formation o f a blood clot (Kranenburg et al., 2002; Allan et al., 2012). Human Pmell 7 
protein forms fibrils which function as sites at which m elanin is synthesized from 
tyrosine in the melanosomes (Figure 14). The Pm ell 7 fibrils also bind reactive melanin 
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Figure 14. Biosynthesis of melanin from tyrosine on human Pm ell7 fibrils
(A) Human Pmell 7 protein forms fibrils in the melanosome o f a melanocyte.
(B) Pmell 7 fibrils are scaffold for melanin biosynthesis (Fowler et al., 2007). This 
schematic is modified from Fowler et al. The symbols shown correlates to the following: 
□  = tyrosine; M  = reactive melanin precursor; 0  = tyrosinase; M M  = melanin polymer.
THE SYNUCLEIN FAMILY
The synuclein family consists o f  small and soluble proteins: a. p and y which are 
primarily expressed in the brain cells o f  vertebrates (George, 2002). The size o f human
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synucleins ranges from 127 to 140 amino acid residues (Yoshida et al.. 2006). a -  and P- 
Synucleins are expressed predominantly in the presynaptic axon terminals o f  the central 
nerv ous neurons including the dopamine producing neurons o f the substantia nigra while 
y-synuclein is expressed in the peripheral nervous system neurons. The three proteins 
are encoded by three specific a-. P-, and y-synuclein genes. In humans, a-, P-, and y- 
genes are located in chromosomes 4. 5 and 10, respectively (Chen et al., 1995;
Spillantini et al.. 1995; Lavedan, 1998). a-Synuclein shares 60% and 78% identity with 
y- and P-synuclein. respectively. P-Synuclein differs from a-synuclein by the deletion of 
a cluster of eleven amino acids in its central region (Uversky et al., 2002; Sung and 
Eliezer, 2006).
The synuclein polypeptide chain is divided into three regions: the N-terminus, 
the central region and the C-terminus (Figure 15). The region of highest hom ology 
among the synuclein proteins is the N-terminal region which contains several degenerate 
eleven amino acid repeats with a KTK(E/Q)GV conserved sequence (Sung and Eliezer,
2007). Their C-terminal domains are diverse, a-and y-Synucleins contain seven repeat 
domains while P-synuclein has five. The sixth and seventh repeat sequences in P- 
synuclein are incomplete because o f  the deletion o f  the eleven amino acid residues in the 
central region (Lavedan. 1998). There is a variation in the KTK(E/Q)GV sequence 
among the three human synucleins, however, the third hexameric sequence is highly 
conserved. Several experimental studies have shown that the synuclein m onom ers are 
random coils in solution but adopt an a-helical conformation when associated with 
phospholipids (Perrin et al.. 2001; Uversky et al., 2002; Sung and Eliezer, 2006; Israeli 
and Sharon. 2009).
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a S M D V F M K S X .  S K A K E G V V A A A  E I C T K Q G V A E A A  G K T K E G V L T V  4 0  
p S M C V F M K G L  S K A K E G V V A A A  E K T K Q G V T E A A  E K T K E G V L Y V  4 0  
y S M D V F K K G F  8 I A K E G V V G A V  E K T K Q G V T E A A  E K T K E G V M Y V  4 0
a s  G S K T K E G V V H G V  A  T  V  A  E K T K E Q V  T  M V  G G A V V T G V T A V A  2 J S  8 0
P S G S K T R E G V V Q 6 V A 3 V A E K T K E Q A S H I . G G A V F S  -  -    7 2




 G A G M I  A  A  A  T G I  V
r V E E A E M I A  V  T  3  G V  V
K K D Q L G K N E E G A P Q E G I L E D M P V D P  1 2 0  
K R E E F P T D L K P E E V A Q E A A E E P L I E  1 0 9  
R K E D L R P S A P Q Q E G E A S K E K E E V A E  1 2 0
a S D N E A Y E M P S E E G  -    Y Q D Y E P E A  1 4 0
P S P L M E P S G E S Y E C P P Q E E Y Q E Y E P E A  1 3 4  
y S E A Q S G G D  1 2 7
Figure 15. Sequence alignment of the human synuclein family
The number o f  amino acid residues in a-, (3- and y-synuclein proteins are 140, 130 and 
127, respectively. The synuclein polypeptides are divided into three regions: the N- 
terminal (blue); the central (boxed area) and the C-terminal (yellow). In the N-terminal 
region there are degenerate 11 amino acid repeats (underlined) with conserved 
KTK(E/Q)GV sequences (red). The sixth and seventh repeats lack the KTK(E/Q)GV 
conservation (Uversky et al., 2002).
a-Synuclein
Human a-Synuclein is a 140 amino acid protein encoded by the a-synuclein gene 
consisting of six exons (Maroteaux et al., 1988; McLean et al.. 2012). Alternative 
splicing in which exon 3 or 5 or both are omitted yields 126. 112 and 98 a-synuclein
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variants, respectively (McLean et al.. 2012). There are conflicting reports about the 
native structure o f a-synuclein. Some researchers insist that the protein exists in vivo 
predominantly as an unstructured monomer (Fauvet et al.. 2012) while others maintain 
that a-synuclein can form a helical tetramer which resists fibril formation under 
physiological conditions (Bartels et al.. 2011; W ang et al.. 2011).
Gurry and coworkers, using simulation approaches, recently reported that though 
a larger fraction o f a-synuclein protein exists in vivo as a monomer, a small fraction 
forms helical trimers and tetramers (Gurry et al., 2013). The researchers suggest that the 
formation o f the helical tetrameric conformation is a mechanism for storing high 
concentrations o f  non-membrane bound monomeric a-synuclein in order to prevent it 
from aggregating (Gurry et al., 2013).
Another group o f researchers have reported that after cross linking a-synuclein in 
the primary neurons and neuroblastoma cells in cell culture, a large fraction o f  the 
protein exists as a helical 60 kDa tetramer with a small fraction o f 80 and 100 kDa 
species and variable amounts o f  the monomer (Dettmer et al., 2013). P-synuclein was 
also shown to exist in the same conformations. This folded form o f a- and P-synuclein 
may be their natural structure in the brain tissue.
The N-terminal region o f a-synuclein forms a-helices when associated with lipid 
membranes. The middle region o f  the protein, which is between residues 65 to 95 is 
prone to aggregation. A portion o f the C-terminus (residues 120 to 140) o f  a-synuclein 
has a net negative charge o f  8, which is contributed by aspartate and glutamate residues 
(Uversky et al., 2002). The central region encompassing residues 65 to 95, has a positive 
charge o f 3. which is contributed by lysine residues (Uversky et al., 2002). Between the
C-terminus and the central region the electrostatic interactions may prevent the central 
regions o f a-synuclein molecules from associating with each other and forming fibrils 
(Bertoncini et al.. 2005). A decrease in the negative net charge increases the propensity 
o f a-synuclein to fibrillate (Uversky et al.. 2001b).
The results o f some experimental studies suggest that the role o f  the conserved 
KTK(E/Q)GV repeat sequence is to maintain a-synuclein in its unfolded state when in 
solution and to interact with membrane phospholipids (Sode et al., 2007). When a- 
synuclein is associated with a micelle, it forms a hairpin structure (Figure 16) (Ulmer et 
al., 2005). One helix covers a stretch that includes residues 3-37 and the other is 
composed of residues between 45 and 92. The loop that joins the two helices 
encompasses residues 38-44.
Figure 16. Micelle-bound a-synuclein based on solution NMR
Under physiological conditions in a neuron, a fraction o f a-synuclein is associated with 
lipid membranes and assumes a hairpin structure. Figure reproduced from Ulmer 
(Ulmer et al.. 2005).
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It is proposed that a-synuclein may first form an a-helical intermediate before 
converting into fibrils (Uversky et al.. 2001a). The degenerate KTK(E/Q)GV sequences 
resist the formation o f  the partially folded a-synuclein. Mutants o f a-synuclein are more 
prone to fibrillation than the unmutated form (Li et al.. 2001). The three point mutations 
A30P. E46K and A53T in the N-terminal region o f  a-synuclein disrupt some o f the 
repeat sequences (Sode et al.. 2007). These m utations are believed to enhance the 
formation o f a-helical intermediates leading to fibril formation (Harada et al.. 2009).
Polymeropoulos and coworkers discovered an A53T point mutation in a- 
synuclein which was associated with early-onset o f  familial Parkinson’s disease 
(Polymeropoulos et al., 1997). A second A30P mutation was reported in 1998 (Kruger et 
al., 1998) and a third E46K a-synuclein mutant w as also reported in 2004 (Zarranz et al., 
2004). Recently, two new mutations H50Q and G51D which are also associated with 
early-onset Parkinson’s disease were reported (Lesage et al., 2013). The five point 
mutations are all in the N-terminal region. It should be noted that early-onset familial 
Parkinson’s disease is actually a rare medical condition.
The physiological function o f a-synuclein in the brain tissue is not clearly 
understood but a number o f  possible functions have been proposed. Several 
experimental studies seem to indicate that a-synuclein is involved in the biosynthesis 
and storage o f the neurotransmitter dopamine (Peng et al., 2005). In addition, a- 
synuclein may be involved in dopamine release and reuptake at the presynaptic 
terminals (Sung and Eliezer, 2007). Dopamine biosynthesis involves the conversion o f 
tyrosine to levo-dihydroxyphenylalanine (L-DOPA) in a reaction that is catalyzed by a 
phosphorylated tyrosine hydroxylase (TH) (Sidhu et al.. 2004b). The enzyme DOPA
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decarboxylase catalyzes the conversion o f L-DOPA to dopamine. A chaperone protein 
14-3-3 binds the phosphorylated TH and stabilizes its phosphoryfated conformation and 
prevents its dephosphorylation (Kleppe et al.. 2001; Obsilova et al.. 2008). a-Synuclein 
can either directly bind the dephosphorylated TH and prevent the phosphorylation o f  TH 
at serines 19 and 40. rendering the TH inactive (Leal et al., 2002; Perez et al., 2002). or 
activate a protein phosphatase 2A that dephosphorylates the TH enzyme (Lou et al..
2010). However, when a-synuclein itself is phosphory lated at serine 129, it cannot 
activate the phosphatase 2A, which in turn will not dephosphorylate the TH enzyme. 
Phosphorylation and dephosphorylation o f TH regulates dopamine synthesis. After 
dopamine is synthesized, it is immediately stored in synaptic vesicles (Perez et al.,
2002). Low levels o f a-synuclein in the nerve term inals due to low expression or 
aggregation, results in increased activity o f  TH with subsequent increase in the 
production o f dopamine. If dopamine levels exceed the ability of the cell to clear the 
neurotransmitter from the cytoplasm, the accumulated dopamine forms dopamine 
quinones and other reactive species including hydrogen peroxide, superoxide anion and 
hydroxyl radicals (Hasegawa, 2010). These ROS can extract electrons from double 
bonds in lipids, proteins and nucleic acids leading to cell damage.
Another possible function for a-synuclein is regulation of the formation o f 
synaptic vesicles. A transmembrane enzyme phospholipase D2 is essential for synaptic 
vesicle formation. The enzyme hydrolyzes phospholipids in order to generate 
phosphatidic acid, which is one o f the building components for the synaptic vesicles 
(Sidhu et al.. 2004a). When a-synuclein binds phospholipase D2, the enzyme is 
inactivated (Jenco et al.. 1998). On the other hand when a-synuclein is phosphorylated at
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position 129 (phospho-Ser 129). it loses its ability to interact with phospholipase D2 and 
allows vesicles to be built (Pronin et al.. 2000; Ellis et al.. 2001). Thus the binding and 
release o f phospholipase D2 by a-synuclein regulates formation o f the synaptic vesicles.
a-Synuclein may also be involved in the reuptake o f dopamine from the synaptic 
cleft by the protein dopamine transporter (DAT) (Chadchankar et al.. 2011). The rate o f 
reuptake o f dopamine must not exceed the rate at which it is repackaged into vesicles, a- 
Synuclein binds to the dopamine transporter with its middle region encompassing 
residues 58 to 107 (W ersinger et al.. 2003). This protein-protein interaction controls the 
amount o f free DAT available for the reuptake o f  dopamine. The regulation o f  the 
amount o f free DAT prevents an excess o f free dopamine in the cytoplasm o f  the 
terminal axon. The acidic pH o f  the storage vesicles prevents a spontaneous oxidation o f 
dopamine (Sidhu et al., 2004a). At physiological pH in the cytoplasm and in the 
presence o f molecular oxygen, dopamine is oxidized and generates reactive quinones, 
superoxide and hydrogen peroxide (Sidhu et al., 2004a). The DAT protein has been 
identified in the intracellular Lewy bodies together with a-synuclein (Bellucci et al., 
2008). As a result o f this retention, dopamine transporter levels in the cell are depleted. 
The rate o f reuptake o f the dopamine from the synaptic cleft is adversely affected.
In order for the synaptic vesicles to release dopamine into the synaptic cleft, they 
must fuse with the presynaptic membrane. a-Synuclein bound to the vesicle SNARE 
protein synaptobrevin- 2  seems to promote the formation o f  the complex between the v- 
SNARE proteins in the vesicle membrane and the t-SNARE proteins in the membrane of 
the pre-synaptic terminal. The fusion o f the two membranes facilitates the release o f  the 
neurotransmitter into the synaptic cleft (Burre et al.. 2010). The absence o f  the three
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synucleins in experimental animals showed a marked decrease in the fusion between the 
v-SNAREs (integral membrane proteins o f the vesicle) and the t-SNAREs (the integral 
membrane proteins o f  the presynaptic terminal).
PARKINSON’S DISEASE
Parkinson's disease is a movement disorder that affects about six million 
individuals world-wide who are over 50 years o f  age (Bellucci et al.. 2012). At the age 
o f 40-50, those affected generally have early-onset Parkinson's disease due in part to 
select mutations already discussed in the previous section. The areas o f  the brain 
affected by the disease include the substantia nigra also known as substantia nigra pars 
compacta (Arias-Carrion et al., 2010) and the striatum (Wersinger et al., 2004). The 
disease is characterized by a progressive loss o f  dopamine producing neurons o f the 
substantia nigra (Figure 17) and the presence o f Lewy bodies and Lewy neurites in the 
terminal axon cytoplasm (Wu, 2011). Depleted levels o f  dopamine due to the loss o f the 
dopamine producing neurons, produces the Parkinson’s disease clinical symptoms. The 
surviving neurons contain Lewy bodies and Lewy neurites inclusions.
Although a-synuclein is the major component in the Lewy bodies, there are also 
several other proteins which are associated with Parkinson’s disease and it appears to be 
a multifactorial problem. The proteins include PINKI, Parkin, DJ-1, leucine-rich repeat 
kinase 2 and Fbxo7 (Bonifati et al.. 2003; Darios et al., 2003; Valente et al., 2004; 
Zimprich et al., 2004; Burchell et al., 2013). Each o f the five proteins plays a role in the 
normal function o f  the mitochondria. Mutations in any one o f  them disrupts the 
mitochondrial function, including the electron transport chain, resulting in the generation 
o f ROS (Murphy. 2009).
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Figure 17. A cross section of the brain showing the substantia nigra pars 
compacta (SNc)
The areas o f the brain mainly affected by Parkinson's disease are the striatum and the 
substantia nigra pars compacta (W ersinger et al., 2004). Axons o f the substantia nigra 
neurons (red) extend into the striatum region (Arias-Carrion et al., 2010). Figure 
reproduced from Arias-Carrion.
The mechanism or therapy by which Parkinson's disease progression can be 
completely stopped has not yet been discovered. Current treatment o f  the disease is the 
administration o f  the dopamine precursor levo-dihydroxyphenylalanine (L-DOPA). 
Once L-DOPA has crossed the blood-brain barrier, it is converted to dopamine in a 
reaction catalyzed by DOPA decarboxylase (Perez et al., 2002). However, the drug L- 
DOPA loses its effect in alleviating the symptoms as the disease progresses. There are 
three other drugs that inhibit a-synuclein fibril formation and they include selegiline, 
entacapone and tolcapone (Braga et al., 2011). Unfortunately, these drugs have serious
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side effects including nausea, hypertension and liver toxicity (Simola et al.. 2010). None 
o f the drugs that inhibit a-synuclein fibrillation or ameliorate Parkinson's disease 
symptoms can stop the progression o f the disease, which further indicates the 
multifactorial nature o f the problem.
Another alternative therapy for combating the disease is the direct replacement 
o f dopamine producing neurons using human embryonic stem cells (W akeman et al.,
2011). However, dopamine producing neurons derived from embryonic stem cells have 
been shown to develop Lewy bodies after eleven to sixteen years (Kordower et al..
2008). Other compounds which can disrupt a-synuclein aggregation in a concentration- 
dependent manner are being tested to assess their effect. Experimental studies have 
shown that rifampicin, an antibiotic used to treat bacterial infection, can inhibit a - 
synuclein aggregation in vitro in a concentration-dependent manner (Li et al., 2004) and 
also dissolve a-synuclein mature fibrils. Flavonoid baicalein from a Chinese herb 
Scutellaria baicalensis was shown to inhibit a-synuclein fibrillation and to disaggregate 
its mature fibrils into non-toxic soluble oligomers both in vitro and in vivo (Li et al., 
2004; Ma et al., 2014). Other compounds that inhibit a-synuclein fibrillation include 
curcumin. polyphenols, nicotine and hydroquinone (Braga et al., 2011).
When misfolded and aggregated a-synuclein cannot be cleared from the 
cytoplasm either by the UPS or the ALP systems, it is isolated into inclusions called 
Lewy bodies. The location o f  the Lewy bodies depends on the type o f  the disease 
(Davies et al., 2011). For example, in Parkinson’s disease the Lewy bodies are found in 
the substantia nigra while in Dementia with Lewy bodies they are present in the 
neocortex and the brain stem (Kruger et al.. 1998). When Lewy bodies in the affected
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neurons are stained with hematoxylin and eosin. they appear spherical with a dense core 
surrounded by a halo o f granular matter (Figure 18).
%
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Figure 18. A Lewy body stained by hematoxylin and eosin stain
A section o f the substantia nigra region stained with hematoxylin and eosin stain shows 
a Lewy body. The Lewy body appears spherical and has a dense core surrounded by 
granular material. Figure reproduced from Spillantini (Spillantini et al., 1997).
a-Synuclein and disease implications
The scientific community believes that a-synuclein may play a role in 
Parkinson’s disease. Its mutants (A30P, E46K , H50Q, G51D and A53T) are associated 
with early-onset Parkinson’s disease (Schulz-Schaeffer, 2010). The cause o f  a-synuclein 
accumulation in the presynaptic terminals has not yet been elucidated. Epidemiological 
studies show that Parkinson's disease is a multifaceted disorder caused by various
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factors both in the body and from the environment (Elbaz and Moisan. 2008). 
Nonetheless, a-synuclein aggregation is potentially a step in the development o f 
Parkinson's disease in select patients.
An experimental study involving mice showed that the expression o f  a-synuclein 
in the substantia nigra decreases with advance in age (Mak et al.. 2009). In another study 
involving monkeys and humans, the results indicated an increase in a-synuclein 
expression with increase in age (Chu and Kordower. 2007). Chu and coworkers 
hypothesized that an increased accumulation o f a-synuclein in the hum an substantia 
nigra may trigger the onset o f Parkinson's disease. Perhaps the accumulation o f  the 
protein is due to age associated inefficiency o f  the ubiquitin-proteasome system to 
remove unwanted a-synuclein protein molecules from the cell. It may not necessarily be 
an overexpression o f the protein in old age.
a-Synuclein is most commonly found in the brain and cerebrospinal fluid (CSF) 
but the protein has also been recently found in red blood cells (Tokuda et al., 2006; 
Fauvet et al., 2012) and recent attempts to quantitatively and reliably determine if  it is in 
blood plasma have been made (Tinsley et al., 2010). Conflicting results on the levels o f 
a-synuclein in individuals with Parkinson’s and in those without the disease have been 
reported. One group o f researchers, using cerebrospinal fluid, observed that a-synuclein 
levels in individuals with Parkinson’s disease w as lower than in non-Parkinson disease 
CSF (Kasuga et al., 2010). Borghi and coworkers reported no significant difference in 
the CSF a-synuclein levels between patients with Parkinson’s disease and control 
subjects (Borghi et al., 2000). Tokuda and coworkers have also reported elevated CSF a- 
synuclein levels in individuals with Parkinson's disease compared to control subjects
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(Tokuda et al.. 2010). The variability may lie in the different methods used to determine 
the a-synuclein concentration.
Different oligomers have been identified that can lead to fibril formation.
Fibrillar oligomers are soluble filaments with a P-sheet structure and develop into 
protofibrils (Apetri et al.. 2006; Hong et al.. 2011). Protofibrils are P-strands arranged in 
parallel with the side chains on the surface o f the P-sheets (Breydo et al.. 2012).
Recently, a group o f researchers has identified a ring shaped a-synuclein oligomer. This 
form is capable o f adversely interacting with artificial cell vesicles in vitro  and causing 
nonspecific ion transport. They can also assemble into fibrils (Giehm et al., 2011).
In cell cultures some oligomers appear to be able to move from one cell to 
another, though the new cells degrade the oligomers in the lysosome (Lee et al., 2011). 
Within neuronal in vitro cell cultures, a-synuclein aggregates can be transmitted from 
cell-to-cell under extreme nonphysiological conditions (Desplats et al., 2009). In 
addition, experimental studies involving neuronal cell cultures have shown that specific 
forms o f exogenous oligomers generated in the presence o f  FeCfi can induce 
intracellular a-synuclein aggregation (Danzer et al., 2009).
a-Synuclein oligomers bind to lipid membranes and can potentially make 
channels in the bilayer membrane thereby creating nonselective membrane channels 
(van Rooijen et al., 2010). These oligomers, and not mature fibrils, could be a more 
responsible factor in Parkinson's disease. For example, cell death in vitro takes place 
before a-synuclein fibrils are detected (Gosavi et al., 2002). In one experiment when 
human a-synuclein was expressed in rat substantia nigra, the death o f  dopaminergic 
neurons occurred before Lewy bodies were formed (Lo Bianco et al., 2002).
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Consequently, a correlation between fibril accumulation and cell death is now 
questionable, suggesting that oligomers are potentially a toxic species or the soluble 
oligomers interact with unknown cofactors. Dopaminergic neurons containing Lewy 
bodies do not necessarily undergo apoptosis faster than the normal population o f 
neurons (Schulz-Schaeffer. 2010). However, the presence o f  a-synuclein oligomers in 
the dopaminergic neurons compromises the integrity o f the cells.
Protein modification, which can occur during protein translation or after 
translation, is a mechanism that regulates the activity, binding affinity and stability o f  a 
protein (Schonichen et al., 2013). a-Synuclein undergoes posttranslational modifications 
including phosphorylation, oxidation, nitration and protein cleavage. Some 
modifications stabilize the protein while others cause it to misfold and form fibrils 
(Oueslati et al., 2010). Phosphorylation o f the serines at positions 87 and 125 protects a- 
synuclein from misfolding and fibrillation (Paleologou et al., 2010; Oueslati et al.,
2012). However, phosphorylation o f serine 129 in the C-terminus o f a-synuclein 
increases the propensity o f  the protein to form fibrils (Fujiwara et al., 2002). a- 
Synuclein in Lewy bodies and Lewy neurites is highly phosphorylated at serine 129 
(Fujiwara et al., 2002; McCormack et al., 2012).
All four methionine residues o f  a-synuclein are prone to oxidation to sulfoxides 
(Met-S-O) in vitro (Glaser et al., 2005). Experimental studies have shown that the more 
methionines oxidized the higher the resistance o f  a-synuclein to fibrillation.
Interestingly, a methionine-oxidized a-synuclein inhibits the fibrillation o f  other non­
modified a-synuclein molecules (Zhou et al., 2010). On the other hand, when metal ions 
bind at the sulfoxide moieties o f  the methionine-oxidized a-synuclein, they promote its
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fibrillation (Glaser et al.. 2005). Zn2+. AL" and Pb2" ions overcome the resistance o f  
methionine-oxidized a-synuclein to form fibrils (Yamin et al.. 2003).
Tyrosine nitration promotes fibril formation (Giasson et al.. 2001). The 20S 
proteasome system is unable to break down a-synuclein molecules that have a nitrated 
tyrosine at position 39 (Hodara et al.. 2004). The failure to clear abnormal a-synuclein 
from the brain tissue results in its accumulation, aggregation and formation o f Lewy 
bodies. Experimental studies have shown that incomplete degradation o f  a-synuclein 
generates synuclein fragments which are more prone to aggregation in vitro than the full 
length a-synuclein (Liu et al.. 2005). It appears that modifications in different regions o f 
the a-synuclein protein have different effects on its structure. Dopamine and other 
positively charged molecules interact with the C-terminal region and induce the protein 
to aggregate (Norris et al., 2005).
Lewy bodies have been reported to contain an abundant amount o f  C-terminally 
cleaved a-synuclein (Liu et al., 2005; Lewis et al., 2010). Cleavage sites lie between 
residues 115 and 135. The C-terminus is cleaved by the protease enzyme calpain-1 
(Dufty et al., 2007). Studies have shown that a C-terminally truncated a-synuclein has a 
high tendency to fibrillate both in vivo and in vitro  (Li et al., 2005; Kim et al., 2010). 
Metals and a-synuclein aggregation
Most o f  a-synuclein protein is copper bound in vivo (Breydo et al., 2012). The 
imidazole o f histidine at position 50 is the anchoring point for copper. a-Synuclein in 
solution binds copper ions with methionine 1. aspartate 2 and histidine 50 (Dudzik et al.,
2013). When a-synuclein is membrane bound, the histidine is spatially unavailable and 
therefore copper is bound by only methionine 1 and aspartate 2 (Dudzik et al.. 2013).
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Copper-bound a-synuclein has ferrireductase enzyme activity that catalyzes the 
reduction o f F e’~ to Fe2̂  (Davies et al.. 2011).
Epidemiological studies conducted in Quebec. Detroit and M ichigan indicated 
that heavy metals were a risk factor for Parkinson's disease (Uversky et al.. 2001b). 
Occupational exposure to manganese, iron, and copper seemed to increase the incidence 
o f Parkinson's disease (Gorell et al.. 1999). Postmortem o f tissues from Parkinson's 
disease brains showed higher levels o f iron, zinc and aluminum in the substantia nigra 
compared with brain tissue unexposed to the metals (Uversky et al., 2001b). Interaction 
between metals and a-synuclein causes changes in the conformation o f  the protein 
(Uversky et al.. 2001b; Santner and Uversky. 2010). When a-synuclein is incubated with 
Al3+ ions, there are changes in the far-UV CD, the UV absorbance and the intrinsic 
fluorescence spectra which are attributed to a partially folded species (Santner and 
Uversky, 2010). Changes in the structure o f a-synuclein eventually lead to fibril 
formation.
The relationship between calcium and a-synuclein appears to be complex. 
Investigators have observed that a-synuclein regulates the channels by which Ca2+ ions 
enter the cell (Mosharov et al.. 2009). However, the interactions between a-synuclein, 
dopamine and Ca2+ ions can cause the death o f substantia nigra neurons (M osharov et 
al., 2009). In addition, Ca2+ ions can interact with the last fifteen amino acid residues o f 
the C-terminus o f  a-synuclein and induce the protein to form the previously mentioned 
ring-shaped oligomers, which can form pores in the cell membrane (Lowe et al.. 2004). 
High concentrations o f Ca2t ions in the cytoplasm cause a-synuclein to bind to lipid
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membrane with both the N- and the C-termini leading to aggregation o f the protein and 
eventual perforation o f  the membrane (Pountney et al.. 2005).
Iron has been implicated in Parkinson's disease (Mounsey and Teismann. 2012). 
Postmortem analysis o f Parkinson's disease brain tissue has shown iron accumulation in 
the substantia nigra (Gorell et al.. 1999: Ayton and Lei. 2014). The elevated levels o f 
iron are accompanied by an increase in the concentration o f  ferritin protein, which binds 
Fe3+ ions (Davies et al.. 2011). In addition, since Fe2+ is a cofactor o f  tyrosine 
hydroxylase, the lower concentration o f Fe2+ ions decreases the rate o f  dopamine 
synthesis (Davies et al.. 2011). The copper-bound a-synuclein maintains a supply o f 
Fe2+ ions by reducing Fe3+through its interaction with the ferrireductase. The loss o f a- 
synuclein through aggregation reduces its ferrireductase activity. Consequently Fe3+ ions 
accumulate resulting in the generation o f ROS.
Lead exposure has been shown to increase a-synuclein expression and induce the 
formation o f inclusion bodies (Zuo et al.. 2009). Pb2+ ions can even overcome the 
resistance o f methionine-oxidized a-synuclein to fibril formation (Yamin et al., 2003). 
The concentration o f magnesium has been known to decrease in the cerebral spinal fluid 
as Parkinson’s disease progresses (Bocca et al., 2006). A study using mice revealed that 
magnesium intake between 1-4 mM concentration was sufficient to protect a-synuclein 
against fibrillation (Oyanagi et al., 2006). At concentrations greater than 10 mM. M g2+ 
ions induced a-synuclein fibrillation (Oyanagi et al., 2006). Furthermore, 1-4 mM 
magnesium concentration was shown to protect dopaminergic neurons from l-m ethyl-4- 
phenylpyridinium (MPP+), a neuron toxin (Hashimoto et al.. 2008). The interaction
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between magnesium and a-synuclein seems to play a protective role by inhibiting 
aggregation o f the protein.
Manganese toxicity produces symptoms that are similar to Parkinson 's disease. 
The clinical symptoms include fixed gaze, slow-ness o f m ovem ent postural difficulties 
and tremor (Lucchini et al., 2009). However, there are no Lewy bodies present in 
manganese induced Parkinsonism and the neurons o f  the substantia nigra region are not 
involved (Bleecker, 1988) When a manganese transporter protein PARK9 is omitted in 
in vitro studies, there is an increase in a-synuclein aggregation and toxicity (Gitler et al.,
2009). Manganese ions can oxidize a-synuclein resulting in the formation o f di-tyrosine 
cross-links both intra- and intermolecular (Uversky et al., 2001b; Santner and Uversky,
2010). This modification makes a-synuclein more prone to aggregation.
Although higher levels o f  zinc have been observed in Parkinsonian substantia
nigra tissue compared with control tissue, the correlation between zinc exposure and 
disease progression is questionable (Forte et al., 2005). However, in vitro studies have 
indicated that zinc can accelerate a-synuclein fibril formation (Uversky et al., 2001b).
On the whole there are two types o f  interactions between metals and a-synuclein. 
One type involves electrostatic interaction between metal ions and the negatively 
charged side chains o f  a-synuclein in the C-terminal region. The second type o f 
interaction between metals and a-synuclein is facilitated by methionine 1 , aspartate 2  
and histidine 50 in the N-terminal region o f the protein (Dudzik et al., 2013). Cu (II) 
binds with high affinity to the N-terminal region o f  a-synuclein specifically the 
’MDVFMKGLS9 and 48VVHGV52 sites and histidine 50 is the anchoring residue. Other
5 6
divalent metal ions have a preference to bind th e 1 i9D PD N EA 124 site in the C-terminal 
region and aspartate 121 is the anchoring residue (Binolfi et al.. 2006).
Many metals stimulate partial folding o f  a-synuclein (Uversky et al.. 2001b).
The partially folded conformation is prone to aggregation. Iron, aluminum, cobalt and 
manganese and high levels o f copper ions are the most effective at inducing a-synuclein 
partial folding with subsequent aggregation (Uversky et al.. 2001b).
APPROACHES TO STUDY PROTEIN FIBRILS IN VITRO 
Transmission electron microscopy
Examination o f a specimen under a transmission electron microscope (TEM) 
gives information about the surface features, size and shape o f an object on a nanometer 
to micrometer scale. A modem TEM consists o f  an electron source, a specimen stage, an 
objective lens system, the magnification lens system and data collection system. The 
magnified electron image is projected onto a fluorescent viewing screen or the image 
can be captured by a charge coupled device camera and displayed on a com puter screen 
(Wang, 2000).
A beam o f electrons generated in a high vacuum by an electron gun is 
accelerated towards the specimen and it interacts with the atoms o f the specimen. The 
interactions and effects on the electron beam are detected and converted into an 
image.(Wang, 2000) Thinner areas o f the specimen allow more unscattered electrons to 
be transmitted and these areas appear light. Areas o f the specimen that are thicker allow 
fewer unscattered electrons to be transmitted and appear dark (Wang. 2000). However, a 
beam o f high energy electrons is not compatible with molecules such as proteins. Such 
molecules would easily dry up and their structure would collapse. In addition, the
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molecules do not have the ability to scatter the electrons (Ohi et al.. 2004). Negative 
staining, for example, the use o f uranvl acetate, has been introduced to insert the 
specimen in a layer o f  dried heavy metal solution. The heavy metal upholds the structure 
o f  the specimen. In addition, the heavy metal can withstand the radiation from electrons 
and is capable o f  scattering the electrons more efficiently than the delicate protein 
specimen.
Atomic force microscopy
As the name implies, atomic force microscopy (AFM ) characterizes the nature o f 
surfaces at atomic scale. The atomic force microscope generates very high resolution 2D 
and 3D images by using a very small probe tip at the end o f  a cantilever (M eyer, 1992). 
Atomic force microscopy is employed to erase nanoscale electronic structures, measure 
surface structures o f biological substances, visualize objects from living cells and to 
conduct drug crystallization studies (Jensen, 2013) The m ain components o f  an AFM  are 
a cantilever with a sharp tip at one end, a source o f  laser beam and a photo detector. 
Interactions between the tip o f  the cantilever and the sample surface are regulated by 
different types o f  forces including van der Waals forces, adhesive forces, capillary 
forces and electrostatic forces (Meyer, 1992). The van der Waals forces are the most 
commonly associated with AFM.
When the cantilever tip is a few angstroms from the surface o f the sample, 
repulsive van der Waals forces have an effect on the tip. But when the tip is several 
angstroms from the sample surface it experiences attractive van der W aals forces 
(Meyer, 1992; H aytonet al.. 2010; Jensen, 2013). The van der Waals forces between the
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tip and sample surface generate electrical signals which are converted into topographic 
images.
The tapping mode AFM is most commonly used for soft and biological samples. 
In the tapping mode atomic force microscopy, the tip oscillates vertically, makes contact 
with the surface and lifts off. The oscillation distance ranges from 20 nm to 100 nm. 
When the tip comes too close to the sample surface, van der Waals forces, dipole-dipole 
interactions and electrostatic forces act on the cantilever and cause a decrease in the 
amplitude o f oscillation (Jensen, 2013). As the cantilever tip scans the sample surface, 
the oscillation amplitude changes with varying contours o f the surface. The changes in 
the amplitude cause the cantilever to reflect the incident laser beam at different angles. 
The photo detector records the changes in amplitude and these signals are converted by 
the computer into images of the sample (Jensen, 2013).
Thioflavin T fluorescence
The fluorescence o f  a benzothiazole dye thioflavin T is an established test for 
detecting and monitoring amyloid fibril formation. Thioflavin T dye is composed o f a 
hydrophobic dimethylamino group attached to a  benzene ring which is linked to a polar 
benzothiazole containing a polar nitrogen and sulfur (Khurana et al., 2005) (Figure 19). 
When a free thioflavin T molecule absorbs a photon o f light, the angle o f  rotation 
between the rings rises to 90°. The dimethylamino benzene ring becomes positively 
charged while the benzothiazole ring is slightly negative (Wolfe et al., 2010). The 
fluorescence o f  the dye at this conformation is weak. When the dye is trapped between 
P-sheets o f  amyloid fibrils and is irradiated, the angle o f  rotation is reduced to 65°, the
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positive charge on the dimethylaminobenzene ring decreases and fluorescence o f  the dye 
is enhanced.
In a polar solvent, the thioflavin dye peak absorption is at 340 nm and its 
maximum emission is at 445 nm (W olfe et al.. 2010). However, when the dye molecule 
is trapped between P-sheets o f protein fibrils that has more o f a nonpolar environment, 
there is a shift in its absorption and emission peaks to 440 nm  and 480 nm respectively 
(Wolfe et al., 2010; Hsu et al.. 2013). Besides limiting the rotation between the 
thioflavin rings, the protein fibrils also reduce the quenching effects o f  the environment 
o f the dye thereby enhancing its fluorescence (Hsu et al., 2013).
C H 3
Figure 19. Structure of a thioflavin T molecule
The benzothiazole ring on the left is linked to the dimethylaminobenzene ring on the 
right. The dimethylaminobenzene is the hydrophobic portion o f the molecule while the 
benzothiazole is the polar portion .There is an angle o f rotation between the rings. When 
the molecule is trapped between p-sheets o f the protein fibrils, the rotation between the 
two rings is restricted causing the bound molecule to fluoresce more than the free 
molecule and there is also no quenching effect.
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SPECIFIC AIMS OF THE RESEARCH PROJECT
The purpose o f  my research project was to contribute to the further 
understanding o f the synuclein proteins and investigate potential treatments for the 
synucleinopathies. Experimental and computational approaches were employed to 
conduct the study. The first aim was to investigate potential methods o f destroying 
protein fibrils with the hope that these methods could be employed to facilitate medical 
treatment o f  fibril related diseases. The second aim  was to explore the mechanism by 
which P-synuclein inhibits a-synuclein fibril formation. In the future, synthetic protein 
molecules mimicking P-synuclein could be employed to arrest a-synuclein fibrillation. 
My third aim was to express and isolate a multimeric P-synuclein from which well 
diffracting crystals could be produced for X-ray crystallographic studies in order to 
elucidate its physiological structure. The fourth aim was to use bioinformatics 
techniques to construct a superfamily for the synucleins in order to identify ancestral 





All reagents were o f  analytical grade. Thioflavin T. phenylmethyl sulfonyl 
fluoride (PMSF) and sodium chloride were purchased from EMD Chemicals Inc. 
(Gibbstown, NJ). Hepes free acid buffer was purchased from AMRESCO (Solon. Ohio) 
and the n-octyl-P-D-glucopyranoside was from Indofine Chemical Company (ICC) 
(Hillsborough, N J) . Carbenicillin disodium salt, sodium dodecyl sulfate (SDS) running 
buffer and tryptone medium were obtained from Teknova (Hollister, CA.). G-75 
Sephadex medium size and Q-Sepharose Fast Flow anion exchange resins were from GE 
Healthcare (Pittsburgh, PA). Isopropyl-P-D-thiogalactoside was purchased from IBI 
Scientific (Peosta, IA). Tris Base and ethylenediaminetetraacetic acid (EDTA) were 
purchased from T.J Baker (Pillipsburg, NJ). Ammonium sulfate was obtained from 
Mallinckrodt (St. Louis, MO). Streptomycin sulfate was from Calbiochem (La Jolla, 
CA). Dithiothreitol (DTT) was purchased from M P Biomedicals. LLC (Solon, OH). 
Competent Escherichia coli BL 21 (DE3) cells were purchased from Aligent 
Technologies Stratagene (Santa Clara, CA).Yeast extract was purchased from Research 
Organic (Cleveland, OH). Buffers were prepared and filtered through a 450 nm or 220 
nm filter purchased from Pall Life Sciences (Ann Arbor, MI). Molecular porous 
membrane for dialysis was obtained from Spectrum Laboratories (Rancho Dominguez, 
CA). Copper grids o f  formvar carbon support 400 mesh, uranyl acetate and round grid
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mats were purchased from Electron M icroscopy Sciences (Hatfield. CA). Ultrapure 
water was used to prepare all the solutions. Gycerol was purchased from Fisher 
Scientific (Fair Lawn. NJ). Rosetta 2(DE3) cells were purchased from EMD Chemicals 
(San Diego. CA).
METHODS FOR THE PROTEIN CHEMISTRY AND BIOPHYSICAL
ANALYSIS OF THE SYNUCLEINS
Transformation
Transformation is a process o f introducing foreign plasmid DNA into a 
competent bacterial cell. A frozen aliquot (50 pi) o f competent E. coli cells was thawed 
on ice for 30 minutes. Then 1-3 pi o f recombinant DNA were added to the cells and the 
reaction mixture was incubated for 30 minutes on ice. The cells were heat shocked in a 
water bath at 42°C for 30 seconds and then placed on ice for 2 minutes. The cells were 
heat shocked again for 15 seconds and placed on ice.
An aliquot o f 950 pi o f SOC nutrient media was added to the bacterial cells and 
the cells were incubated at 37°C in an incubator shaking at 150 rpm for 1 hour. Bacterial 
cells were then centrifuged at 300 rpm for 5 minutes. 900 pi of the m edia were removed 
and discarded. Transformants were selected by plating the bacterial cells on agar plates 
containing carbenicillin (100 pg/ml) and incubating the plates at 37°C overnight. 
Bacterial cells that grew on the agar had the recombinant DNA since the plasmid 
conferred resistance against the carbenicillin antibiotic. Refer also to IBC 
rDNA/biosafety protocol # 12-006.
6 3
Protein Expression
Expression and purification o f a- and P-synuclein were performed according to 
the protocol o f  Conway and coworkers with a few modifications (Conw ay et al.. 1998). 
Human wild type recombinant a-synuclein was expressed in Escherichia coli 
BL21(DE3) cells using a pT7-7 human wild-type a-synuclein plasmid. Similarly human 
wild-type recombinant p-synuclein was also expressed in Escherichia coli BL21(DE3) 
cells using a pRK172 human P-synuclein plasmid.
Following induction with 1 mM isopropyl-p-D-thiogalactoside (triggers 
transcription and expression o f  the protein) for 4 hours, bacterial cells were harvested by 
centrifuging at 7000 rpm for 30 minutes at 4°C. Cells were lysed (20 mM Tris Base, pH 
8.5, 1 mM EDTA and 1 mM PMSF) by sonication in a lysis buffer. The lysate was 
boiled in a water bath at 100°C for 30 minutes and then centrifuged at 9000 rpm at 4°C 
for 1 hour. Streptomycin sulfate at a 10 mg/ml concentration was used to precipitate the 
nucleic acids. After centrifugation, ammonium sulfate was added to the supernatant at 
361 mg/ml to precipitate a- or P-synuclein.
Protein purification procedure
The a-synuclein pellet was dissolved in 20 mM Tris Base buffer (pH 8.5) and 
loaded onto a Q-Sepharose Fast Flow anion exchange column equilibrated with the same 
buffer and eluted in a gradient o f 0-0.6 M NaCl. Protein solution from the column was 
collected in 5 ml fractions. Fractions containing a-synuclein were verified by 
Coomassie-stained SDS-PAGE, then the protein was dialyzed against ultrapure water 
and lyophilized. A Q-Sepharose Fast Flow anion exchange column for P-synuclein was 
equilibrated with 25 mM Tris base buffer containing 1 mM EDTA. 0.1 mM DTT and
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0.1 mM PMSF at pH 7.4. The protein was eluted with a gradient o f  0-0.5 M NaCl. 
Fractions containing P-synuclein were verified by Coomassie-stained SDS-PAGE. 
dialyzed against ultrapure water and lyophilized. Protein concentration was determined 
by dividing the absorbance of the protein solution at 280 nm by the molar extinction 
coefficient o f the monomeric a- and P-synuclein (0.3541 and 0.3583). respectively.
The second step in the purification process involved gel filtration. Lyophilized a- 
synuclein protein (14.0 kDa) was dissolved in 20 mM Tris base buffer, pH 8.5 and 
loaded onto a Sephadex G-75 gel filtration size exclusion column and eluted with 0.3M 
NaCl in 20 mM Tris Base at pH 8.5. a-Synuclein fractions were pooled together, 
dialyzed against ultrapure water, lyophilized and stored at -80° C. p-Synuclein was also 
loaded onto a Sephadex G-75 gel filtration size exclusion column and eluted with 50 
mM NaCl in 50 mM Tris base containing 0.1 mM DTT and 0.1 mM PMSF at pH 8.3. 
Purified protein was dialyzed against ultrapure water, lyophilized and stored at -85°C. 
Calibration of G-75 size exclusion column
The G-75 size exclusion column was standardized with protein standards from 
Sigma-Aldrich: blue dextran, chymotrypsinogen A, ovalbumin, albumin and 
ribonuclease. They were donated to us by Professor Ellis Bell (Richmond University, 
Virginia). The blue dextran standard was run on its own by injecting the colum n 3mls o f 
the protein at 1 mg/ml concentration. The second run was a combination o f albumin and 
chymotrypsinogen. 10 mg o f each protein was dissolved in 3 ml o f ultra-pure w ater and 
the protein solution was injected the column. Similarly a combination o f  ribonuclease 
and ovalbumin were dissolved in 3 ml o f  ultrapure water and injected into the column. 
The resulting G-75 chromatogram is shown in the appendix (Figure A).
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Isolation of multimeric Ji-synudein
The same protocol for the expression o f monomeric p-synuclein was used. 
However, the Rosetta 2(DE3) cells instead o f  the BL21(DE3) cells were used to express 
the protein. Hepes buffer (100 mM Hepes. 1 mM EDTA. 1 mM PMSF. pH 7.4) was 
used in place o f  Tris Base. Hepes buffer offers a more conducive environment to the 
tetramer than the Tris Base buffer. After sonication. the lysate was not boiled (to 
preserve multimeric forms) but centrifuged at 4000 rpm at 4°C to separate soluble and 
insoluble fractions. The supernatant was loaded onto a Q-Sepharose Fast Flow anion 
exchange column equilibrated with Hepes buffer (100 mM Hepes, 10% glycerol, 0.1% 
n-octyl-p-D-glucopyranoside. 0.1 mM EDTA, 0.1 mM PMSF). The P-synuclein was 
eluted at 2 ml/min in a gradient o f 0-0.5 M NaCl in Hepes buffer (100 mM Hepes. 10% 
glycerol, 0.1% n-octyl-P-D-glucopyranoside, 0.1 mM EDTA, 0.1 mM PMSF). The 
multimeric complex was concentrated by centrifuging at 4000 rpm at 4°C at intervals o f 
one hour until the desired volume o f the protein solution was achieved.
The second step in isolating the multimeric complex involved gel-filtration. The 
concentrated multimeric p-synuclein solution was injected into a Sephadex G75 size 
exclusion column equilibrated with Hepes buffer (100 mM Hepes, 10% glycerol, 0.1% 
n-octyl-P-D-glucopyranoside. pH 7.4). The multimeric P-synuclein protein was eluted 
with 0.15 M NaCl in Hepes buffer at 1 ml/min and stored in 1 ml aliquot solutions at - 
80°C.
Synuclein fibril formation
A modified method o f Hoyer and coworkers was developed for a-and p- 
synuclein fibrillation (Hoyer et al.. 2002). Using sealed sterile eppendorf tubes, proteins
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were dissolved in 20 mM Tris base buffer containing 0.2 M NaCl. pH 7.5 and incubated 
at 37° C with agitation at 190 rpm in a New Brunsw ick Scientific Incubator Shaker 
Model 25 for up to 14 days.
Monitoring fibril formation
Fibril formation was monitored by thioflavin T (ThT) fluorescence using a black 
and flat bottom 96 well microtiter plate and microplate reader Synergy HT (BioTek Inc., 
VT). 15 gl o f fibril solution were added to 3 ml o f  50 pM thioflavin T solution (Nilsson, 
2004). The excitation and emission wavelengths were 440 nm and 485 nm, respectively. 
All samples were run in triplicates.
Secondary structures of P-synuclein fibrils determined by circular dichroism
In order to determine the secondary structures o f p-synuclein fibrils, fibril 
solutions were diluted to a final concentration o f 0.2 mg/ml for far-UV CD. The 
concentration was determined by absorption at 280 nm on a  Varian Cary UV 
spectrophotometer (Varian Inc., NC). Using a MOS 450 (Bio-logic, France), the 
monomeric and fibril samples were analyzed in the 200-250 nm far-UV range in a 1 mm 
path length quartz CD cuvette. Slit widths were set to 1 mm. Spectra were repeated 30 
times. The machine signal was converted to molar ellipticity which takes into account 
the concentration o f the protein being measured. The average was graphed and analyzed 
using Sigma Plot (version 10).
Secondary structure of the multimeric p-synuclein
CD was used to determine the secondary structures o f  the multimeric p-synuclein 
protein. The protein was measured at 0.2 mg/ml in the far-UV CD range (200-250 nm) 
on a MOS 450 (Bio-logic, France) using a 1 mm path length quartz CD cuvette. Slit
6 7
widths were set to 1 mm. The machine signal w as conv erted to molar ellipticity w hich 
takes into account the concentration o f  the protein being measured. The average was 
graphed and analyzed using SigmaPlot (version 10).
Atomic force microscopy imaging of fibrils
In our experimental studies, AFM  was used to examine a- and P-synuclein 
fibrils. The fibril samples were diluted to 2 mg/ml for imaging on a Veeco DI 
Nanoscope 3D Atomic Force M icroscope using the tapping force mode (Veeco Inst.. 
NY). From each sample, 2 pi o f  the dilute fibrils were placed onto a mica grid and 
spread evenly. The sample was allowed to air dry and then washed 4-5 tim es with 20 pi 
o f ultrapure water and allowed to stand for 1 -2  m inutes before removing the excess 
solution. The dried sample was then examined for fibrils. These studies were conducted 
with the assistance o f Mr. Jason Collins (Old Dominion University, Greene Group). 
Transmission electron microscopy imaging o f fibrils
To prepare samples for TEM, a 5pi aliquot o f a-synuclein fibril solution was 
adsorbed onto a film of 400 mesh formvar carbon coated copper grid. A fter 60 seconds 
o f adsorption, excess fibril solution was blotted and the grid was washed several times 
with ultrapure water. The grid was air dried. Then the fibrils were stained with 10 pis of 
2% uranyl acetate for 25 seconds before final blotting. The grid was washed by dipping 
it several times in ultrapure water and then drying it in air. The grids were examined for 
fibrils under a JEOL TEM at the Applied Research Center (Newport News, VA). 
Destruction of a-synuclein fibrils by low temperature plasma jet
Plasma is a neutral medium composed o f  positively and negatively charged gas 
molecules. The ‘plasma penciF generated the room temperature (or cold) plasma which
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was employed to break a-synuclein fibrils into smaller fragments. A sample o f the a- 
synuclein fibril solution ( 6  mg/ml) was placed in a small tube (0 .2  ml) and exposed to 
the plasma for varying lengths o f time up to 1 0  minutes under the following conditions: 
high voltage pulse 7.5 kV: frequency 5 kHz; pulse width 1 ps; operating gas helium flow 
rate 5 L/min. The distance between the nozzle o f  the pen and the samples was 2 cm. 
These plasma studies were conducted with Dr. Erdinc Karakas (Old Dominion 
University, Laroussi Group). After exposure, the fibrils were fixed onto 400 mesh 
formvar coated copper grids for analysis by TEM.
Chemical and biosafety
Wet lab experiments were conducted under Biosafety level 2 conditions. The 
Greene lab is a designated BSL-2 laboratory. The Basic Biosafety and NIH 
Recombinant DNA CITI training was successfully completed and is on file with the 
Office o f  Research. Biohazard waste was disposed o f in accordance with the Old 
Dominion University ‘Regulated Medical Waste Management G uidelines', through the 
Biological Sciences Support Facility and the Office o f  Environmental Health and Safety. 
Hazardous chemical waste was disposed o f through the Office of Environmental Health 
and Safety. Standard Biosafety Operating Procedures and Material Safety Data Sheets 
are maintained for reference in the Greene laboratory. Safety education included training 
in proper experimental procedures, good laboratory practice, hygiene, the proper wear o f 
personal protective equipment (ie. lab coats, goggles, disposable gloves), hazards, 
decontamination, disposal and emergency procedures. Refer also to IBC recombinant 
DNA/biosafety protocol # 12-006.
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METHODS FOR THE COMPUTATIONAL ANALYSIS OF THE SYNUCLEINS
In order to trace the origins o f  the synuclein proteins as w ell as assist in better 
understanding their structure and function we used bioinformatics approaches. This 
included searching for related proteins, aligning sequences, searching for related protein 
structures and functional sites. A flow chart indicates how the synuclein ancestral 
relatives were retrieved from databases (Figure 20). The program FASTA (Lipman and 
Pearson, 1985) retrieved protein sequences in an appropriate format from the NCBI 
(National Center for Biotechnology Information) protein database. The position-specific 
iterative basic local alignment search tool (PSI-BLAST) (Altschul et al., 1997) at the 
NCBI used a-, P- or y-synuclein sequences as probes to search the database for proteins 
with similar sequences. The identified related proteins were each aligned with several a-, 
P- and y-synucleins from various species. The program. Multiple Sequence Comparison 
by Log-Expectation (MUSCLE) (Edgar, 2004), was used to create the multiple sequence 
alignment o f  proteins in order to determine positions o f  identity. Identity or similarity 
between sequences was considered significant when the statistical e-value was less than 
5 x 10‘3. The structures o f  the synucleins, endoglucanase, CRE-DUR-1, Tasmanian 
Devil protein and cytochrome c were constructed using the program, SW ISS-M ODEL 
(Biasini et al., 2014). The structure modelling was conducted with the assistance o f  Ms. 
Nardos Sori (Old Dominion University, Greene Group).
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FASTA from the NCBI protein database
Human a-,p* and y-synuclein amino acid sequences 
(Probe)
BLAST
(Search the sequence databases at NCBI)
Identify potential related proteins
Analysis reveals family and superfamily members
Family members
Species from variants of a-, p- and y- 
synucleins
Superfamily members (a-synuclein as query):
Endoglucanase (30% identity), e-value = 3 x 10*4
CRE-DUR-1 (39% identity), e-value = 5 x 10' 5
Tasmanian Devil protein (60% identity), 
e-value = 2 x 1 0 ‘2c Cytochrome c (35% identity), e-value = 3 x 10"3
Figure 20. The flow chart showing the construction of the synuclein superfamily
FASTA retrieved protein sequences from NCBI protein database. PSI-BLAST was run 
against the protein database to identify sequences similar to synuclein proteins.
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To further confirm the evolutionary relationship between the synucleins and the 
retrieved proteins other algorithms, the scan prosite and the scan motif, were employed. 
ProSite is a database for domains, functional sites and amino acid patterns (Falquet et 
al.. 2002). The scan prosite algorithm searches for functional sites or amino acid patterns 
that match those o f the query sequence. The hum an sy nucleins and their related proteins 
were used as query sequences in order to identify functional sites at conserved locations 
(Appendix B).
The phylogenetic tree of the synucleins and the disparate proteins
The Phylogeny.fr computer program was used to construct a phylogenetic tree 
from the human synucleins and disparate protein sequences. The Phylogenetic.fr 
(program reconstructs and analyzes the evolutionary relationship between protein 
sequences (Dereeper et al., 2008).
Websites for the bioinformatics computer programs
PSI-BLST http://www.ebi.ac.uk/Tools/sss/psiblast/
MUSCLE http://www.ebi .ac.uk/T ools/msa/muscle/
Scan prosite http://prosite.expasy.org/scanprosite/
M otif scan http://myhits.isb-sib.ch/cgi-bin/motif_scan
Phylogeny.fr http://www.phylogeny.fr/




DESTRUCTION OF a-SYNUCLEIN BASED AMYLOID FIBRILS BY LOW  
TEMPERATURE PLASMA JET 
INTRODUCTION
Plasma is considered the fourth state o f  matter (Heinlin et al., 2010), consisting 
o f  neutral molecules, excited atoms, electrons, and positive and negative ions (Niemira. 
2012). In low temperature (or cold) plasma, the temperature o f the electrons is higher 
than that o f the ions and neutral molecules. Such plasmas are classified as non­
equilibrium because o f the difference between the energies o f  the electrons and o f  the 
heavier particles (Heinlin et al., 2010). Heat, electricity or laser radiation are the sources 
o f  energy that ionizes gas molecules into plasma (Niemira. 2012).
The biomedical application o f  low temperature or cold plasma is emerging as a 
field o f great interest to physicists, engineers, chemists, and medical researchers.
Various groups have shown that non-equilibrium plasmas can inactivate bacteria, help 
the proliferation o f human fibroblasts and coagulate blood (Laroussi, 2009; Brun et al.,
2012). Low temperature plasma technology is also finding application in the food 
industry. Microbial organisms on fruits, vegetables and meats can be inactivated by 
reactive species in the plasma (O2 . O2', O3 0 , 0 +, 0 \  N 2. N 2*, ionized ozone and free 
electrons) making the food products safe for consumption (Niemira. 2012). The 
investigators did not observe any adverse effects o f  the plasma on the quality o f  the food 
products. Cold plasma has been successful in sterilizing packaging materials (M isra et
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al.. 2014; Pankaj et al.. 2014). Also. E. coli suspensions in liquid media in a sealed 
package have been completely inactivated by cold plasma (Ziuzina et al.. 2013). In the 
future, food products can be disinfected after they are packaged.
The treatment o f chronic wounds by cold atmospheric argon plasma decreases 
the bacterial load o f the wounds and promotes healing (Isbary et al.. 2010). It appears 
bacterial cells resistant to antibiotics succumb to cold plasma. Both in vitro and in vivo . 
cold plasma activates the human dermal fibroblast genes. The products o f  these genes 
are essential for wound healing and repair (Arndt et al.. 2013). In addition, cold plasma 
was shown to eradicate cancer cells both in vitro and in vivo  (Keidar et al.. 2013). 
Laroussi and coworkers, also demonstrated that in vitro. low temperature plasm a can kill 
leukemia cells in a dose-dependent manner (Barekzi and Laroussi, 2012). These 
important findings indicate that plasma has a potential role in sterilization, 
decontamination, wound healing and cancer therapy.
The plasma jet/plume used in our study was generated by a device (the plasm a 
pencil) capable o f emitting a long cold plasma plume in ambient air (Laroussi and Lu, 
2005) (Figure 21). The plasma pencil is driven by short (nanoseconds to microseconds 
in width) high voltage pulses and uses helium as a carrier gas. Other gas mixtures can 
also be used (such as helium/oxygen mixtures, argon/oxygen mixtures, air). The plasma 
plume which appears as a continuous plasma je t is in fact a train o f small packets of 
plasma (generally known as “plasma bullets’") traveling at supersonic velocities (Shi et 
al., 2008: M ericam-Bourdet et al., 2009) (Figure 22). These plasma bullets are vehicles 




Figure 21. Photograph of the plasma pencil
The pen is indicated in red and the purple color is the plasm a issuing from the pen. 
Figure reproduced from Karakas (Karakas et al.. 2010).
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Figure 22. Image of plasma packets or bullets
High-speed camera images show that the plasm a plume, in fact, consists o f  a series o f  
packet structures called plasma bullets. These bullets propagate in the surrounding air 
with supersonic velocities in order o f  104-105 m/s without any external electric field. The 
exposure time o f the camera is 20 nanoseconds. Figure reproduced from Karakas 
(Karakas et al., 2010).
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The aim o f this study was to explore potential methods in w hich the use o f  cold 
plasma could destroy a-synuclein fibrils in vitro. Potentially, this method could also be 
applied to the destruction o f fibrils in the jo in t spaces that are formed by p2 - 
microglobulin in patients undergoing prolonged renal dialysis and amylin fibrils that can 
form in the pancreas o f patients with diabetes for example. Additionally, prion proteins 
could be destroyed, which would have value in decontamination processes in the meat 
industry.
The human protein a-synuclein was selected as the initial model system. In this 
experiment, the plasma pencil generated the plasma bullets that were applied directly to 
the prepared a-synuclein fibril samples. The operating conditions o f  the plasma were the 
following: voltage pulse magnitude = 7.5 kV; pulse width = 500 ns; frequency = 5 kHz, 
helium flow rate = 5 L/min. In Figure 23, the intensity o f  the chemical species is on the 
Y-axis and the distance between the plasma pen and sample is on the X-axis. This 
information enables the researcher to determine the distance between the plasm a pencil 
and the biological samples downstream o f the plasm a jet.
The synuclein fibrils in solution were placed into small tubes (0.2 ml), after an 
initial trial on glass slides was not effective, and exposed to the plasma pencil for 
varying lengths o f time (up to 10 minutes). The distance between the nozzle o f  the 
device and the samples was 2 cm. After exposure the fibrils were immediately fixed 
onto 400 mesh formvar coated copper grids for analysis by electron transmission 
microscopy.
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Figure 23. Intensities of He , N2 , N2+, OH and O as a function of distance from 
nozzle
The intensities of the excited He*, N2*, N 2 , OH and O* species emitted by the 
plasma pencil vary with distance from the plasm a pencil. Experimental conditions were 
as follows: voltage pulse magnitude, 7.5 kV; pulse repetition frequency, 5 kHz; helium 
gas flow rate, 5 L/min; pulse width, 500 ns; fibril solution placement, 20 mm from 
pencil. Figure reproduced from Karakas (Karakas et al.. 2010).
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RESULTS
Aliquots were taken from the original tubes used to form the fibrils as described 
in the methods chapter. The fibril solutions were exposed to plasma for varying lengths 
o f  time (2. 4. 6  and 10 minutes). Each tube w as exposed to one time frame. 10 pi 
samples from each tube, was placed onto 400 mesh formvar carbon coated grids and 
stained with 2% uranyl acetate to fix the fibrils. The grids were then analyzed by TEM 
at the Applied Research Center (Newport News. VA).
The experimental results show that the plasma bullets emitted by the plasma 
pencil and delivered to a solution o f  a-synuclein fibrils can break these fibrils into 
smaller units. Protein fibrils are otherwise very stable and difficult to destroy. The 
results (Figure 24 A and B) clearly show that a six minute exposure to the plasm a caused 
major damage to the fibrils, resulting in extensive breakage. Evidence o f breakage 
started showing up after only two minutes exposure to the plasma.
DISCUSSION
Although preliminary, these are extremely important results as this methodology 
provides a facile mechanism whereby protein fibrils can be easily destroyed. This work 
is also very timely as quite recently, three other methods have also been shown to break 
fibrils. These are laser beam irradiation, ultrasonication (Chatani et al., 2009; Ozawa et 
al.. 2009; Yagi et al., 2010) and mechanical breakage by stirring at 1000 rpm (Xue et al., 
2009). However, unlike these methods which rely on physical mechanisms, the cold 
plasma method is based on the chemical species o f  the plasma. Non-equilibrium plasmas 
such as the one generated by the plasma pencil are sources o f  ROS and reactive nitrogen 
species, which are known to chemically denature cellular lipids and proteins. We
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Figure 24. Cold plasma breaks a-synuclein fibrils
(A) TEM image o f mature intact a-synuclein fibrils.
(B) TEM image of the fibrils after six minutes exposure to the plasma plume, showing 
clear evidence o f extensive breakage. Experimental conditions were as follows: voltage 
pulse amplitude, 7.5 kV; pulse repetition frequency. 5 kHz; helium gas flow rate. 5 
L/min; pulse width, 500 ns. Figure reproduced from (Karakas et al., 2010).
expect that under plasma exposure the fibrils undergo chemical reactions that 
compromise their structural as well as chemical integrity.
Microglial cells, which are the macrophages o f  the central nervous system, are 
known to engulf and destroy AP fibrils (Gaikwad et al., 2009). Thus, these cells may 
take up and destroy the broken a-synuclein fibrils generated by the plasma. W hile this 
hypothesis was a driving force behind the cold plasma experiments, the microglial 
experiment has yet to be undertaken.
The fact that protein fibrils are associated with debilitating medical conditions 
such as Parkinson's and possibly A lzheim er's disease makes these results o f  even 
greater relevance. However, what remains to be tested is the cytotoxicity o f  plasm a with
7 9
regard to neurons/neuronal cells. Although studies on other types o f  eukaryotic cells 
have shown that low power doses o f cold plasma do not cause the cells irreversible 




INHIBITION OF p-SYNUCLEIN FIBRIL FORMATION IN VITRO BY a- 
SYNUCLEIN 
INTRODUCTION
a- and P-synuclein colocalize in the presynaptic axon terminals o f  the central 
nervous system including the dopamine producing neurons o f the substantia nigra. A 
number o f  previous studies, both in vitro and in vivo , have indicated that soluble, 
monomeric p-synuclein can inhibit the fibrillation or aggregation o f a-synuclein 
(Shaltiel-Karyo et al., 2010; Vigneswara et al., 2013). This discovery led to the 
suggestion that P-synuclein plays a protective chaperone role in vivo. Inhibition studies 
by Uversky and coworkers, for example, demonstrated that a 1:1 (a:P) m olar ratio 
significantly reduced the rate o f  a-synuclein fibrillation and increased the lag period 
before fibrils were observed in vitro (Uversky et al., 2002). The 1:2 molar ratio further 
increased inhibition and the 1:4 molar ratio resulted in almost complete inhibition even 
after an incubation period o f several weeks (Uversky et al., 2002). Interestingly, one 
study indicated that in patients with Parkinson's disease, the expression o f  P-synuclein 
was down regulated and a-synuclein up-regulated (Beyer et al., 2011). Based on these 
findings, P-synuclein" s physiological role may be the prevention o f  a-synuclein 
fibrillation and suggests that it may have therapeutic value (Park and Lansbury. 2003; 
Hashimoto et al., 2004).
While a-synuclein rapidly and easily forms fibrils in vitro, it appears as if
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formation of P-synuclein fibrils in vitro is neither facile nor rapid (Serpell et al.. 2000; 
Uversky et al.. 2002; Park and Lansbury. 2003). However. Yamin and coworkers 
demonstrated that the inclusion o f certain additives such as divalent metal. Cu2U Zn2+ 
and Pb2+ as well as select pesticides could induce the protein to rapidly form fibrils 
(Yamin et al.. 2005). The aim for conducting inhibition studies in the present 
dissertation research was to elucidate the mechanism for P-synuclein inhibition o f  a- 
synuclein fibrils.
Although a- and p-synuclein fibrils have been produced in various laboratories, 
conditions for fibril formation seem to differ from one lab to another. Therefore 
conditions for a- and p-synuclein fibril formation had to be established for our lab. 
Fibrils formed when the synuclein proteins were each dissolved in 20 mM Tris Base 
containing 0.2 M NaCl, pH 7.5, and incubated at 37°C in a shaking incubator at 190 rpm 
for 14 days (see methods for more details). In order to study the inhibitory effect o f 
synuclein fibrillation, two studies were conducted. In the first experiment, 3.5 mg o f a- 
synuclein and 7 mg o f P-synuclein were combined to give an approximate 1:2 ratio and 
incubated under the physiological conditions mentioned above to form fibrils. In the 
second study, a 1:4 ratio was used (a:p, 4 mg: 16 mg). Fibril formation was monitored by 
thioflavin T fluorescence under physiological conditions in triplicates.
Circular dichroism and atomic force microscopy studies were conducted to 
confirm the presence and character o f p-synuclein fibrils. In order to assess the 
secondary structure content o f  the P-synuclein fibrils, the fibril solution was diluted to 
0.2 mg/ml for far-UV CD and then analyzed in the 200-250 nm far-UV range. Samples 
for atomic force microscopy imaging were diluted to 2 mg/ml. Then a 2 pi aliquot o f  the
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dilute fibrils was air dried onto a grid and then the sample was examined for fibrils using 
the tapping mode atomic force microscope.
RESULTS
Several in vitro trials were conducted until conditions that were conducive to 
produce a- and p-synuclein fibrils were successfully determined. The formation o f 
fibrils was monitored by fluorescence spectroscopy and thioflavin T dye over time 
(Figures 25-26). In the analysis o f the fibril formation o f  a-synuclein (Figure 25), there 
was a lag period between day 0  and day 1 which is the period when the fibril nuclei may 
form. A sharp rise in fluorescence occurred after day 1 indicating growth o f  protein 
fibrils. After five days o f incubation, the thioflavin T fluorescence reached its maximum 
peak when soluble, monomeric a-synuclein was possibly all used. The slight dip in 
fluorescence at day 8 is due to inadequate amount o f fibrils drawn into the pipet when 
sampling the fibril solution, possibly due to matting. Thus the fewer fibrils there were to 
interact with the dye and the lower the fluorescence intensity.
In the analysis o f the fibril formation o f P-synuclein (Figure 26), the lag period 
for the P-synuclein was about three days. Thioflavin T fluorescence levels o ff at about 
day seven when possibly all soluble, monomeric P-synuclein protein solution is used to 
form fibrils. The sharp drop in fluorescence at day eleven is a problem o f  sampling the 
fibrils. As the fibrils grow, they tend to form a mat which makes it difficult to draw them 
into the micropipet tip. Fewer fibrils interacting with the thioflavin T dye can result in 
lower fluorescence intensity.
In both o f the inhibition experiments o f  the 1:2 and 1:4 ratios, it appears that p- 
synuclein fibrillation is inhibited by a-synuclein (Figures. 27-28). This conclusion is
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based on the mixture o f  a- and P-synuclein showing reduced rate o f  fibril formation in 
comparison to P-synuclein alone. In the 1:4 ratio inhibition experiment the a-synuclein 
control does not appear to be forming fibrils. The insert in figure 28 shows that the 4 mg 
a-synuclein control may be forming a small amount o f  fibrils. The fluorescence intensity 
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Figure 25. a-Synuclein time course of fibril formation
6  mg/ml o f a-synuclein in Tris Base buffer. pH 7.5, was incubated at 37°C with 
agitation at 190 rpm in sealed sterile eppendorf tubes. a-Synuclein fibrillation was 
monitored by thioflavin T fluorescence. 15 pi o f  synuclein fibril solution was added to 3 
mis o f 50 mM Thioflavin T solution. The excitation and emission wavelengths were 440 
nm and 485 nm, respectively. A graph was constructed using the scientific graphing 
program, SigmaPlot (version 11). Error bars were derived from calculated standard 
deviations among replicates (n=3).
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Figure 26. p-Synuclein time course of fibril formation
7 mg/ml o f P-sy nuclein in Tris Base buffer, pH 7.5, was incubated at 37°C with 
agitation at 190 rpm in sealed sterile eppendorf tubes. p-Synuclein fibrillation was 
monitored by thioflavin T fluorescence. 15 pis o f  synuclein fibril solution was added to 
3 mis o f 50 mM Thioflavin T solution. The excitation and emission wavelengths were 
440 nm and 485 nm, respectively. The graph was constructed using the scientific 
graphing program, Sigma Plot (version 11). Error bars were derived from the standard 
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Figure 27. Inhibition studies of an approximate 1:2 ratio
Open triangle = p-synuclein control (16 mg/ml); filled/inverted triangle = p-synuclein 
control (7 mg/ml); open circle = (a:P; 3.5 mg:7 mg); filled circle = a-synuclein control 
(3.5 mg/ml), a- and P-Synuclein were incubated in Tris Base buffer, pH 7.5 at 37°C with 
agitation at 190 rpm in sealed sterile eppendorf tubes. Fibril formation was monitored by 
thioflavin T fluorescence by adding 15 pis o f  synuclein fibril solution to 3 mis o f  50 pM 
Thioflavin T solution. The excitation and emission wavelengths were 440 nm and 485 
nm, respectively. The graph was constructed using the scientific graphing program. 
Sigma Plot (version 11). Error bars were derived from the standard deviations among 
replicates (n=3). p-Synuclein fibril growth in the mixture appears to be inhibited by the 
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Figure 28. Inhibition studies of an approximate 1:4 ratio
Filled/inverted triangles = p-synuclein control (16 mg/ml); open circles = (a:P; 4 mg: 16 
mg); filled circles = a-synuclein control (4 mg/ml), a- and p-Synuclein were solubilized 
in Tris Base buffer, pH 7.5, and incubated at 37°C with agitation at 190 rpm. Fibril 
formation was monitored by thioflavin T fluorescence after adding 15 pis o f  synuclein 
fibril solution to 3 mis o f  50 pM  Thioflavin T solution. The excitation and emission 
wavelengths were 440 nm and 485 nm. respectively. Error bars are derived from 
calculated standard deviations among replicates (n=3). The insert is an expanded view of 
the fibrillation o f the a-synuclein control 4 mg/ml. The P-synuclein fibrillation appears 
to be inhibited by a-synuclein.
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Results of the far-UV circular dichroism analysis indicated that monomeric p- 
synuclein is intrinsically unstructured in solution. The negative molar ellipticity at 
around 200 nm wavelength is characteristic o f a random coil conformation (Figure 29) 
(Whitmore and Wallace. 2008). After incubating the protein at 37°C. with agitation, the 
P-synuclein fibrils appears to have a P-sheet secondary structure content as seemingly 
evidenced by the beta-ellipticity with a single minimum at approximately 216 nm (Kelly 
et al.. 2005).
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Figure 29. Far-UY circular dichroism analysis of monomeric P-synuclein
Monomeric P-synuclein at concentration 0.2 mg/ml in Tris base buffer, pH 7.5 was 
scanned been 200 nm and 250 nm. The machine signal was converted to molar 
ellipticity which takes into account the concentration o f the protein being measured. 
Spectra were repeated 30 times and the average was graphed and analyzed using Sigma 
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Figure 30. Far-UV circular dichroism analysis of p-synuclein fibrils
p-synuclein fibril solution at concentration 0.2 mg/ml in Tris Base buffer. pH 7.5 was 
scanned between 200 nm and 250 nm. The machine signal was converted to molar 
ellipticity which takes into account the concentration o f the protein being measured. The 
spectra were repeated 30 times and the average was graphed and analyzed using Sigma 
Plot (version 10). The presence o f P-sheet structure is indicated by the signature beta- 
ellipticity with a single minimum at approximately 216 nm in comparison to the random 
coil signature.
AFM studies were conducted to visually confirm the presence o f  fibular 
structures. Subjectively, the AFM images o f a-synuclein fibrils (Figure 31 A and B) are 
shorter and more dispersed in comparison to what is seen in the literature, which tend to 
be elongated filaments (Conway et al., 2000; Sweers et al.. 2012). This result may be
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due to the nature o f using AFM versus TEM and the variability in making fibrils in 
general. In addition, the scales vary between studies (Bisaglia et al.. 2009).
Conversely. P-synuclein has many long entangled fibrils (Figure 32 A and B) which is 
similar to reports o f  a-synuclein fibrils (Conway et al.. 2000: Lemkau et al.. 2013). p- 
Synuclein forms long entangled fibrils in the presence o f sodium dodecyl sulfate (Rivers 
et al.. 2008). Size analysis indicates a possible "matting effect" or oligom erization o f 
single fibril strands o f  P-synuclein. The original concentrations o f the proteins that made 
the 1:2 molar ratio (a:P) were 3.5 mg for a-synuclein and 7 mg for P-synuclein. The a / p 
synuclein amyloid fibril solution at 2  mg/ml concentration was used for microscopic 
imaging. Subjectively, the mixed fibrils (1 :2 ratio) appear to have a thicker morphology 
more similar to the p-synuclein fibrils (Figure 33 A and B).
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Figure 31. Tapping mode atomic force microscopy of a-synuclein fibrils
(A) 2D image o f  a-synuclein fibrils is shown at high magnification. 2 gil o f  a 2 mg/ml 
solution was imaged.
(B) 2D image o f  a-synuclein fibrils is shown at low magnification. 2 gl o f  a 2 mg/ml 
solution was imaged.
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Figure 32. Tapping mode atomic force microscopy of p-synuclein fibrils
(A) 2D image o f P-synuclein fibrils is shown at high magnification. 2 pi o f  a 2 mg/ml 
solution was imaged.
(B) 3D image o f P-synuclein fibrils is shown at high magnification. 2 pi o f  a 2 mg/ml 
solution was imaged.
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Figure 33. Tapping mode atomic force microscopy of a/p-synuclein fibrils
(A) 2-D image o f  the a/p-synuclein fibrils is shown at high magnification. 2 jal o f  a 2 
mg/ml solution was imaged.
(B) 3D image o f  a/p-synuclein fibrils is shown at high magnification. 2 pi o f a 2 mg/ml 
solution was imaged.
DISCUSSION
Interestingly, under the experimental conditions o f  our study, we observe that P- 
synuclein can form fibrils rapidly under the same conditions as a-synuclein. P-synuclein 
fibrils have higher fluorescence intensity when they bind thioflavin T dye compared 
with those of a-synuclein. In the literature, P-synuclein forms fibrils rapidly in the 
presence o f sodium dodecyl sulfate (mimics lipid micelles) and metal ions (Yamin et al., 
2005; Rivers et al., 2008). To the best o f  our knowledge this is the first study o f a co­
incubation o f two fibril forming proteins under fibrillation promoting conditions, which 
may be the reason this observation has not been previously reported. Further, we
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observ e that a-synuclein can inhibit the formation o f P-synuclein fibrils when incubated 
together. In the two trials, the P-synuclein fibrils formed at a similar rate irrespective o f 
concentration. One or a combination o f the different forms o f a-synuclein including the 
monomer, protofibril or mature fibrils inhibited P-synuclein fibrillation. Considering the 
putative chaperone activity of the synucleins, it is possible that the monomeric a- 
synuclein decelerated the aggregation of the P-synuclein by binding it to form a soluble 
high molecular weight (MW) complex. Rekas and coworkers have reported that the full 
length a-synuclein and the a-synuclein (61-140 residues) fragment can prevent a heat 
stressed catalase enzyme from aggregating in vitro (Rekas et al., 2012). They also 
observed that the fibrillated full length a-synuclein had better chaperone activity than the 
soluble monomer. Their results appear to suggest that the chaperone activity o f a- 
synuclein is in the amyloidogenic region (61-95). The C-terminus solubilizes the high 
molecular complex o f  the synuclein and its substrate thereby preventing its precipitation 
or aggregation (Park et al., 2002; Rekas et al., 2012). It appears that the P-sheet 
conformation enhances a-synuclein’s protein-protein interaction with its substrates. Our 
studies also indicate that p-synuclein fibrils can form reasonably rapidly under the same 
conditions in vitro as a-synuclein, with p-synuclein showing a short lag phase o f 
approximately 2-3 days (Figure 26). In our study, a form(s) o f  a-synuclein was capable 
o f inhibiting P-synuclein fibrillation, which at the time the study was conducted was a 
very novel finding.
Also, most importantly the results o f  this research suggest that when two proteins 
capable o f  forming fibrils under the same conditions are incubated together, an 
inhibitory effect can occur. Our results suggest that two different fibril forming proteins
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can exert an inhibitory effect on each other in vivo, although in nature, fibril associated 
proteins each occupy distinct niches within or outside various tissues in the body. These 
findings may provide new lines o f investigation regarding the design o f  inhibitors as 
well as facilitate our general understanding o f the mechanism of fibril formation. The 
outcome o f  this study has not yet answered the initial goal to understand the mechanism 




INITIAL INVESTIGATION TO ISOLATE SYNUCLEIN TETRAMERS 
INTRODUCTION
Since their isolation from the brains o f  vertebrates, the synuclein proteins have 
been believed to exist only in an unstructured conformation (Lavedan, 1998; Uversky et 
al., 2002). This assumption may have arisen from the fact that the protocols used in the 
standard purification process involves a step in which the bacterial lysate is boiled in a 
water bath at 100°C for thirty minutes (Conway et al., 1998). As a result, any multimeric 
species o f  the proteins may have been dissociated and denatured by the heat.
Researchers have been able to determine structures o f  full-length and segments 
o f  a-synuclein. Some examples o f such structures include micelle-bound full length a- 
synuclein (pdb code: lx q 8 ), full length a-synuclein bound to detergent sodium lauroyl 
sarcosinate (pdb code: 2kkw), N-terminally acetylated a-synuclein peptide complexed 
with calmodulin (pdb code: 2m55) (Figure 34) (Ulmer et al., 2005; Rao et al., 2010; 
Gruschus et al., 2013)(Ulmer et al., 2005; Rao et al., 2010; Gruschus et al., 2013). NMR 
structures o f fragments o f a-synuclein bound to maltose-binding protein have been 
determined including segments 1-19 residues (pdb code: 3q25), segment 9-42 residues 
(pdb code: 3q26), segment 32-57 residues (pdb code: 3q27) and segment 58-79 residues 
(pdb code:3q28) (Zhao et al., 2011).
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Figure 34. Model structure of N-terminally acetylated a-synuclein peptide (cyan) 
complexed with calmodulin protein (blue) (pdb code: 2m55)
The unbound peptide (yellow) forms a helical conformation (cyan) when complexed 
with the calmodulin protein (Gruschus et a l .  2013). The acetyl (CH3-CO) group is 
attached to methionine l(M ') o f  a-synuclein (Kang et al., 2012). This structure is 
visualized with Rasmol (version 2.7.1).
In spite o f conflicting reports from various groups at Harvard University,
Stanford University and Ecole Polytechnique Federale de Lausanne in Switzerland about 
the native structure o f the synucleins, a growing body o f  information suggests that a 
multimeric form of the proteins may exist in equilibrium with its monomeric fraction 
(Wang et al., 2011). Protocols in which denaturing conditions, such as boiling the lysate 
were omitted during the purification process, yielded a helical tetrameric a-synuclein 
(Bartels et al., 2011; Wang et al.. 2011; Dettmer et al., 2013). The investigators suggest 
that the tetramer is composed o f  helices (Figure 35).
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Figure 35. A model structure of the helical tetrameric a-synuclein
The helices are represented by the cylinders. Each pair o f  cylinders is an a-helix with an 
N-and C-terminus. The portion o f the a-synuclein that makes a-helix includes residues 
1-103 which is the N-terminal region o f the synuclein. ‘N ’ indicates the N-terminus and 
‘C ’ indicates the C-terminus. This figure is reproduced from Wang (W ang et al., 2011).
All o f these findings are still at their infant stage and need further investigation. 
In our attempt to isolate the multimeric form o f P-synuclein, recombinant P-synuclein 
was expressed in Rosetta 2(DE3) cells. Hepes buffer which offers a more conducive 
environment for the multimeric forms than the Tris Base was used. A fter breaking open 
the cells by sonication, the lysate was not boiled in order to preserve the multimeric 
forms o f P-synuclein. In addition, we added to the Hepes buffer glycerol and n-octyl-P- 
D-glucopyranoside which were meant to stabilize the multimeric forms o f  the protein. 
The final step in isolating the multimeric P-synuclein involved gel-filtration. The 
multimeric P-synuclein was eluted with 0.15 M NaCl in Hepes buffer and stored in 1 ml
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aliquots at -80°C. The details o f  the first and final steps in the purification process are 
described in the Materials and Methods section. Far-UV studies were conducted to 
determine the secondary structure content o f the P-synuclein.
RESULTS
The expression of recombinant human p-synuclein in which we did not boil the 
bacterial lysate, yielded a high MW P-synuclein. A protein standard, glutamic 
dehydrogenase initially believed to have a MW o f  55.6 kDa was run through the same 
Sephadex G-75 gel filtration size exclusion showed a sim ilar elution profile (Figures 36- 
37) as the p-synuclein complex. A MW o f 55.6 kD a which is almost 4 times the MW o f 
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Figure 36. G-75 size exclusion chromatography elution profile of a high molecular 
weight P-synuclein
The high MW P-synuclein eluted with a sharp peak at fraction 20. Each fraction is 5 ml. 
The absorbance o f  protein in each fraction was determined at 280 nm using a UV-Vis 
spectrophotometer by hand. The graph was constructed by plotting absorbance against 
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Figure 37. G-75 size exclusion chromatography elution profiles of p- and a- 
synuclein and glutamic dehydrogenase
p-synuclein complex (dashed line), a-synuclein complex (dotted line) and glutamic 
dehydrogenase (solid line) are all eluting at fraction 20. Each protein was run separately. 
The absorbance o f  the protein in each fraction was determined at 280 nm using a UV- 
Vis spectrophotometer by hand. The graph of each protein was constructed by plotting 
absorbance against fraction number in M icrosoft Excel (version 2010). The m olecular 
weight o f  glutamic dehydrogenase is annotated on the graph according to the weight 
listed on the bottle purchased from Sigma-Aldrich.
A computer program K2D3 (Louis-Jeune et al.. 2011) used the far-UV circular 
dichroism spectra to estimate that the P-synuclein complex was 6 8 % a-helical, 6.7% P- 
sheet and 25.2% random coil (Figure 38). The computer program com pares the CD 
spectrum o f the protein under investigation to a reference set of CD spectra o f  proteins
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whose structures have been resolved. The program then predicts or estimates the 
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Figure 38. Far-UV circular dichroism spectra for P-synuclein random coil (empty 
circles) and high molecular weight p-synuclein (filled circles)
According to the K2D3 program prediction o f secondary structure, the high MW (3- 
synuclein is 6 8 % helical, 6.7% pand 25.2% random coil and the random coil is 4% a- 
helical, 34.9% P-sheet and 61.1% random coil.
DISCUSSION
The groups o f researchers who attempted to isolate the multimeric form o f  a- 
synuclein reported a range of molecular weights for the complex: 56 kDa, 58 kDa and 
60 kDa (Bartels et al.. 2011; Wang et al., 2011; Dettmer et al.. 2013). Our P-synuclein
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complex under non-denaturing conditions is about 56 kDa or larger. (We discuss how to 
ascertain the absolute size in future work.) A small fraction o f the expressed P-synuclein 
was a multimeric complex (0.5 mg/L o f  Luria broth culture). The rem ainder o f  the 
protein was the monomeric form. One group that successfully isolated a tetrameric a- 
synuclein reported a yield o f 1 mg/L o f  Luria broth culture (Wang et al.. 2011). From 
the disproportionately small yield o f multimeric protein versus the monomeric protein, it 
is possible that the multimeric form o f the synucleins does not normally exist in the 
cytoplasm but may exist when bound to the cell membrane. Reports in the literature 
indicate that the synucleins acquire secondary structure when bound to the cell 
membrane (Jain et al., 2013; Wietek et al., 2013). Therefore, when recombinant 
synucleins are expressed in bacteria, the multimeric forms are likely to fall apart in the 
cytoplasm o f the bacterial cells.
The acetylation o f the a-synuclein in the neuronal cells has been shown to 
enhance and stabilize the helical structure o f the membrane bound protein (Trexler and 
Rhoades, 2012; Dikiy and Eliezer, 2014). In addition, an acetylated N-term inus o f  a- 
synuclein has been shown to decelerate fibrillation (Kang et al., 2012; Kang et al.,
2013). When the synuclein proteins are expressed in bacterial cells, the acetylation 
modification does not take place. The expression o f the synuclein in bacterial cells 
deprives the protein o f the essential acetylation modification, which appears to be 
critical for helical formation. However, one cannot base the formation o f multimeric 
complex o f the synucleins on N-terminus acetylation alone. Other factors in the cell, yet 
to be elucidated, may also be critical for the formation and stabilization o f  the 
multimeric synucleins.
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Additionally, in our experiment, glutamic dehydrogenase was selected based on 
looking for a protein that would serve as an ideal MW m arker for the gel-filtration 
column. The choice was based on studying the available protein and their reported 
molecular weights in the Sigma-Aldrich catalogue. However, subsequently, after the 
studies were conducted and in discussion with Professor Ellis Bell (Richmond 
University. Virginia), he indicated that at neutral pH this protein is a hexamer 
(Sakamoto et al., 1975; Norouzi et al., 2010). Therefore, at pH 7.4. the eluted glutamic 
dehydrogenase was possibly a hexamer which is six times the size o f  the monom er (55.6 
kDa). The G-75 size exclusion column cannot optimally separate proteins greater than 
60 kDa. All proteins that are equal or greater than 55.6 kDa can elute to the same 
location. Thus, the p-synuclein eluted may either be a higher MW species than originally 
thought or be the desired tetramer but was not well separated in the column and came 
out in the void volume. The methodology to further test the size and confirm that the 
eluted species is actually a tetramer is discussed in Future Work.
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CHAPTER VI 
COMPUTATIONAL ANALYSIS OF THE SYNUCLEINS 
INTRODUCTION
New protein sequences continue to be added to those already stored in the 
protein and nucleic acid databases at the National Center o f  Biotechnology Information 
(NCBI) in Maryland. Their corresponding protein structures are being determined at a 
slower rate and are deposited in the Research Collaboratory for Structural 
Bioinformatics Protein Data Bank (RCSB-PDB) at Rutgers University (New Jersey). 
Computational approaches are now complementing experimental methods to accelerate 
the process o f determining the structure and biological function o f proteins.
The structure and function o f an uncharacterized protein may be elucidated from 
its ancestral relatives whose native structure and function have been resolved. Ancestral 
relatives are identified by certain features that persist in a superfamily from one 
generation to the next. Despite structural modifications as the protein evolves over time, 
evolution tends to conserve those motifs o f the sequence that are responsible for 
structure stability and function (Redfern et al., 2009).
In order to trace the origins o f  proteins, researchers use bioinformatics 
approaches which include searching for related protein sequences, searching for related 
protein structures and analyzing the nature o f  the relationship. Bioinformatics algorithms 
which include PSI-BLAST (Altschul et al., 1997), MUSCLE (Edgar. 2004) and scan
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ProSite (Falquet et al.. 2002) are employed to construct evolutionary families and 
superfamilies o f  proteins.
A protein family is composed o f proteins that originate from a common ancestor 
and generally share a common structure and function and significant sequence identity. 
The work o f Todd. Orengo and Thornton and other research groups led to the conclusion 
that proteins which are >40% similar in their sequences have a specific conserved 
function (Todd et al.. 2001). However, there are instances when the same gene can 
encode a protein with a dual function or multiple functions. For example, in a duck 
(Anasplatyrhynchos). the s-crystallin structural protein in the eye lens can also serve as 
an enolase and lactate dehydrogenase (W istow et al., 1987; Wistow et al., 1988). Such 
proteins with multiple functions are now referred to as moonlighting proteins (Huberts 
and van der Klei, 2010). A superfamily is composed o f  proteins that have a common 
ancestor, a common 3D structure and conserved features for folding but little or no 





Family Com m on
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Figure 39. Hypothetical schematic o f a protein family and superfamily
Each blue dashed circle is a family o f  proteins. The green circle contains all the families 
o f proteins that make a superfamily. Proteins in the superfamily are related by a 
common ancestor (solid purple circle). They can be identified by a consensual sequence 
signature, common 3D structure and may have a  similar function. Segments o f  a protein 
that are responsible for structural stability and function are conserved as the protein 
evolves in order to adapt to its environment.
A number o f factors which cause changes in the structure and function o f a 
protein as it evolves include gene deletion, gene insertion, point mutation, gene 
duplication and oligomerization (Garrett and Grisham, 2013). In gene deletion and 
insertion, one or more base pairs are removed from or added to a gene, respectively. The 
deletion or insertion can cause a frame shift resulting in inappropriate incorporation o f  
the next amino acid residues in the protein encoded by the gene. Alterations in the amino
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acid sequence may lead to a change in the conformation and/or the function o f  the 
protein. Point mutations where a single nucleotide is replaced by another may result in a 
change in the coded amino acid residue. Gene duplication can result in a change of 
function when one o f the copies undergoes mutation (Magadum et al., 2013). Variation 
o f structure and function may result from oligomerization when multiple domains, either 
homo- or heterodimers, trimers or tetramers. are formed (Zhang, 2003; Kottyan et al.. 
2012).
Researchers across the world employ both experimental and computational 
methods to determine the native structure and function o f  the synuclein family yet both 
remain elusive and controversial. The results published in recent Nature and Proceeding 
o f the National Academy o f Science journals indicate that a-synuclein forms a helical 
tetramer (Bartels et al., 2011; Wang et al., 2011; Dettmer et al., 2013). This folded form 
o f a-synuclein may be its natural structure in brain tissue but remains highly 
controversial. We employed bioinformatics algorithms including PSI-BLAST,
MUSCLE, scan prosite and scan m otif to construct a superfamily in order to further our 
understanding o f the structure and as yet unresolved native function o f  the a-, P~ and y- 
synucleins. Our hypothesis proposed that identifying synuclein relatives, whose 3D 
structure and function have been resolved, would facilitate the elucidation o f  the 
physiological structure and function o f  the synucleins and illuminate their evolutionary 
history. Understanding the structure and function o f the synucleins would facilitate an 
understanding o f the mechanisms o f protein folding and misfolding, and potentially 
assist in finding an effective therapy for protein misfolding related diseases including 
Parkinson's disease.
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Human a-. P- and y-synucleins were the probe sequences used to identify similar 
sequences in protein databases. The similarity was considered significant when the 
statistical e-value was less than 5 x 10'3. Then, the identified proteins were aligned to the 
synucleins from various species in order to establish positions of identity and similarity 
in the sequences. A phylogenetic tree was also constructed from the human synucleins 
and the identified related proteins in order to determine their ancestor.
Unlike humans who succumb to neurodegenerative diseases as they age. animals 
such as the giant tortoise can live for 255 years. A further analysis o f  the synuclein 
alignments was made in order to identify any differences between humans and other 
animals, particularly for those that live longer than humans. Neurodegenerative diseases 
have been observed in domestic animals including horses, dogs and cats (Siso et al., 
2006).
RESULTS
Among the a-synuclein proteins, interestingly there is variation in size. The sizes 
range from 121 to 151 amino acid residues. In the case o f  the house mouse a-synuclein, 
an extra eleven amino acid residues have been added to the N-terminal o f  the protein. 
The minke whale a-synuclein protein lacks the first four residues at the N-terminal and 
the last 12 residues at the C-terminal (Figure 40).
The PSI-BLAST search with hum an a-, p- and y-synuclein probe sequences 
identified an endoglucanase enzyme from the bacterium Acetobacter pomorum, the 
CRE-DUR-1 protein from a nematode and the Tasmanian Devil protein. The Tasmanian 
Devil protein identified cytochrome c protein from the spiral bacterium Thiomicrospira 
crunogena. The percentage similarity between the synucleins and their related proteins.
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the e-values and the portion o f the synucleins (% coverage) similar to the related 
proteins are summarized in Tables 2-4.
Table 2. Similarity' between a-synuclein and the three disparate proteins
Protein % a-synuclein coverage % Similarity E-value
Endoglucanase 65 35 1 x 1 0 '3
CRE-DUR-1 77 36 1 x 1 0 ’5
Tasmanian Devil 71 65 1 x 1 0 ‘28
Table 3. Similarity between p-synuclein and the three disparate proteins 
Protein % p-synuclein coverage % Similarity E-value
Endoglucanase 95 20 2 x 1 O' 3
CRE-DUR-1 76 32 2 x l 0 ' 6
Tasmanian Devil 77 55 2 x l 0 "27
Table 4. Similarity between y-synuclein and the three disparate proteins
Protein % y-synuclein coverage % Similarity E-value
Endoglucanase 81 27 1 x 1 0 " 3
CRE-DUR-1 96 36 4 x  1 0 '10
Tasmanian Devil 95 80 2 x 10~54
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Endoglucanase enzyme
The three human synucleins share 20-35% identity with the endoglucanase. The 
putative (predicted from its nucleotide sequence) endoglucanase protein contains several 
conserv ed KTKEGV sequences. A multiple sequence alignment o f endoglucanase w ith 
a-synuclein proteins from 14 different species was constructed (Figure 40). The blue 
color represents positions o f identity; the purple are positions with hydrophobic 
character; the red are positions o f  hydrophilic character and the green indicates positions 
where a given amino acid residue is highly prevalent. The endoglucanase enzyme is 
composed o f 218 amino acid residues and the portion which is significantly similar to 
the N-terminal region of the synucleins is between amino acid residues 61 and 177. The 
first 60 residues have no relationship with the a-synuclein proteins and do not contain 
the KTKEGV sequences. The second, fourth and fifth KTKEGV motifs o f  the a- 
synucleins are highly identical to those o f the endoglucanase enzyme. The most 
conserved residues between the synucleins and the endoglucanase enzyme are 




61  AEEGVI.GRAWDNTRE C . T e h a W N K T K E G T N K A W E K T S N  GTE1CVWDK TKD OSRKAMDKTSEG w n d o q l u c a n e a e
1 — MDVFMKGLSKAKEGWAAAEKTKQGVAEAAGKTKEGVLTVGSKTKEG W H G  h u m a n
1 — MDALMKGFSMAKEGMAAAAEKTKQSVSDAAEKTKEGVMXMGTKTKE S s e a  l a m p r e y
1 — MDVFMKGLSKAKEGWAAAEKTKQGVAEAAGKTKEGVLTVGSKTKEG---------------- W H G  c h i n e s *  h a m s t e r
1 — MDVFMKGLSKAKEGWAAAEKTKQGVAEAAGKTKEGVLrVGSKTKEG----------------W H G  m o l e  r a t
1 — MDVEUKGLNKAKEGWAAAEKTKQGVAEAAGKTKE GVLTVGSRTKE G---------------- W H G  c h i c k e n
1 — MDVFWKGLSKAKE GWAAAEKTKQGVAEAAGKTKE GVLTVGSRTKE G---------------- W H G  z e b r a  f i n c h
1 — MDVFMKGLSKAKEGWAAAEKTKQGVAEAAGKTKEGVI.TVGSKTKEG----------------W H G  n o r m ;  r a t
10  LAMDVFMKGLSKAKEGWAAAEKTKQGVAEAAGKTKEGVLTVGSKTKEG W H G  h o u s e  m o u s e
1 ------------ MKGLSKAKEGWAAAEKTKQGVAEAAEKTKEGVLTVGSKTKEG---------------- W H G  m i n k *  W h a le
1 ------------ MKGLSKAKEGWAAAEKTKQGVAEAAEKTKEGVLTVGSKTKEG---------------- W H G  h a r b o r  p o r p o i a e
1 — MDVFMKGLSKAKEGWAAAEKTKQGVAEAAGKTKEGVLTVGSKTKEG----------------W H G  e l e p h a n t
1 — MDVFMKGLSKAKEGWAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEG----------------W H G  s q u i r r e l  m o n k e y
1 — MDVEXKGLSKAKEGWAAAEKTKQGVAEAAGKTKEGVX.YVGSKTKEG----------------W H G  o r a n g u t a n
1 — MDVFMKGLSKAKEGWAAAEKTKQGVAEAAGKTKEGVX.YVGSKTKEG----------------W H G  s h e e p
1 — MDVFMKGLSKAKEGWAAAEKTKQGVAZAAGRTKEGVLTVGSKTKEG----------------W H G  c a t t l e
1 — MDVEMKGLSKAKEGWAAAEKTKQGVAEAAGKTKEGVLTVGSKTKEG----------------W H G  p i g
V VI VII
1 2 1  s e k a w d ^ t k e g ^ h n a w d ^ t h e g W k t w d k t k e g s h k v w n k t s e g t d k v w d k - t i c d g s r k a
5 2  VATVAEKTKEQyTNVGGAWTGVTAVAQKTVEGAGSIAAATGFVlCKDQLGK-NEEGAPQ-
4 8  VATVAEKTKE--------AGGAVVSGVTSVAHKTVEGAENMAAATGLVKKGEPGA-KPEGMP—
5 2  VTTVAEKTKEQVTNVGGAWTGVTAVAQKTVEGAGNIAAATGFVKKDQLGK— TGGGSIA
5 2  VTTVAEKTKEQVTNVGGAWTGVTAVAQKTVEGAGHIAAATGFVKKDQLGK-------------------
5 2  VTTVAEKTKEQVSNVGGAWTGVTAVAQKTVEGAGNIAAATGI.VKKDQIAKQNEEGFLQ- 
5 2  VTTVAEKTKEQVSNVGGAWTGVTAVAQKTVEGAGNIAAATGLVKKDQLAKQHEEGFIiQ- 
5 2  VTTVAEKTKEQVTNVGGAWTGVTAVAQKrVEGAGNIAAATGFVKKDQMGK-GEEGTPQ- 
6 3  VTTVAEKT KEQVTNVGGAVVT GVTAVAQK TVEGAGNIAAATGFVKKDQMGK-GEEGYPQ- 
4 8  VTTVAEKTKEQVTNVGEAWTGVTAVAQKTVEGAGSIAAATGPGKKDQLGK— SEGASQ- 
4 8  VTrVAEKTKEQVTNVGEAWTGVTAVAQKTVEGAGSIAAATGFGKKDQLGK— SEGASQ- 
5 2  VTTVAEKTKEQVTMVGEAWTGVTAVAQKTVEGAGSIAAATGFGKKDQMGK-GEEGAPQ- 
5 2  VATVAEKTKEQVTNVGGAWTGVTAVAQKTVEGAGNIAAATGFVKKDHLGK-SEEGAPQ- 
5 2  VATVAEKTKEQVTNVGGAWTGVTAVAQKTVEGAGSIAAATGFVKKDQLGK-NEEGATQ- 
5 2  VTTVAEKTKEQVTHVGEAWTGVTAVAQKTVEGAGSIAAATGPOCKDHLGK-GEEGASQ- 
5 2  VTrVAEKTKEQVTNVGEAWTGVTAVAQKTVEGAGSIAAATGFGKKDHMGK-GEEGASQ- 
5 2  VTTVAEKTKEOVTNVGEAWTGVTAVAQKTVEGAGSIAAATGFGKKDQLGK-NEEGAPQ-
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c h i c k e n
z e b r a  f i n c h
n o r m ;  r a t
h o u s e  m o u s e
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Figure 40. Sequence alignment of 16 variant a-synucleins with endoglucanase
The portion of the protein that is similar to the a-synucleins is between 
residues 61 and 177. The first 60 amino acid residues o f  the endoglucanase do not 
contain the KTK(E/Q)GV sequences. The portion o f the a-synucleins that is similar to 
the endoglucanase lies between residues 1 and 109. The KTK(E/)GV repeats are marked 
I-VII. In the sixth sequence, the KTKE residues have been substituted. Color scheme: 
blue (sequence identity); red (conserved hydrophilic character); purple (conserved 
hydrophobic character); green indicates positions where a residue is highly prevalent. 
The alignment was constructed with MUSCLE (Edgar, 2004: Me William et al.. 2013).
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Figure 41. Regions of human a-synuclein (pdb code: lxq8) similar to the 
endoglucanase
The color coding in the figure indicates the regions o f the human a-synuclein that are 
similar to the endoglucanase enzyme. The figure was rotated 180 degrees. Color 
scheme: blue (sequence identity); red (conserved hydrophilic character); purple 
(conserved hydrophobic character); green indicates positions where a residue is highly 
prevalent. The letter ‘N ’ designates the N-terminus and ‘C ’ designates the C-terminus o f 
the protein. These structures are visualized with Rasmol (version 2.7.1).
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The portion o f the endoglucanase that shares identity with the P-synucleins is 
between amino acid residues 48 and 163 (Figure 42). The shift from the 61-177 residue 
a-synuclein alignment is a result o f the long p-synuclein from the naked mole rat. The 
protein is composed o f  210 amino acid residues, with a 76 amino acid peptide added to 
the N-terminus. The second repeat sequence o f the P-synucleins has the highest degree 
o f identity with the endoglucanase.
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4 8  GAAM FA LSLPG W iA EEG V LG RA W D H TO EG TEH A W N K TraG TN K A W EK TSN G TEK V W D fri? 
-----------------------------------M EV FM K G LSK A K EG W A A A EK TK Q G V A EA A EK TK EG V LY V G SK T-
-----------------------------------m e v f m k g l s k a k e g w a a a e k t k q g v a e a a e k t k e g v l y v g s k t -
-----------------------------------m d v f m k g l s m a k e g w a a a e k t k q g v t e a a e k t k e g v l y v g s k t r
-----------------------------------M DVFM KGLSM AKEGW AAAEKTKQGVTEAAEKTKEGVLYVGSKTR
-----------------------------------m d v f m k g l s m a k e  g w a a a e  k t  k q g v t e a a e  k  t k e  g v l y v g s  KT -
-----------------------------------MDVFMKGLSMAKE G W A A A EK TK Q G V TEA A EK TK EG V LTV G SK TK
V CV CDRV TW CVQAARD VFMKGLSMAKE G W A A A E  KTKQGVTEAAE K TK E GVLYVGSKTR
-----------------------------------m d v f m k g l s m a k e g w a a a e k t k q g v t e a a e k t k e  g v l y v g s k t r
-----------------------------------MDVFMKGLSMAKE G W A A A EK TK Q G V TEA A EK TK E GVLYVGSKTR
-----------------------------------M DVFM KGLSKAKDGM AIAAEKTKEGAALAAEKTKEGAM FIGTKAK
-----------------------------------MDVFMKGLSKAKEGMAVAAEKTKEGVAVAAEKTKEGVMFVGSKTK
-----------------------------------m d v f m k g l s k a k e g m a v a a e k t k e g v a v a a e k t k e g v m f v g t k a k
-----------------------------------m d v f m k g l s k a k e g m a v a a e k t k e g v a v a a e k t k e g v m f v g n k a k
-----------------------------------MDVFMKGLSKAKE GMAVAAE K TKE GVAVAAEK TK E GVMFVGNKAK
e n d o g l u c a n a s e  
c h i c k e n  
z e b r a  f i n c h  
r h e s u s  m o n k e y  
h u m a n
h o u s e  m o u s e
n o r w a y  r a t
m o l e  r a t
c a t t l e
p i g
s a l m o n
z e b r a f i s h
r a i n b o w  s m e l t
f u g u  r u b r i p e s
s a b l e  f i s h
V
1 0 8  D G S RKAWDKTSEGSEKAW DRTKEGTHNAW DKTHEGTEKTW DKTKEGSHKVW NKTSE
4 5  Q G W Q G V T  SVAE KA1CE QAS Q LG EA A FS G A G N I AA A  T G LV K K EE FPA D  LKAEEVAQEAVE E
4 5  Q G W Q G V TSV A EK A K EQ A SQ LG EA A FSG A G N IA A A TG X V K K EEFPA D LK A EEV A Q EA V EE 
4  6  EGVVQ---------V A EK TK EQ A SH LG G A V FSG A G N IA A A TG LV K R EEFPTD LK PEEV A Q EA A EE
4 6  E  G W Q G V k S  V A E  K TKE QAS H L  GGAVF S  G A G N I AAA T G LV K R EE F P T D  L K P E E  VAQEAAE E
4 5  SG W Q G V A SV A EK TK EQ A SH LG G A V FSG A G N IA A A TG LV K K EEFPTD LK PEEV A Q EA A EE 
1 2 1  E  G W Q G V A SV A E K TKE QAS H L  GGAVF S  GAGN I  AA A  T G LV K K EE F P T D  LK PEEV A Q EA A E E
4 6  E G W Q G V A SV A E K TK E Q A SH L G G A V FSG A G N IA A A T G IV K K EE FPSD L K PEE V A Q E A A E E  
4 6  E  G W Q G V A S V A E K TKEQ A S H LG G A V FS G A G N I AAA. T G LV K K EE F P T D  LK PEEV A Q EA A E E 
4 6  E  G W Q G V A S VAE K TKE Q ASH LGGAVFSGAGN IA A A TG LV K K E EFPA D L K FEE V A Q E A A EE
4 6  DGV----------------------------GSAKOLAGGAM-------GN IA A A TG LG K K D EFPSD M N PEEY G Q EA M E-
4 6  D SV  A TV A EK TK EQ A SQ LG G A V M SG A G N IA A A TG LV K K D EFPSD M N FE-FG Q EA TEE
4 6  D SV  GSGAEKMKEQASNFGGAH G N IA A A TG LV K K D EFPTD M N PEEY G Q EA M EE
4 6  D SV --------- G TV A EK TT-----------------GAM-------- GNIVAATGLVK K D EFPTD M N PEEY G Q EA M EG
4 6  D SV --------- G SV A EK TT-----------------GAV-------- G NIVAATGLGKK DEFPADM NPEEYGQEA M EG
e n d o g l u c a n a s e  
c h i c k e n  
z e b r a  f i n c h  
r h e s u s  m o n k e y  
h u m a n
h o u s e  m o u s e
n o r w a y  r a t
m o l e  r a t
c a t t l e
p i g
s a l m o n
z e b r a f i s h
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f u g u  f i s h
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Figure 42. Sequence alignment of 14 variant P-synucleins with endoglucanase
The portion o f the endoglucanase that shares significant similarity with the P-synucleins 
is between residues 48 and 163. Among the P-synucleins, there is variability in the 
repeat sequences except in the third. Color scheme: blue (sequence identity); red 
(conserved hydrophilic character); purple (conserved hydrophobic character); green 
indicates positions where a residue is highly prevalent. The alignment was constructed
with MUSCLE (Edgar. 2004; Me William et al.. 2013).
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The alignment between the endoglucanase and the y-synucleins from 16 species 
indicates that the filth repeat sequence o f  the synuclein proteins is highly identical to the 
endoglucanase (Figure 43). A multiple sequence alignment between the endoglucanase 
and the a-. (3- and y-synucleins altogether shows that the second and fifth repeat 
sequences o f  the synucleins share the highest identity with those o f  the endoglucanase 
enzyme (Figure 44).
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6 1  AEEGVLGRAW DNTREGTEHAW NKTKEGTNKAW EKTSNGTEKVW DKTKDGSRKAW DKTSEG e n d o g l u c a n a s e  
1  — M D V FK K G FSIA K EG W D A V E K T K Q G V T EA A E K TK EG V M Y V G A K T K EN W Q SV TSV A E - h u m a n  
1  — M D V FK K G FSIA K E  G W A A A EK TK Q G V TEA A EK TK E G V M TV G TK TK EG W Q SV T S V A E -  t u r k e y  
1  - -M D V F K K G F S IA K E  G W A A A EK TK Q G V TEA A EK TK E G V M TV G TK TK EG W Q SV T S V A E -  c h i c k e n  
1  --M D V F K K G F S IA K E G W G A V E K T K Q G V T E A A E K T K E G V M T V G A K T K E N W Q S M T S A A E - m o l e  r a t  
1  — M D V FK K G FSIA K E  G W G A V E K T K Q G V T E A A E K T K E G V M rvG T K T K E N W Q SV T  S V A E - h o u s e  m o u s e  
1  --M D V FK K G F S IA K E G W G A V E K T K Q G V T E A A E K T K E G V M T V G A K T K E G W Q S M T S V A E - e l e p h a n t
1 ----------- MHKG-------R Q E G W G A V E K T K Q G V T E A A E K T K E G V L T V G A K T K E N W Q S V T S V A E - d o g
1  --M D V F K K G F S IA K E G W G A V E K T K Q G V T E A A E K T K E G V M T V G A K T K E N W H S V T S V A E - r a b b i t  
1  --M D V FK K G F S IA K E G W G A V E K T K Q G V T E A A E K T K E G V M T V G T K T K E N W H S V T S V A E - r h e s u s  m o n k e y  
1  --M D V F K K G F S IA K E G W G A V E K T K Q G V T E A A E K T K E G V M T V G A K T K E N W Q S V T S V A E - o r a n g u t a n  
1  — M D V F K K G F S IA K E G W G A V E K T K Q G V T E A A E K T K E G V H T V G A K T K E K W Q SV T SV A E - g o r i l l a  
1  --M D V F K K G F S IA K E G W G A V E K T K Q G V T E A A E K T K E  G V M TV G T K T K EG W Q SV T  S V A E -  h o r s e  
1  — M D V FK K G F S IA K E G W G A V E K T K Q G V T E A A E K T K E G V L T V G V K T K E G W Q S V T S V A E - s h e e p  
1  --M D V F K K G F S IA K E G W G A V E K T K Q G V T E A A E K T K E G V M T V G A K T K E G W Q S V T S V A E - c a t t l e  
1  — M D V FK K G FSIA K E G W G A V E K T K Q G V T EA A E K TK EG V M TV G A K TK E G W Q SV T SV A E- p i g  
1  — M D V FK K G FSIA K E G W G A V E K T K Q G V T E A A E R T K E G V M T V G A K T K E N W Q SV T SV A E - c a t
V  V I V I I
1 2 1  SEKAWDKTKEGTHNAWDKTHEGTEKTWDKTKEGSH1CVWNKTSEGTDKVWDKTKDGSRKAW e n d o g l u c a n s e
5 8 ------------- K T K E Q A H A V S E A W S S V N T V A T K T V E E A E N IA V T S — G W R K E D L R P S A P Q Q E G  h u m a n
5 8 ------------- K TK EQ A N W X X X X X X SV N T V A N K T V EG A ET IV A TT — GVXKK ED LA PQ Q PA A EG  t u r k e y
5 8 ------------- K T K E Q A N W G E A W A S V N T V A N K T V E G A E T IV A T T — G W K K E D L A P Q Q P A A E G  c h i c k e n
5 8 ------------- K T K E Q A N A V S E A W M S V N T V A T K T V E E A E N IW T A — G W R K V S L V S S C P R P G R  m o l e  r a t
5 8 ------------- K T K E Q A N A V S E A W S S V N T V A N K T V E E A E N IW T T — G W R K E D L E P F A Q D Q E A  h o u s e  m o u s e
5 8 -----------KTKEQANWSEAWASVNTVATKTVEEAENIAVTS— GWRKEDLVKPVPPQDK e l e p h a n t
5 2 ------------- K T K E Q A N A V S E A W T S IN T V A V K T V E E A E N IA IT S — G W R K E D L E Q P A A P Q E D  d o g
5 8 ------------- K T K E Q A N A V S E A W T S V N T V A T K T V E E A E N IW T S — G W R K E D L K P S A P P Q E G  r a b b i t
5 8 ------------- K T K E Q A N A V S E A W S S V N T V A A K T V E E A E N IA V T S — G W R K E D L K P S A P Q Q E G  r h e s u s  m o n k e y
5 8 ------------- K T K E Q A N A V S E A W N S V N T V A T K T V E E A E N IA V T S — G W R K E D L K P S A P Q Q E G  o r a n g u t a n
5 8 --------------K T K EQ A N A V SEA W SSV N T V A TK  TV EE A EN  IA V T  S — G W R K E D F K P S A P Q Q E G  w e s t e r n  g o r i l
5 8 ------------- K TK EQ A N A V SG A W A SV N TV A TK A V EEV EN V A LTA — G W R K E D L E Q P A P P Q E D  h o r s e
5 8 ------------- K T K E Q A N A V S E A W S S V N T V A T K T V E E V E N IA V T S — G A V R K EA LK Q PV PSQ ED  s h e e p
5 8 ------------- K T K E Q A N A V S E A W S S V N T V A T K T V E E V E N IA V T S — G W H K E A L K Q P V P S Q E D  c a t t l e
5 8 ------------- K T K E Q A S A V S E A W S S V N T V A T K T V E E A E N IA V T S — G W R K E D L H Q P A P S Q D E  p i g
5 8 ------------- K T K E Q A N A V S E A W T S V N T V A IK T V E E A E N IA X T S — G V X R K ED LEQ PA PSQ ED  c a t
Figure 43. Sequence alignment of 16 variant y-synucleins with endoglucanase
The portion o f the endoglucanase that shares significant identity with the y-synucleins 
lies between residues 61 and 171. The fifth repeat sequence o f the y-synucleins shares 
the highest identity with the endoglucanase. Color scheme: blue (sequence identity); red 
(conserved hydrophilic character); purple (conserved hydrophobic character); green 
indicates positions where a residue is highly prevalent. The alignment was constructed 
with MUSCLE (Edgar. 2004; McWilliam et al.„ 2013).
1 1 8
I II II I IV
6 1  AEEGVLGRAWDNTREGTEHAWNKTKEGTNKAHEKTSNGTEKVHDKTKDGSRKAWDKTSEG
1 — MDVFKKG F SIAKE. S W D  A VE K T KQ GVTEAAF. K TKE GVMTVGAKTKEN--------------- W Q S
1 — MDVFKKGFSIAKEGWGAVEKTKQGVTEAAEKTKEGVMTVGAKTKEG--------------- W Q S
1 — MDVFKKGFSIAKEGWGAVEKTKQGVTEAAEKTKEGVMTVGTKTKEN--------------- W Q S
1 — MDVFKKGFS IA K E GW GAVEKT KQGVTEAAE KTKE GVMTVGTKTKEN--------------- W H S
1 — MD VFKKGFS IA K E GWAAAEKTKQGVTEAAEKTKE GVMTVGTKTKEG--------------- W Q S
1 — MDVFKKGFSMAKE GWAAAEKTKQGVTEAAEKTKE GVMTVGAKTKEG--------------- W H S
1 — MDVEMKGLSMAKE GWAAAEKTKQGVTEAAEKTKE GVLTVGSKTREG--------------- W Q G
1 — MDVFMKGLSKAKDGMAIAAEKTKEGAALAAEKTKEGAMFIGTKAKDG----------------- VGS
1 — MDVFMKGFSKAKEGWAAAEKTKQGVAEAAEKTKEGVLYVGNKTRDG--------------- W Q G
1 — MEVFMKGLSKAKEGWAAAEKTKQGVAEAAEKTKEGVLTVGSKT-QG--------------- W Q G
1 — MDVFMKGLSMAKE GWAAAEKTKQGVTEAAEKTKE G V LTV G SK T-SG --------------- W Q G
1 — MDVFMKGLSMAKE GWAAAEKTKQGVTEAAEKTKE GVLTVGSKTREG--------------- W Q G
1 — MDVFMKGLSKAKEGWAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEG--------------- W H G
1 — MDVFMKGLSKAKEGWAAAEKTKQGVAEAAGKTKEGVLYMGSKTKEG--------------- W H G
1 0  LAMDVFMKGLSKAKEGWAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEG--------------- W H G
1 -------------MKGLSKAKEGWAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEG--------------- W H G
1 — MDVEMKGLSKAKEGWAAAEKTKQGVABAAGKTKEGVLTVGSKTKEG--------------- W H G
1 — MDVFMKGLSKAKEGWAAAEKTKQGVAEAAGRTKE GVLTVGSKTREG--------------- W H G







P h u m a n  
p - s a l m o n  f i s h  
P f r o g
p z e b r a  f i n c h  
P h o u s e  s i o u s e  
p c a t t l e  
a  h u m a n  
o  f r o g
a  h o u s e  m o u s e  
a  e l e p h a n t  
a  s h e e p  
a  c a t t l e
V I V II
1 2 1  SEKAWDKTKEGTHNAHDKTHEGTEKTWDKTKEGSHKVWNKTSEGTDKVWDKTKDGSRKAW
5 2  VTSVAEKTKEQANAVSEAW SSVNTVATKTVEEAEHIAVTS---------G W R K E D L  RJPS
5 2  VTSVAEKTKEQANAVSEAW SSVNTVATKTVEEVENIAVTS---------G W H K E A L  KQP
5 2  V TSV AEKTKEQ AHAVSEAW SSVN TVAHKTVEEAENIW TT---------G W R K E D L -------------E
5 2  VTSVAEKTKEQANAVSEAW SSVNTVAAKTVEEAEMXAVTS---------G W R K E D L  KPS
5 2  VTSVAEKTKEQAHW XXXXXXSVNTVANKTVEGAETIVATT---------GV IK K ED L APQ
5 2  VSTV AEKTKEQANW GGAW SGVNQVASKTVEGTEHIVGTT---------GLVKKEDLHPGQPEE
5 2  VASVAEKTKEQASHLGGAVFS------------------------ GAGMIAAAT---------GLVKREEFPTDLKPE
5 1  AKDLA----------------------GGAM--------------------------------- GMIAAAT---------GLGKKDBFPSDMNFE
5 2  VTSVAEKTKEQASHLGGAVMS------------------------ GAGMIAAAT--------- GLVKKDEFPTDLKPE
5 1  VTSVAEKAKEQASQLGEAAFS------------------------ GAGMIAAAT---------GLVKKEE FPAD LKAE
5 1  VASVAEKTKEQASHLGGAVFS------------------------ GAGNIAAAT---------GLVKKEE FPTD  LKAK
5 2  VASVAEKTKEQASHLGGAVFS------------------------ GAGMIAAAT--------- GLVKKEE FPTD  LKPE
5 2  VATVAEKTKEQVTNVGGAWTGVTAVAQKTVEGAGSIAAAT---------GFVKKDQL— GKNEE
4 2  VTTVAEKTKEQVSNVGEAWTGMTAVAQKTVEGAGMIAAAT---------GLVKKDQK NES
6 3  VTTVAEKTKEQVTNVGGAWTGVTAVAQKTVEGAGMIAAAT---------GFVKKDQM— GKGEE
4 8  VTTVAEKTKEQVTNVGEAWTGVTAVAQKTVEGAGSIAAAT---------GFGKKDQM— GKGEE
5 2  VTTVAEKTKEQVTNVGEAWTGVTAVAQKTVEGAGSIAAAT---------GFGKKDHL— GKGEE











P zebra finch 
P house aiouse 
P cattle 
a  human 
a  frog
a  house aiouse 
a  elephant 
o sheep
a  cattle
Figure 44. Summary sequence alignment of endoglucanase with 18 species 
variants of a-, P- and y-synucleins
It appears the endoglucanase matches with the N-terminal region o f the synuclein 
protein. The KTK(E/Q)GV sequence is the element o f similarity between the 
endoglucanase and the synucleins. Color scheme: blue (sequence identity); red 
(conserved hydrophilic character); purple (conserved hydrophobic character); green 
indicates positions where a residue is highly prevalent. The alignment was constructed
with MUSCLE (Edgar. 2004: McWilliam et al.. 2013).
1 19
CRE-DUR-1 protein
The PSI-BLAST search with the human a-. (B- and y-synuclein probe sequences 
also identified a putative CRE-DUR-1 protein from a nematode. The CRE-DUR-1 
protein is composed o f  524 amino acid residues. The CRE-DUR-1 shares 32%-36% 
identity with human synucleins in the overlapping region. The sequence alignment 
between the CRE-DUR-1 and a-synucleins from various species indicates that the first 
356 amino acid residues o f  the protein share no identity w ith the synucleins (Figure 45). 
The regions o f the human a-synuclein that are similar to the CRE-DUR-1 protein are 
marked on the helical structure o f the a-synuclein in Figure 46. The CRE-DUR-1 
alignment with a-. (3- and y-synucleins is shown in Figure 47.
1 2 0
yETKKQACTVTCTRYIsCHVM RRIRHLKMLHKECTGLEIELEKiDQLLM RLHhW DMSM DVM c r « ~ d u r ~ X
o m o l e  r a t
a c h i c k e n
--------------------------------------------- ----------------------------------------------------- — g a v w s k n t s i a m d v f a h o u s e  m o u s e
a w h a l e
a e l e p h a n t
a h o r s e
a s h e e p
a c a t t l e
--------------------------------------------------------------------------------------------------------------------------------- MDVF a p i g
----------------------------------------------------------------------------------------------------------------------------------MDVF a m o n k e y
--------------------------------------------------------------------------------------------------------------------------------- MDVF a h u m a n
I II I I I  IV
3 6 1  ER PLH ElttlK Q LM LQ LK EPV K N A Y EK TK EfM H V A EK A K EG A A EG Y EK TK EG A EA A Y EK T1 c r e - d u r - 1
5  MKGL---------------------------------------------SKAKE G W A A A E KTKQGVAEAAGKTKE GVLYVGSKT a  m o l e  r a t
5  MKGL---------------------------------------------NKAKEGW AAAEKTKQGVAEAAGKTKEGVLYVGSRT a  c h i c k e n
1 6  MKGL---------------------------------------------SKAKE G W A A A E KTKQGVAEAAGKTKE GVLYVGSKT a  h o u s e  m o u s e
1 MKGL---------------------------------------------SKAKEGW AAAEKTKQGVAEAAZKTKE GVLYVGSKT a  w h a l e
5  MKGL----------------------------------------------- SKAKEGW AAAEKTKQGVAEAAGKTKEGVLYVGSKT a  e l e p h a n t
5  MKGL---------------------------------------------SKAKE G W A A A E KTKQGVAEAAGKTKE GVLYVGSKT «  h o r s e
5  MKGL---------------------------------------------SKAKE G W A A A E KTKQGVAEAAGKTKE GVLYVGSKT a  s h e e p
5  MKGL---------------------------------------------SKAKE G W A A A E KTKQGVAEAAGRTKE GVLYVGSKT a  c a t t l e
5  MKGL---------------------------------------------SKAKE G W A A A E KTKQGVAEAAGKTKE GVLYVGSKT a  p i g
5  MKGL---------------------------------------------SKAKE G W A A A E KTKQGVAEAAGKTKE GVLYVGSKT a  m o n k e y
5  MKGL---------------------------------------------SKAKE G W A A A E KTKQGVAEAAGKTKE GVLYVGSKT a  h u m a n
VI
4 1 1  KEG AETAVEKTKHGAGW YDAAAEGASHMAQ-SMHDAGKSAGDAFV-GGAEAAGE
4 5  KEGW HGVTTVAEKTKEQVTNVGGAW TGVTAVAQKTVEGAGNIAAATGF-VKKDQLGK 
4 5  KEGW HGVTTVAEKTKEQVSNVGGAW TGVTAVAQKTVEGAGHIAAATGL-VKKDQLAK 
4 5  KEGW HGVTTVAEKTKEQVTNVGGAW TGVTAVAQKTVEGAGNIAAATGF—VKKDQMGK 
4 0  KEGW HGVTTVAEKTKEQVTNVGEAW TGVTAVAQKTVEGAGSIAAATGF-GKKDQLGK 
4 5  K £G W H G V TTVAEK TKEQVTNV GEAW TGVTAVAQKTVEGA GSIAAATGF—GKKDQMGK
4 5  k e g w h g v t t v a e k t k e q v t h v g e a w t g v t a v a q k t v e g a e s i a a a t g f - g k k d h l g k  
4 5  k e g w h g v t t v a e k t k e q v t n v g e a w t g v t a v a q k t v e g a g s i a a a t g f - g k k d b l g k
4 5  KEGW HGVTTVAEKTKEQVTNVGEAW TGVTAVAQKTVEGAGSIAAATGF-GKKDHM GK 
4 5  KEGW HGVTTVAEKTKEQVTNVGEAW TGVTAVAQKTVEGAGSIAAATGF-GKKDQLGK 
4 5  KEGW HGVATVAEKTKEQVTNVGGAW TGVTAVAQKTVEGAGNIAAATGF-VKKDHLGK 
4 5  KE GW HGVATVAE KTKEQVTNVGGAW TGVTAVAQKTVEGAGSI AAATGF—VKKDQLGK
c r e - d u r - 1  
a  m o l e  r a t  
a  c h i c k e n  
a  h o u s e  m o u s e  
a  w h a l e  
a  e l e p h a n t  
a  h o r s e  
a  s h e e p  
a  c a t t l e  
a  p i g  
a  m o n k e y  
a  h u m a n
1 2 1
Figure 45. Sequence alignment of CRE-DUR-1 protein with 11 variant a- 
synucleins
The portion o f the protein sequence related to the synucleins lies between residues 356 
and 463. When the CRE-DUR-1 was used as a sequence probe, the greater part o f  the a- 
synucleins were identified as being similar. The conserved repeat KTKEG sequences I- 
V o f the synucleins are also contained in the CRE-DUR-1 protein. Color scheme: blue 
(sequence identity); red (conserved hydrophilic character); purple (conserved 
hydrophobic character); green indicates positions where a residue is highly 
prevalent. The alignment was constructed w ith MUSCLE (Edgar, 2004; M cW illiam et 
al., 2013).
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Figure 46. Regions of human a-synuclein similar to CRE-DUR-1 protein
The colors in the figure indicate the regions within human a-synuclein that are sim ilar to 
the CRE-DUR-1 protein (pdb code: lx q 8 ). The figure was rotated 180 degrees. Color 
scheme: blue (sequence identity); red (conserved hydrophilic character); purple 
conserved hydrophobic character); green indicates positions where a residue is highly 
prevalent. The letter ‘N ’ designates the N-terminus and ‘C ’ designates the C-terminus o f 
the protein. These structures are visualized with Rasmol (version 2.7.1).
12 3
-MRTLFILVSLCAALCFSAPVSEQASGLRAKRNLEEAASTGAEAVAEKHTL
— MDVFK--------------------------------------- K G FSIA K E --------------- G W G A V EK T--
— MDVFK--------------------------------------- K G FSIA K E --------------- GW GAVEKT—




















-GW GAVEKT—  
-GW AAAEKT—  
-GW AAAEKT—  
-GW AAAEKT—  
-GW AAAEKT—  
-GW AAAEKT—  
-GW AAAEKT—  






Y rhesus monkey 
p chicken
p house mouse 
p human 
p cattle 
a  chicken 
a  cattle 
a  house mouse 
a  human
IV



















-  KQGVTEAAEKT KE G V L Y V G SK T -SG W - 
-KQGVTEAAEKTKE GVLYVGSKTREG W - 
-KQGVTEAAEKTKEGVLYVGSKTREGW -
-  KQGVAE AAGKT KE G VLYVGSRTKEG W -
-  KQGVAE AAGRT KE GVLYVGSKTKEGW -
-  KQGVAE AAGKTKEGVLYVGSKTKEGW -
-  KQGVAE AAGKTKE GVLYVGSKTKEGW -
V II
4 1 1  EGAEAAYf: K TKE GAE TAVEKTKHGAGWYDAAAE GASNMAQ SMHDAGKSAGDAFVGGAEA
5 0  QSVTSVAEKTKEQANAVSEAWSSVNTVATKTVEEVENIAVT------SGWHKEALKQPVPS
QSVTSVAEKTKEQANAVSEAW SSVNTVANKTVEEAENIW T TGWRKEDLEPPAQD
QSVTSVAEKTKEQAHAVSEAWSSVNTVATKTVEEAEHIAVT SGW RKEDLRPSAPQ
HSVTSVAEKTKEQAHAVSEAWSSVNTVAAKTVEEAENIAVT SGW RKEDLRPSAPQ
4 9  QGVTSVAEKAKEQASQLGEAAFS------------------------ GAGNIAAA----- TGLVKKEE FPADLKA
4 9  QGVASVAEKTKEQASHLGGAVFS------------------------ GAGNIAAA----- TGLVKKEE FPTD  LKP
5 0  QGVASVAEKTKEQASHLGGAVFS------------------------ GAGNIAAA----- TGLVKREE FPTD  LKP
5 0  QGVASVAEKTKEQASHLGGAVFS------------------------ GAGNIAAA----- TGLVKKEE FPTD  LKP
HGVTTVAEKTKEQVSNVGGAWTGVTAVAQKTVE GAGNIAAA------TGLVKKDQLA-------- K
HGVTTVAE KTKEQVTNVGEAWTGVTAVAQKTVEGAGSI AAA------TGFGKKDHM-----------G
6 1  HGVTTVAE KTKEQVTNVGGAWTGVTAVAQKTVE GAGNIAAA------TGFVKKDQM----------- G









Y rhesus monkey 
p chicken




a  cattle 






Y rhesus monkey 
P chicken
p house Bouse 
P human 
P cattle 
a  chicken 
a  cattle 
a house amuse 
a  human
Figure 47. Sequence alignment of CRE-DUR-1 with 12 species variants of a-, 0- 
and y-synucleins
The KTK(E/Q)GV sequence is the element o f  similarity between the CRE-DUR-1 and 
the synucleins. Color scheme: blue (sequence identity); red (conserved hydrophilic 
character); purple (conserved hydrophobic character); green indicates positions where a 
residue is highly prevalent. The alignment was constructed with MUSCLE (Edgar.
2004; McWilliam et al.. 2013).
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The Tasmanian Devil protein
The marsupial protein shares 65%. 55% and 80% identity with a-. (3- and y- 
synucleins. respectively in the overlapping regions. The sequence alignment between the 
Tasmanian Devil protein and human synucleins indicates that the N-terminal region o f 
the protein is almost identical to the N-terminal regions o f  the a-synucleins (Figure 48). 
The remainder o f  the protein appears unrelated to synucleins. The regions o f  the human 
a-synuclein that are similar to the Tasmanian Devil protein are shown in Figure. 49. 




















Figure 48. Sequence alignment of the putative Tasmanian Devil protein and the 
human a-, 0- and y-synucleins
The first 100 amino acid residues o f the Tasmanian Devil are almost identical to the N- 
terminal regions o f  the synucleins The remainder o f the protein is unrelated to the 
synucleins. Color scheme: blue (sequence identity); red (conserved hydrophilic 
character); purple (conserved hydrophobic character); green indicates positions where a 
residue is highly prevalent. The alignment was constructed with MUSCLE (Edgar. 
2004; McWilliam et al„ 2013).
I II III IV
1 MDVFKKGFSIAKE GWGAVEKTKQGVTEAAEKTKEGVMYVGTKTKENWQSVTSVAEKTK 













1 3 3 ----------------- YQDYEPEA--------- ----------------------------------------------------------------------





Figure 49. Regions of the human a-synuclein similar to the Tasmanian Devil 
protein
The colors in the figure indicate the regions within human a-synuclein that are similar to 
the Tasmanian Devil protein (pdb code: lx q 8 ). The figure was rotated 180 degrees.
Color scheme: blue (sequence identity); red (conserved hydrophilic character); purple 
(conserved hydrophobic character); green indicates positions where a residue is highly 
prevalent. The letter ‘N ‘ designates the N-terminus and ‘C* designates the C-terminus o f 
the protein. These structures are visualized the Rasmol (version 2.7.1).
1 2 7
Cytochrome c
The Tasmanian Devil protein identified in the protein database cytochrome c 
from the bacterium Thiomicrospira crunogena. It shares 35% identity w ith cytochrome c 
in the overlapping region and the e-value is 4 x 1 O'3. The synucleins were thus linked to 
cytochrome c through linkage with the Tasmanian Devil protein. The alignment between 
the synucleins and cytochrome c is shown in Figure 50. The regions o f  the human a- 
synuclein that are similar to the cytochrome c are highlighted on the helical structure o f  
a-synuclein protein in Figure 51. The cytochrome c class I identified by the Tasmania 
Devil protein consists o f  192 amino acid residues. The portion of the protein which is 
similar to the N-terminus o f the synucleins is between residues 15 and 120 and the 
similarity lies in the conserved repeat sequences II-V. The cytochrome c protein which 
transports electrons between complex III and IV in the electron transport chain is a 
member o f  the class I cytochromes (Battistuzzi et ah, 2001). The alignment between the 
synucleins and the disparate proteins is shown in Figure 52.
1 2 8
ll i l l
-MHLNRWKLNPLVLSLTVMK3GALLAACSDDSQQKAAEAVEDVKQSTSEAYEEAKETTQE
---------------------------------MD VFKKGFS I A ------------- KEGWGAVEKTKQGVTEAAEKTKEGVMY
---------------------------------MDVFKKGFSMA------------- KEGWAAAEKTKQGVTEAAEKTKEGVMY
---------------------------------M D VFKKGFSIA------------- KEGWAAAEKTKQGVTEAAEKTKEGVMY
---------------------------------M D VFKKGFSIA------------- KEGWGAVEKTKQGVTEAAEKTKEGVMY
---------------------------------M D VFKKGFSIA------------- KEGWGAVEKTKQGVTEAAEKTKEGVMY
---------------------------------M D VFKKGFSIA------------- KEGWGAVEKTKQGVTEAAEKTKEGVMY
---------------------------------M D VFKKGFSIA------------- REGWGAVEKTKQGVTEAAEKTKEGVMY

















c y t o c h r o m e  c
Y h u m a n
Y f r o g
Y t u r k e y
Y c a t t l e
Y P i -9
Y h o u s e  m o u s e
Y n o r w a y  r a t
Y r h e s u s  m o n k e y  
P h u m a n
P n o n r a y  r a t  
P h o u s e  a m u s e  
P r h e s u s  m o n k e y  
p  g o r i l l a  
p  m o l e  r a t  
P c a t t l e  
P P i-9  
a  h u m a n  
a  m o l e  r a t  
a  c h i c k e n  
a  e l e p h a n t  
a  c a t t l e  
a  m o n k e y  
a  n o r w a y  r a t  
o  h o u s e  m o u s e
IV V VI VII
6 0  VM3ETQEAVSDSVDSVEEATESAGEAVSDMTESANETTKDAINEAAEEVDEAVTTASVSG c y t o c h r o m e  c .
4 0  VGAKTKEHW QSVTSVAEKTK--EQ A N A V SEA W SSV N TV A TK TV EEA EN IA V TSG W R  Y h u a u u i
4 0  VGAKTKEGWHSVNTVAEKTK--EQ A H W G G A W SG V N Q V SSK TV EG TEN W SSTG LV K  Y f r o g
4 0  VGTKTKEGW QSVTSVAEKTK--EQANW XXXXXXSVNTVANKTVEGAETIVATTGVIK Y t u r k e y
4 0  VGAKTKEGW QSVTSVAEKTK--EQ A H A V SEA W SSV N TV A TK TV EEV ZH IA V TSG W H  y  c a t t l e
4 0  VGAKTKEGW QSVTSVAEKTK--E Q A SA V SEA W SSV N TV A TK TV EEA EN IA V TSG W R Y p i g
4 0  VGTKTKEHW QSVTSVAEKTK--E Q A N A V SEA W SSV N TV A N K TV E EA E N IW TT G W R  Y h o u s e  m o u s e
4 0  VGTKTKEHW QSVTSVAEKTK--E Q A N A V SEA W SSV N TV A T K TV EE A EN IW T TG W R  Y n o r w a y  r a t
4 0  VGTKTKENW HSVTSVAEKTK--EQ A N A V SEA W SSV N TV A A K TV EEA EN IA V TSG W R y  r h e s u s  m o n k e y
4 0  VGSKTREGW QGVASVAEKTK--EQASHLGGAVFS GAGMIAAATGLVK P h u m a n
4 0  VGSKTREGW QGVASVAEKTK---EQASHLGGAVFS--------------------------- GAGMIAAATGLVK p  n o r w a y  r a t
4 0  V G SKT-SGW Q GVASVAEK TK---EQASHLGGAVFS--------------------------- GAGMIAAATGLVK p  h o u s e  m o u s e
4 0  VG SK TREG W Q  VAEKTK---EQASHLGGAVFS----------------------------GAGMIAAATGLVK p  r h e s u s  m o n k e y
4 0  V----------------------------- VAEKTK-----EQASHLGGAVFS----------------------------GAGMIAAATGLVK P g o r i l l a
1 1 5  VGSKTREGW QGVASVAEKTK--EQASHLGGAVFS GAGMIAAATGLVK P m o l e  r a t
4 0  VGSKTREGW QGVASVAEKTK--EQASHLGGAVFS GAGMIAAATGLVK P c a t t l e
4 0  VGSKTREGW QGVASVAEKTK--EQASHLGGAVFS GAGMIAAATGLVK p  p i g
4 0  VGSKTKEGW HGVATVAEKTK--EQVTNVGGAW TGVTAVAQKTVEGAGSIAAATGFVK a  h u m a n
4 0  VGSKTKEGW HGVTTVAEKTK--EQVTNVGGAWTGVTAVAQKTVEGAGNIAAATGFVK a  m o l e  r a t
4 0  VGSRTKEGW HGVTTVAEKTK--EQVSMVGGAWTGVTAVAQKTVEGAGMIAAATGLVK a  c h i c k e n
4 0  VGSKTKEGW HGVTTVAEKTK--EQVTNVGEAW TGVTAVAQKTVEGAGSIAAATGFGK a  e l e p h a n t
4 0  VGSKTKEGW HGVTTVAEKTK--EQVTNVGEAWTGVTAVAQKTVEGAGS IAAATGFGK a  c a t t l e
4 0  VGSKTKEGW HGVATVAEKTK--EQVTNVGGAWTGVTAVAQKTVEGAGNIAAATGFVK a  m o n k e y
4 0  VGSKTKEGW HGVTTVAEKTK--EQVTMVGGAWTGVTAVAQKTVEGAGNIAAATGFVK a  n o r w a y  r a t
5 1  VGSKTKEGW HGVTTVAEKTK--EQVTNVGGAWTGVTAVAQKTVEGAGMIAAATGFVK a  h o u s e  m o u s e
1 2 9
Figure 50. Sequence alignment of the predicted cytochrome c and 18 synucleins 
(a, p and y) from various species
The portion of the protein similar to the synucleins is between residues 15 and 119. The 
region of similarity involves the repeat sequences II. III. IV and V. Color scheme: blue 
(sequence identity); red (conserved hydrophilic character): purple (conserved 
hydrophobic character); green indicates positions where a residue is highly prevalent.
The alignment was constructed with MUSCLE. (Edgar. 2004; McWilliam et al., 2013).
1 3 0
180°
Figure 51. Regions of the human a-synuclein similar to cytochrome c
The colors in the figure indicate the regions within human a-synuclein that are similar to 
the cytochrome c class I protein (pdb code: lx q 8 ). The figure was rotated 180 degrees. 
Color scheme: blue (sequence identity); red (conserved hydrophilic character); purple 
(conserved hydrophobic character); green indicates positions where a residue is highly 
prevalent. These structures are visualized with Rasmol (version 2.7.1). The letter ‘N ’ 
designates the N-terminus and ‘C ' designates the C-terminus of the protein. These 
structures are visualized with Rasmol (version 2.7.1).
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TDVAYICHKAFEYLPLM IRFSLKK M YFVSNYSFRTAATTLLGAAM FALSLPGAHAEEGVL
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2 0  CVG LCLQLSG RV D V R PRRSV SD G PC A FERPPV LY V H V SV SW C V CD RV TW C V Q A A FD V F
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II III IV
66 GRAWDNT------------------- REGTEHAWNKTKEGTNKAWEKTSNGTEKVWDKTKDGSRKAJIDKT
1 9  MGGALLAACSD DSQQKAAEAVEDVKQSTSEAYEEAKETTQEVM DETQEA--------------- V
3 6 1  e r p l k e k l i k q u *l q l k e p v k n a y e k t k e g a e h v a e k a k e g a a e g t e k t k e g -----------------
5  K K G F S IA ------------------- KEGWGAVEKTKQGVTEAAEKTKEGVMYVGTKTKEN---------------- V
5  K K G F S IA ------------------- KEGWGAVEKTKQGVTEAAEKTKEGVMYVGAKTKEN---------------- V
5  K K G F S IA ------------------- KEGWGAVEKTKQGVTEAAEKTKEGVMYVGAKTKEG---------------- V
5  KKGFSMA------------------- KE GW AAAEKTKQGVTEAAEKTKE GVMYVGAKTKEG---------------- V
1 6  MKGLSKA------------------- KEGW AAAEKTKQGVAEAAGKTKEGVLYVGSKTKEG---------------- V
5  MKGLSKA------------------- KEGW AAAEKTKQGVAEAAGKTKEGVXYVGSKTKEG---------------- V
5 MKGLSKA------------------- KEGW AAAEKTKQGVAEAAGKTKEGVLYVGSKTKEG---------------- V
5 MKGLSKA------------------- KEGMAVAAEKTKEGVAVAAEKTKEGVMFVGSKTKDS------------------
5  MKGLSMA------------------- KE GW AAAEKTKQGVTEAAEKTKE GVLTVGSKTREG---------------- V
8 0  MKGLSMA------------------- KE GW AAAEKTKQGVTEAAEKTKE GVLYVGSKTREG---------------- V
e n d o g l u c a n a s e  
c y t o c h r o m e  c  
c r e - d u r - 1  
s > a r s u p i a l
Y h u m a n
Y c a t t l e
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p  h u m a n  
p  m o l e  r a t
VI V II
1 1 7  SEGSEKAWDKTKEGTHNAWDKTHEGTEKTWDKTKEGSHKWfNK TSEGTDKVW----------
6 9  SDSVDSVEEATESAGEAVSDM TESANETTKDAINEAAEEVDEAVTTASVSGQEVYSTCVG
4 1 3  AEAAYEKTKEGAETAVEKTKHGAGWYDAAAEGASNMAQSMHDAGKSAGDAF----------
4 9  VQSVTSVAEKTKEQANM VSDAM VASVNTVASKTVEEAENIW T------T G IV R K E D L  VH
4 9  VQSVTSVAEKTK EQ A M A V SEA W SSV H TV A TK TV EEA EH IA V T------S G W R K E D L -----------
4 9  V Q SV TSV A EK TK EQ A N A V SEA W SSV N TV A TK TV EEV EN IA V T------S G W H K E A L -----------
4 9  V H SV N TV A EK TK EQ A N W G G A W SG V N Q V SSK TV EG TEN W SS------TGLVKKEDL-----------
6 0  VHGVTTVAEKTKEQVTNVGGAW TGVTAVAQKTVEGAGNIAAA------TGFVKKDQM-----------
4 9  VHGVTTVAEKTKEQVTNVGEAW TGVTAVAQKTVEGAGSIAAA------TGFGKKDQM-----------
4 9  VHGVATVAEKTKEQVTNVGGAWTGVTAVAQKTVF.GAGSIAAA------TGEVKKDQL-----------
4  8  VATVAEKTKE QASQLGGAVMSG-------------------------AG H IA A A ------TGLV1CKDEF-----------
4 9  VQGVASVAEKTKEQASHLGGAVFSG-------------------------AG N IA A A ------T G LV K R EEF-----------
1 2 4  VQGVASVAEKTKEQASHLGGAVFSG-------------------------A G N IA A A ------TG LV K K EEF-----------
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Figure 52. Sequence alignment of variant synucleins with disparate proteins
The seemingly disparate proteins contain the synuclein N-terminal domain.
Color scheme: blue (sequence identity); red (conserved hydrophilic character); purple 
(conserved hydrophobic character); green indicates positions where a residue is highly 
prevalent. The alignment was constructed with MUSCLE (Edgar, 2004; M cW illiam et 
al.. 2013).
Modification sites
The scan prosite algorithm identified sites where a myristic fatty acid and 
phosphate moieties are predicted to be added to the human synucleins and the disparate 
sequences. The glycine residues, to which the fatty acid molecules are added by the N- 
myristoyltransferase. were identified in conserved locations. The threonine/serine and 
tyrosine residues to which phosphate groups are added by the enzymes casein kinase II 
and tyrosine kinase respectively, were also identified (Figure 53). The modification sites 
are highlighted on the helical structure o f human a-synuclein (Figure 54).
67 GR------------------------------------ -AW- ---------DNTREGTEHAHNKTKEGTNKAHEKTSNGTE e n d o g l u c a n a s e
361 ERPLHEKLIKQLMLQLKEFVKNAY- ---------EKTKEGAEHVAEKAKEGAAEGYEKTKEGAE c r e - d u r - 1
19 MG------------------------------------ -GALLAACSDDSQQKAAEAVEDVKQSTSEAYEEAKETTQ c y to c h r o m e  c
5 KK------------------------------------ -G F - ---------S IAKE GWGAVEKTKQGVTEAAEKTKEGVM m a r s u p i a l
5 KK------------------------------------ -G F - ---------SIAKE GWGAVEKTKQGVTEAAEKTKEGVM y -m o u a e
5 KK------------------------------------ -G F - y -c o w
5 KK------------------------------------ - g f - ---------SIAKE GWGAVEKTKQGVTEAAEKTKEGVM y - m u l a t a
5 KK------------------------------------ - gf- ---------SIAKE GWGAVEKTKQGVTEAAEKTKEGVM y -h u m a n
5 KK------------------------------------ - g f - ---------SIAKE GWGAVEKTKQGVTEAAEKTKEGVM y -p o n g o  a b e l i
5 MK------------------------------------ -G F - ---------SKAKDGWAAAEKTKQGVTGAAEMTKDGVM a - r u b r i p e s
5 MK------------------------------------ -G L- ---------NKAKEGWAAAEKTKQGVAEAAGKTKEGVL a - c h ic J c e n
5 MK------------------------------------ -G L- ---------SKAKEGWAAAEKTKQGVAEAAGRTKEGVL a -c o w
16 MK------------------------------------ -G L- ---------SKAKE GWAAAEKTKQGVAEAAGKTKEGVL a -m o u s e
5 MK------------------------------------ -G L- ---------SKAKE GWAAAEKTKQGVAEAAGKTKEGVL a - h u a a n
5 MK------------------------------------ -G L- ---------SMAKEGWAAAEKTKQGVTEAAEKTKEGVL P -m o u se
5 MK------------------------------------ -G L- ---------SMAKEGWAAAEKTKQGVTEAAEKTKEGVL p -h u m an
5 MK------------------------------------ -G L- ---------SMAKEGWAAAEKTKQGVTEAAEKTKEGVL p -c o w
5 MK------------------------------------ -G L- ---------SKAKE GMAVAAEKTKEGVAVAAEKTKEGVM p - r u b r i p e s
5 MK------------------------------------ ---------SKAKE OlAVAAEKTKEGVAVAAEKTKEGVM p - d a n a r i o
101 KVWDKTKDGSRKAWDKTSE3SEKAWDKTK-----EGTHNAHDKTHEGTEKTWDKTKEGSHKV e n d o g l u c a n a s e
415 AAYEKTKEG-------AETAVE-- ------- -KTK-----HGAGWYDAAAE---------------------GASNM c r e - d u r - 1
59 EVMDETQEAVSDSVDSVEE-- -ATESAGEAVSDMTESANETTKDAINEAAEEVDEA c y to c h r o m e  c
39 YVGTKTKENWQSVTSVAE -  - -KTK— EQANMVSDAMVASVNTVASKTVEEAENI m a r s u p i a l
39 YVGTKTKENWQSVTSVAE -  - -KTK— EQANAVSEAWSSVNTVANKTVEEAENI y -m o u se
39 YVGAKTKE GWQ SVT SVAE -  - ------- -KTK-----EQAHAVSEAWSSVNTVATKTVEEVENI y -c o w
39 YVGTKTKENWH SVT SVAE -  - -KTK-----EQANAVSEAWSSVNTVAAKTVEEAENI y - m u l a t a
39 YVGAKTKENWQSVTSVAE-- ------- -KTK-----EQANAVSEAWSSVNTVATKTVEEAENI y -h u m an
39 YVGAKTKENWQSVTSVAE -  - ------- -KTK- -  -EQAKAVSEAWNSVNTVATKTVEEAENI y - p o n g o  a b e l i
39 FVGTKTKDG-------VTWAG- - ------- -KTV—  SGVSQVGGAMVTGVTAVAQKTVESAGSI a - r u b r i p e s
39 YVGSRTKE GWHGVTTVAE— ------- -KTK-----EQVSNVGGAWTGVTAVAQKTVEGAGNI a - c h i c k e n
39 YVGSKTKE GWHGVTTVAE— -KTK-----EQVTNVGEAWTGVTAVAQKTVEGAGS I a -c o w
50 YVGSKTKE GWHGVTTVAE— -KTK- -  -EQVTNVGGAWTGVTAVAQKTVEGAGNI a -m o u s e
39 YVGSKTKE GWHGVATVAE -  - -KTK- -  -EQVTNVGGAWTGVTAVAQKTVEGAGSI a -h u m a n
39 YVGSKT -  S GWQGVASVAE -  - -KTK-----EQASHLGGAVFS---------------------GAGNI P -m o u se
39 YVGSKTREGWQGVASVAE— ------- -KTK-----EQASHLGGAVFS---------------------GAGNI P -hum an
39 YVGSKTREGWQGVASVAE— ------- -KTK-----EQASHLGGAVFS---------------------GAGNI p -c o w
39 FVGNKAKDS-------VGTVAE— ------ -KTT-------------------GAM-----------------------------GNI p - r u b r i p e s
39 FVGSKTKDS-------VATVAE— ------ -KTK-----EQASQLGGAVMS---------------------GAGNI p - d a n a r i o
1 3 4
Figure 53. Sites for mvristoylation and phosphorylation in the synuclein and 
disparate proteins
The blue color indicates the sites where myristic acid is predicted to be added to the 
proteins by the enzyme N-myristoyltransferase; the red color indicates sites predicted for 
phosphory lation by casein kinase II; and the green color indicates sites predicted for 
phosphorylation by the tyrosine kinase enzyme. The disparate proteins and the 
synucleins are myristoylated at N-terminal glycines (G) that are in conserved locations. 
The phosphorylation by casein kinase II occurs at either a threonine (T) o r serine residue 
(S) also in a conserved location. Phosphorylation by tyrosine kinase occurs at tyrosine 
(Y) residues in a conserved location. The alignment was constructed with MUSCLE 
(Edgar, 2004; McWilliam et al„ 2013).
1 35
Figure 54. Sites for myristoylation and phosphorylation in the a-synuclein
The blue regions are sites o f  myristoylation o f N-terminal glycines by the N- 
myristoyltransferase, the green region is the site for phosphorylation o f specific tyrosine 
residues by tyrosine kinase enzyme and the red is the region for phosphorylation o f 
specific threonine/serine residues by the enzyme casein kinase II. The letter ‘N" 
designates the N-terminus and ‘C ‘ designates the C-terminus of the protein. This 
structure is visualized with Rasmol (pdb code: lx q 8 ) (version 2.7.1).
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Protein size, coverage and sequence similarity
The sizes o f the human synucleins and their related proteins are summarized in 
Table 5. The sequence similarity and overlap between each human synuclein and the 
four disparate proteins according to our results are summarized in Tables 6 -8 . The 
percentage similarity between synucleins and the related proteins was obtained as 
follows: the number o f  residues o f the related protein that were identical or similar to the 
synuclein was divided by the total length o f the related protein and then multiplied by 
100. The percentage synuclein coverage was obtained as follows: the length o f  the 
synuclein containing regions which were similar to the related protein was divided by 
the total length o f the synuclein and then multiplied by 100. The percent related protein 
coverage was obtained as follows: the length o f the related protein containing regions 
similar to the synuclein was divided by the total length o f the related protein and then 
multiplied by 1 0 0 .
Table 5. Sizes of the synucleins and the disparate proteins







Cytochrome c class I 192
1 37
Table 6. Similarity between a-synuclein and the four disparate proteins
Protein %
Similarity
aLength of a- 
synuclein









Endoglucanase 24 1 0 9 (1 -1 0 9 ) 78 1 2 0 (6 1 -1 8 0 ) 55
CRE-DUR-1 9 1 0 0 (1 -1 0 0 ) 71 1 0 8 (3 5 7 -4 6 4 ) 21
Marsupial 27 1 1 3 (1 -1 1 3 ) 81 1 2 0 (1 -1 2 0 ) 39
Cytochrome c 23 9 6 ( 1 - 9 6 ) 69 1 0 6 (1 5 -1 2 0 ) 55
“Length (residues) o f  a-synuclein containing regions similar to the related protein. 
bLength (residues) of  the related protein containing regions similar to a-synuclein.
Table 7. Similarity between p-synuclein and the four disparate proteins











Endoglucanase 21 105 (1 -105) 78 1 1 6 (4 8 -1 6 3 ) 53
CRE-DUR-1 7 89 (1 -89) 66 1 0 8 (3 5 7 -4 6 4 ) 21
Marsupial 25 107 (1 -107) 79 1 2 0 (1 -1 2 0 ) 39
Cytochrome c 22 85 (1-85) 63 106 (1 5 -1 2 0 ) 55
“Length (residues) o f  p-synuclein containing regions similar to the related protein. 
bLength (residues) o f  the related protein containing regions similar to the P-synuclein.
Table 8. Similarity between y-synuclein and the four disparate proteins
Protein %
Similarity











Endoglucanase 22 1 0 9 (1 -1 0 9 ) 85 120 (6 1 -1 8 0 ) 55
CRE-DUR-1 9 1 0 0 (1 -1 0 0 ) 79 1 0 8 (3 5 7 -4 6 4 ) 21
Marsupial 27 1 1 7 (1 -1 1 7 ) 92 1 2 0 (1 -1 2 0 ) 39
Cytochrome c 24 9 6 ( 1 - 9 6 ) 76 1 0 6 (1 5 -1 2 0 ) 55
“Length (residues) o f  y-synuclein containing regions similar to the related protein. 
bLength (residues) of  the related protein containing regions similar to y-synuclein.
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The organisms in which the four disparate proteins related to the synucleins are 
found range from a bacterium to a vertebrate (Figure 55). In this figure are shown 
images or illustrations o f  the Caenorhabditis rem and  nematode, the gram negative 
bacilli Acetohacter pom orum . the gram negative spiral shaped Thiomicrospira 
crunogena and the Tasmanian Devil. A phylogenetics analysis was conducted using the 
synucleins and the protein sequences identified from these organisms. From the 
phylogenetic tree constructed the CRE-DUR-1. endoglucanase and P-synuclein proteins 
seems to be the closest to the ancestor protein and the furthest from the ancestor are y- 
synuclein and cytochrome c (Figure 56). The relative distances o f the proteins from the 
ancestor are summarized in Table 9.
1 3 9
C D
Figure 55. Organisms in which proteins related to the synucleins are found
(A) The protein CRE-DUR-1 is from Caenorhabditis remanei nematode. The figure is 
reproduced from Timmermeyer (Timmermeyer et al., 2010).
(B) Endoglucanase enzyme is from a gram negative bacillus (Sokollek et al., 1998).
(C) Cytochrome c class I is from a motile gram negative spiral shaped bacterium 
Thiomicrospira crunogena. This figure is reproduced from (Jannasch et al.. 1985).
(D) The Tasmanian Devil protein is from the Tasmanian Devil. The figure is reproduced 
from the website: www.devilsatcradle.com.
1 4 0
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Figure 56. The phylogenetic tree constructed from the human synucleins and the 
four related proteins
The numbers in red indicate the relative distances between the ancestor and the
individual proteins.
Table 9. Relative distances of the proteins from the ancestor
Protein Relative distance from ancestor
CRE-DUR-1 (0 .109  +  0 .3086) 0 .4176
Endoglucanase (0 .09242  +  0 .4185) 0 .51092
p-synuclein (0 .109  +  0 .4088  +  0 .0 4 1 8 7 ) 0 .55967
a-Synuclein (0 .109+  0 .4088+  0 .0 8 8 9 6 ) 0 .6 0 6 7 6
Marsupial (0 .109  +  0 .4088  + 0 .1197  + 0 .01186) 0 .6 4 9 3 6
Cytochrome c (0 .09242  +  0 .6161) 0 .70852
y-Synuclein (0 .109  + 0 .4088  +  0 .1197  + 0 .0 3 1 0 4 ) 0 .66854
Modeling the protein structures
Interestingly, the model structures o f the four disparate proteins show helical and
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hairpin structures similar to the micelle bound a-synuclein in Figure 16. Models o f  the 








Figure 57. The predicted three-dimensional structure of the disparate proteins 
related to the synucleins using Swiss-Model
(A) Endoglucanase from a gram negative bacillus Acetobaclerpomorum.
(B) CRE-DRU-1 protein from the Caenorhabditis remanei nematode.
(C) Tasmanian Devil protein from the Tasmanian Devil mammal.
















Point mutations and exon locations
An investigation to distinguish any differences between human synucleins and 
those o f other animals, particularly in connection with the A30P. E46K. H50Q. G51D 
and A53T point mutations was conducted. All of these point mutations are associated 
with early-onset Parkinson's disease in humans. The mutations from one amino acid to 
another are caused by one base change either in the first or second position o f  the 
triplet codon. The codons and base m utations o f  the amino acids are show n in Table 
10. The color red highlights the point mutations and the green is the normal base 
present.
Table 10. Codons of amino acid mutations associated with 
early-onset Parkinson’s Disease_______________________
Codon Amino acid Codon Amino acid
GCU C A U
GCC C A C Histidine
GCA C A A
GCG Alanine C A G Glutamine
ACU GGU
ACC G GC Glycine
AC A G A U
ACG Threonine G A C Aspartate
ecu G A A
CCC G A G Glutamate
CCA A A A
C C G Proline A A G Lysine
1 4 4
In the A30P and the A53T mutations, the guanine (green) base in the alanine 
codon is substituted with an adenine (red) and cytosine (red) to generate a threonine and 
a proline residue respectively. The change of the uracil or cytosine base in the third 
position (green) in the histidine codon to adenine or guanine results in a glutamine 
residue in the H50Q mutation. When the guanine base (green) in the second position o f 
the glycine codon is replaced by an adenine (red) the result is an aspartate residue in the 
G51D mutation. Finally, in the E46K mutation, the guanine base (green) in position one 
o f the glutamate codon is substituted with an adenine (red) and a lysine is produced.
The life spans o f humans and other animals whose synucleins were used to study 
the differences in the synuclein mutations are shown in Table 11. They come from a 
wide variety o f animals ranging from mammals to amphibians, reptiles and birds for 
example. The ages differ from 4 years for the mouse to 255 for the giant tortoise.
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Table 11. The life span o f various anim als including humans












Crab eating monkey 37
Spider monkey 33
Horse 25-33











Gerbil (dessert rat) 5
The source o f  this information com es from the follow ing: Rowe, (1996): Larsen et 
al., (2009) and http://sonic.net/-petdoc/lifespan.htm _______________________________
An alignment o f  human and other primate a-synucleins was constructed (Figure 
59). The green color indicates locations where the mutations A30P, E46K, H50Q, G51D 
and A53T can occur in humans. The purple color indicates regions in the synucleins that 
are prone to aggregation (Kumar et al., 2009). The red color indicates amino acid 
residues different from those o f the human a-synuclein at the same location. The a- 
synucleins o f  the spider and the woolly monkeys have the mutant A53T while the rest of 
the primates have the conserved alanine (A), glutamate (E). histidine (H). glycine (G) 
and alanine (A) at locations 30, 46. 50. 51 and 53 respectively. Simulations studies have
1 4 6
also shown that the l6GVLYVG41 sequence forms the loop between the two helices o f  a- 
synuclein associated with lipid membrane, while the sequence 68GAVVTGVTAVA 78 is 
in the second helix (Kumar et al.. 2009) (Figure 60). Both sequences are conserved in 
the primates compared to a-synuclein.
30 36j41 46 50 51 53
* p -y .  1 W 11  MDVFMKGLSKAKEGWAAAEKTKQGVAEAAGKTKEGVXYVGSKTKEGWHGVTTVAEKTK 
1  MDVFMKGLSKAKEGWAAAEKTKQGVAEAAGKTKEGVTYVGSKTKEGWHGVTTVAEKTK 
1  MDVFMKGLSKAKEGWAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGWHGVATVAEKTK 
1  MDVFMKGLSKAKEGWAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGWHGVATVAEKTK 
1  MDVFMKGLSKAKEGWAAAEKTKQGVAEAAGKTKEGVI.YVGSKTKEGWHGVATVAEKTK 
1 MDVFMKGLSKAKEGWAAAEKTKQGVAEAAGKTKEGVI.YVGSKTKEGWHGVATVAEKTK 
1 MDVFMKGLSKAKEGWAAAEKTKQGVAEAAGKTKEGVX.YVGSKTKEGWHGVATVAEKTK 
1  MDVFMKGLSKAKEGWAAAEKTKQGVAEAAGKTKEGVT.YVGSKTKEGWHGVATVAEKTK 
1  MDVFMKGLSKAKEGWAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGWHGVATVAEKTK 
1  MDVFMKGLSKAKEGWAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGWHGVATVAEKTK
68t78
r-------  \  ___
6 1  EQVT SV G G A W T  GVTA VAQKTVEGAGNIAAATGFVKKD H S  GK SE  E GAPQE GILEDM FVD P
6 1  EQVTSVGGA W TGVTAVAQKTVEGAGNIAAATGFVKKDHSGKSEEGAPQEGILEDM PVDP
6 1  EQVTNVGGAW TGVTAVAQKTVEGAGNIAAATGFVKKDHIX5KSEEGAPQEGILEDMPVDP
6 1  EQVTNVGGAW TGVTAVAQKTVEGAGSIAAATGFVKKDQLGKNEEGAPQEGILEDM PVDP
6 1  EQVTNVGGAWTGVTAVAQKTVEGAGSIAAATGFVKKDQLGKNEEGAPQEGXEEDMPVDP
6 1  EQVTNVGGAWTGVTAVAQKTVEGAGS IAAATGFVKKDQLGKNEEGAPQEGILEDM PVDP
6 1  EQVTNVGGAW TGVTAVAQKTVEGAGSIAAATGFVKKDQLGKNEEGAPQEGILEDM PVDP
6 1  EQVTNVGGAWTGVTAVAQKTVEGAGS IAAATGFVKKDQLGKNEEGAPQEGILEDM FVDP
6 1  EQVTNVGGAWTGVTAVAQKTVEGAGS IA A A TG FIKKDQLGKNEEGA PQEGILQDM PVDP
6 1  EQVTNVGGAWTGVTAVAQKTVEGAGS IAAATGFIKKDQLGKNEEGAPQEGXLQDM PVDP
Figure 59. Sequence alignment of human and other primate a-synucleins
The green color indicates the locations where mutations A30P, E46K, H50Q. G 51D and 
A53T can occur. The red color indicates amino acids different from human a-synuclein. 
The purple regions are prone to aggregation (Kumar et al., 2009). The spider and woolly 
monkey have a threonine (T) instead o f  an alanine in location 53. The star symbol 
indicates identical residues; two dots, very similar; one dot, moderately similar. The 
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Figure 60. Amyloidogenic regions (blue) of human a-synuclein
This structure was generated by molecular dynamics simulations (Kumar et al., 2009). 
The figure is reproduced from Kumar (Kumar et al., 2009).
A comparison between human a-synuclein and a-synucleins from wild animals 
other than primates and from domestic animals showed that all the animals have a 
threonine residue (T) at location 53 instead o f the alanine (A) (Figure 61). The birds 
including the zebra finch, canary, duck and turkey differ significantly from the human a- 
synuclein in the sequence stretch between residues 113 and 120. The advantage o f  this 
difference from other animals is not yet known.
1 48
T 36^41 i  irr
1 MDVFMKGLS K A K EG W A A A EK TK Q G V A EA A G K TK EG V LY V G SRTK EG W H G V TTV A EK TK  z e b r a  f i n c h  
1 MD VFM KGLS K A KEGW AAAEKTKQGVAEAAGKTK E GVL Y V G SR TK E G W H  GVT TV A EK T K  c a n a r y  
1 MDVFM KGLNKAKEGW AAAEKTKQGVAEAAGKTKE GVL Y V G SR TK E G W H G V T T V A E K T K  d u c k  
1 MDVFMKGLNKAKEGW AAAEKTKQGVAEAAGKTKE GVL Y V G S R T K E G W H  GVT TV A EK T K  t u r k e y  
1  MDVFM KGLSKAKEGW AAAEKTKQGVAEAAGKTKE GVL Y V G SK TK EG W H G V T TV A EK TK  h o u s e  m o u s e  
1 MDVFM KGLSKAKEGW AAAEKTKQGVAEAAGKTKE GVL Y V G SK TK EG W H G V T TV A EK TK  r a b b i t  
1 M D VLM KGLSKAKEGW AAAEKTKQGVAEAAGKTKE GVL Y V G SR TK E G W H  GVT TV A EK TK  v a m p i r e  b a t  
1 M DVFMKGLSKAKEGW AAAEKTKQGVAEAAGKTKE GVL Y V G SK TK EG W H G V T TV A EK T K  f o x  
1 M D V FM K G LSK A K EG W AAAEKTKQGV AEAAGK TKEGVLY VGSKTKEGW HGVA TVAEKTK h u m a n  
1 M DVFMKGLSKAKEGW AAAEKTKQGVAEAAGKTKE GVL Y V G SK TK EG W H G V T TV A EK T K  d o g  
1 M D VFM KGLSKAKEG W AAAEKTK Q G V A EA A G K TK EG V LY V G SK TK EG W H G V TTV A EK TK  h o r s e  
1  M DVFM KGLSKAKEGW AAAEKTKQGVAEAAGKTKE GVL Y V G SK TK EG W H G V T TV A EK T K  s h e e p  
1 M DVFM KGLSKAKEGW AAAEKTKQGVAEAAGRTKE GVL Y V G SK TK EG W H G V T TV A EK T K  c a t t l e
68^78 1 1 3 -1 2 0
6 1  EQVSNVGGAW TGVTA VAQKTVEGAGN IAAATGLVKKDQLAKQNEEGFLQEGM VNNTGVA z e b r a  f i n c h  
6 1  BQVSNVGGAW TGVTAVAQKTVEGAGNXAAATGLVKKDQLAKQNEEGFLQEGM VNNTGAA c a n a r y  
6 1  EQ V SNVGGAW TGVTA VAQKTVEGAGN IAAATGLVKKDHIiAKQNEEGFLQEGM VNNTDVP d u c k  
6 1  EQ V SN V G G A W TG V TA V A Q K TV EG A G N IA A A TG LV K K D Q LA K Q N EEG FLQ EG W N N TD  I P  t u r k e y  
6 1  EQ yTN V G G A W TG V TA V A Q K TV EG A G N X A A A TG FV K K D Q M G K -G EEG Y PQ EG ILE— DMP h o u s e  m o u s e  
6 1  EQ V TN V G EA W TG V T A V A Q K T V EG A G SIA A A T G FV K K D Q Q G K -SE EG A PQ E G ILE — AM P r a b b i t  
6 1  EQ V TN V G EA W TG V TA V A Q K TV EG A G N IA A A TG FG R K D Q LG K - S E E G A P Q E G IL E — DMP v a m p i r e  b a t  
6 1  EQVTNV G EA W TG V TA V A Q K TV EG A G S IA A A T G F G R K D Q L G K -S E E G A P Q E G IL E — DM P f o x  
6 1  EQ V TN V G GAW TG VTAVAQ KTVEGAGS X A A A TG FV K K D Q L G K -N EE G A PQ E G IL E — DM P h u m a n  
6 1  EQ V TN V G EA W TG V TA V A Q K TV EG A G SX A A A TG FG K K D Q LG K -SEEG G PQ EG X LE— DM P d o g  
6 1  EQ V TN V G EA W TG V TA V A Q K TV EG A ES XAAATGFGKKDHIX5K- S E E G A A Q E G IL E — DM P h o r s e  
6 1  E Q V TN V G EA W TG V TA V A Q K TV EG A G SIA A A TG FG K K D H LG K - G E E G A S Q E G IU S — DM P s h e e p  
6 1  EQ V TN V G EA W TG V TA V A Q K TV EG A G S IA A A TG FG K K D H M G K - G E E G A S Q E G IL E — DMP c a t t l e
* * * * * * *  * * * * * * * * * * * * * * * * *  * * * * * * . * • •  * * * ■
Figure 61. Sequence alignment of human, domestic and wild animal a-synucleins
All the animals have the A53T mutation. The a-synucleins o f  the birds differ 
significantly from the human a-synuclein between residues 113 and 120. The purple 
amyloidogenic regions are intact except for glutamate (E) substitutions for the glycine 
(G) at position 6 8  o f the 68-78 residue sequence. Color code: green are locations o f 
mutations; purple are the amyloidogenic regions; and red are amino acid residues that 
are different from those o f  the human a-synucleins at a given location. In the alignment: 
the star symbol indicates identical residues; the two dots, very similar; one dot, 
moderately similar. The alignment was constructed with MUSCLE (Edgar, 2004; 
McWilliam et al.. 2013).
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The a-synucleins o f long-lived animals have threonine (T) at location 53 (Figure 
62). The alignment also indicates truncations o f the long-lived animal synucleins at both 
the N- and the C-termini. The long-lived animals lack the 'MDVF4 and the 
l30EEGYQDYEPEAl40sequences that are present in the human a-synuclein. The 
truncations result in shorter a-synucleins ranging from 124-125 amino acids in length. 
Interestingly, this is not observed in other animals (Figure 62).
The P-synuclein alignment indicates that some animals have a substitution at the 
glutamate (E) location (46). The observed substitutions are aspartate (D). glutamine (Q) 
or serine (S) (Figure 63). Also, some animals have threonine (T) or glycine (G) instead 
o f the alanine (A) at position 53. The salmon, zebra, rainbow smelt fish and the African 
clawed frog have several substitutions in the 36-41 amyloidogenic sequence. Both 
humans and animals have extensive substitutions in the 68-78 amyloidogenic sequence. 
Interestingly, both humans and other animals have glutamine (Q) at location 50 instead 
o f a histidine (FI) as was observed for a-synucleins.
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30 3641  46 50 51 53i ,-JU i u \
1 --------- M K G LSK A K EG W A A A EK TK Q G V A EA A EK TK E GVL Y V G SK TK E G W H  GVT TVAEKTK m in k e  w h a le
1 --------- M K G LSK A K EG W A A A EK TK Q G V A EA A EK TK E GVL Y V G SK TK E G W H  G V TTV A EK TK  p o r p o i s e  w h a le
1 --------- M K GliSK A K EG W A A A EK TK Q G V A EA A G K TK E GVL Y V G SK TK E G W H  G V TTV A EK TK  e l e p h a n t
1 --------- M K G LSKAKEGW AAAEKTKQGVAEAAGKTKE GVL Y V G SK TK E G W H  G V TTV A EK TK  s t u r g e o n  f ish
1 --------- M K GLSKAKEGW AAAEKTKQGVAEAAGKTKE GVL Y V G S K T K E G W H  GVTTV A EK TK  g i a n t  to r to i s e
1 --------- M K GLSKAKEGW AAAEKTKQGVAEAAGKTKE GVL Y V G SK TK E G W H  G V TTV A EK TK  c r o c o d i le
XM DVFM KGLSKAKEG W A A A EK TRQ G V A EA A G K TK EG V LY V G SK TK EG W H G V A TV A EK TK  h u m a n
68^78
5 7  E Q V T N V G E A W T  GVTAVAQKTVE GAGS XAAATGFGKKDQLGK S  -  E  G A S Q E G I  LED T FV D  P  
5 7  EQVTNVG EA W T G V T A V A Q K T V E G A G S IA A A T G F G K K D Q L G K S -E G A S Q E G IL E D T P V D P  
5 7  EQ V TN V G EA W T G V T A V A Q K T V EG A G SIA A A T G FG K K D Q H G K G EE G A PQ EG IL EN V FV D P 
5 7  EQ V TN V G EA W TG V TA V A Q K T V EG A G SIA A A T G FG K K D Q H G K G EE G A PQ EG IL EN V PV D P 
5 7  EQ V TN V G G A W TG V TA V A Q K TV EG A G SIA A A TG FV K K D Q LG K N EEG A PQ EG X LED M PV D P 
5 7  EQVTNVG GAW TG VTA V A Q K TV EG A G SX A A A TG FV K K D Q IiG K N EEG A PQ EG X LEO M PV D P 
6 1  EQVTNVG GAW TG VTA V A Q K TV EG A G SX A A A TG FV K K D Q LG K N EEG A PQ EG X LED M PV D P
1 1 6  D N EA Y EM PS-------------------------- m in k e  w h a le  (5 0  y e a r s )
1 1 6  D SEA Y EM PS-------------------------  p o r p o i s e  w h a le  (1 5 -2 0  y e a r s )
1 1 6  D N EA Y EM PS-------------------------  e l e p h a n t  (6 0 -7 0  y e a r s )
1 1 6  D N EA Y EM PS-------------------------  s t u r g e o n  f ish  (5 5  y e a r s
1 1 6  D N EA Y EM PS-------------------------  g i a n t  t o r to i s e  (2 5 5  y e a r s )
1 1 6  D N EA Y EM PS-------------------------  c r o c o d i le  ( 7 0 -1 0 0 )
1 2 1  D N EA Y EM PSEEG Y Q D Y EPEA  h u m a n  (6 8 -1 1 2  y e a r s )
* a *******
Figure 62. Sequence alignment o f human and long-lived animal a-synucleins
The animals have shorter a-synucleins ranging from 124 to 125 amino acid residues. 
There are truncations at the N- and the C-terminus. There is a threonine residue (T) at 
location 53 in all the animals. Color code: green are locations of possible mutations; 
purple are the amyloidogenic regions; and red are amino acid residues different from 
those o f the human a-synucleins at a given location. The alignment was constructed with
m in k e  w h a le  
p o r p o i s e  w h a le  
e l e p h a n t  
s tu r g e o n  f ish  
g i a n t  to r to i s e  
c r o c o d i le  
h u m a n
MUSCLE (Edgar, 2004; Me William et al., 2013).
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30 36-41
IICQGVTEAAEKTKEGVDYA--------------------------------- M DVFM KGLSM AKEGW AAAEKTKQG  G LTyVGS K TR
--------------------------------- MDVLMKGFSKAKEGW AAAEKTKQGVAEAAEKTKEGVDYMGSKTR
--------------------------------- m e v f m k g l s k a k e g w a a a e k t k q g v a e a a e k t k e g v l y v g s k t -
--------------------------------- m e v f m k g l s k a k e g w a a a z k t k q g v a e a a z k t k e g v l y v g s k t -
--------------------------------- m d v f m k g l s m a k e g w a a a e k t k q g v t e a a e k t k e g v l y v g s k t -
--------------------------------- m d v f m k g l s m a k e g w a a a e k t k q g v t e a a z k t k e g v l y v g s k t k
--------------------------------- m d v f m k g l s m a k e g w a a a e k t k q g v t e a a e k t k e g v l y v g s k t r
VCVCDRVTW CVQAARDVFM KGLSM AKEGW AAAEKTKQGVTEAAEKTKEGVI.rVGSKTR
--------------------------------- m d v f m k g l s m a k e g w a a a e k t k q g v t e a a e k t k e g v l y v g s k t k
--------------------------------- M DVFM KGLSMAKEGW AAAEKTKQGVTEAAEKTKE GVL YVG S K TR
----------------------------------m d v f m k g l s m a k e g w a a a e k t k q g v t e a a e k t k e g v l y v g s k t r
----------------------------------MDVFMKGLSMAKEGWAAAEKTKQGVTEAAEKTKEGVLYVGSKTR
--------------------------------- m d v f m k g l s m a k e g w a a a z k t k q g v t e a a k k t k e g v l y v -----------
--------------------------------- m d v f m k g l s m a k e g w a a a e k t k q g v t e a a e k t k e g v l y v g s k t r
--------------------------------- m d v f m k g l s m a k e g w a a a e k t k q g v t e a a e k t k e g v l y v ----------
--------------------------------- MDVFMKGLSMAKEGWAAAEKTKQGVTEAAEKTKEGVDYVGSKTR
--------------------------------- m d v f m k g l s m a k e g w a a a e k t k q g v t e a a e k t k e g v l y v -----------
----------------------------------M DVFHKGLSKAKDGM AIAAEKTKZGAALAAEKTKEGAM FIGTKAK
----------------------------------MDVFMKGLSKAKEGMAVAAEKTKEGVAVAAEKT1CEGVMFVGSKTK
--------------------------------- MDVFMKGLSKAKEGMAVAAEKTKZGVAVAAEKTKEGVMFVGTKAK
; * ; * * *  *  * * : *  * * * * * * * * ;  ******** ̂
4 6  SO 5 1 5 3  6 8 j7 8
4 6  ^G w iiv lsV A Z K T K E Q A S H L G dA V F S G A G N lA A A T G L V K R Z E F P T D  LKPEEVAQEAAEE 
4 6  DGW QG VTSVAEM TKEQA SQ LGGAVM SGAGNIAAATGLVK KDEFPTD IKFEEEGQEA LEE 
4 5  QGW QGVTSVAEKAKEQASQLGEAAFSGAGNIAAATGLVKKEEFFADLKAEEVAQEAVEE 
4 5  Q G W Q  GVT SVAEKAKEQ ASQ 1GEAAFS GAGN I  AAATGLVKKEE FPA D  LKAEEVAQEAVEE
4 5  SGW QGVASVAEKTKEQASHLGGAVFSGAGNIAAATGLVKKEEFPTDLKAKEVAQEAAEE
4 6  EGW QGVASVAEKTKEQASHLGGAVFSGAGNIAAATGLVKKEEFPTDLKAKEVAQEAAEE 
4 6  EGW QGVASVAEKTKEQASHLGGAVF SG A G N I A A A TGLV KREEFPTDLKPEEVAQEAAEE
1 2 1  E G W Q  GVASVAEKTKEQAS HLGGAVF S GAGNIAAATGLVKKEE F P  SD LKPEEVAQEAAEE 
4 6  EGW QGVASVAEKTKEQASHLGGAVFSGAGNIAAATGLVK KEEFPTDLKFEEVAQEAA EE 
4 6  E GW QGVASVAEKTKEQASHLGGAVFSGAGNI AAATGLVKKEE F P  AD LKPEEVAQEAAEE 
4 6  EGW QGVASVAEKTKEQASHLGGAVFSGAGNIAAATGLVKKEEFPADLKPEEVAQEAAEE 
4 6  E G W Q  GVASVAEKTKEQAS HLGGAV F  S  GAGN IA A A TG LV K K EE FPT D  LKPEEVAQEAA EE
4 1 --------------------VAEKTKEQASHLGGAVFS GAGN I  AAATGLVKKEE FPTD LK PEEV A Q EA A EE
4 6  EGW QGVASVAEKTKEQASHLGGAVFSGAGNIAAATGLVK KEEFPTDLKPEEVAQEAA EE
4 1 ------------------- VAEKTKEQASHLGGAVFSGAGNIAAATGLVKREEFPTDLKPEEVAQEAAEE
4 6  E G W Q  VAEKTKEQASHLGGAVFSGAGNIAAATGLVKREEFPTDLKPEEVAQEAAEE
4 1 ------------------- VAEKTKEQASHLGGAVFSGAGNIAAATGLVKK EEFPTDLK PEEV AQEAA EE
4 6  DGV---------------------------GSAKDLAGGAM GNIAAATGLGKKDEFPSDM HPEEYGQEAM EG
4 6  DSV ATVAEKTKEQASQLGGAVMS GAGNIAAATGLVKKDE FPSD M N P-  E  FGQEATEE
4 6  DSVGSG AEKMKEQASNFGGAM GNIAAATGLVKKDEFPTDM NPEEYGQEAM EE
★★**★**** * •***•★•• * *★* **
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Figure 63. Sequence alignment of human and other animal p-synucleins
Color code: green are locations o f  possible mutations: purple are the amyloidogenic 
regions; red are amino acid residues different from those o f  the human a-synucleins at a 
given location. In the alignment: the star symbol indicates identical residues; the two 
dots, very similar ones: and one dot. moderately similar ones. The alignment was 
constructed with MUSCLE (Edgar. 2004; McWilliam et al., 2013).
1 5 3
y-Synucleins in both humans and animals have the threonine (T) at location 53 
(Fig. 64). Fish and frog have asparagine (N) instead o f  threonine at this position. The 
leucine (L) in the 36-41 amyloidogenic sequence is substituted with either isoleucine (I) 
or methionine (M). The 68-78 amyloidogenic sequence is extensively substituted. The 
alanine (A) in position 30 and the glutamate (E) in position 46 are conserved in both 
humans and animals. y-Synuclein in humans and the majority of animals have glutamine 
(Q) instead of histidine (H) in location 50. serine (S) instead of glycine (G) at location 






46 S O S 153
1 lit
1 MDVXKKGFSMAKDGWAAAEKTKAGVEGAATKTKEGVI YVGNKTMEGWTSVNTVAHKTT 
1 MDVTKKGFSMAKEGWGAVEKTKQGVTEAAERTKEGVMYVGTKTKEGWNSVNTVAEKTK 
1 MDVFKKGFSMAKEGWAAAEKTKQGVTEAAEKTKEGVMYVGAKTKEGWHSVNTVAEKTK 
1 MDVFKKGFS IAKEGVVAAAEKTKQGVTEAAEKTKEGVMYVGTKTKEGVVQSVT SVAEKTK 
1 MDVFKKGFS IAKEGW AAAEKTKQGVTEAAEKTKZGVMYVGTKTKEGW QSVT SVAEKTK 
1 MDVFKKGFSIAKEGWGAVEKTKQGVTEAAEKTKEGVMTVGAKTKENWQSMTSAAEKTK 
1 MDVFKKGFSIAKEGWGAVEKTKQGVTEAAEKTKEGVMYVGAKTKEGWQSMTSVAEKTK
1  MHKG RQEGWGAVEKTKQGVTEAAEKTKEGVLYVGAKTKENWQSVTSVAEKTK
1 M DVFKKGFSIAKEGW GAVEKTKQGVTEAAEKTKEGVM rVGTKTKENW QSVTSVAEKTK 
1 MDVFKKGFSIAKEGWGAVEKTKQGVTEAAEKTKEGVMYVGAKTKENW H SVT SVAEKTK 
1 MDVFKKGFS IAKEGW GAVEKTKQGVTKAAEKTKEGVMYVGAKTKENW QSVT SVAEKTK 
1 MDVFKKGFS IAKEGW DAVEKTKQGVTEAAEKTKEGVMYVGAKTKENWQ SVT SVAEKTK 
1 MDVFKKGFS IAKEGW GAVEKTKQGVTEAAEKTKE GVMYVGTKTKENWH SVT SVAEKTK 
1 MDVFKKGFS IAKEGVVGAVEKTKQGVTEAAEKTKEGVMYVGTKTKEGVVQ SVT SVAEKTK 
1 MDVFKKGFS IAKEGW GAVEKTKQGVTEAAEKTKE GVL YVGVKTKEGW QSVT SVAEKTK 
1 MDVFKKGFS IA K E GWGAVEKTKQGVTEAAEKTKE GVMYVGAXTKEGWQ SVT SVAEKTK 
1 MDVFKKGFS IA K E GWGAVEKTKQGVTEAAEKTKE GVMYVGAKTKEGWQSVT SVAEKTK 
1 MDVFKKGFS IA K E GWGAVEKTKQGVTEAAEKTKE GVMYVGAKTKENWQSVT SVAEKTK
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6 1  EQANIIADTAVSGANEVAQSAVEGVENAAVASGLV SLEEA G P— VSEKA—GVPNTEA
61  ESAQAVSGAWSGVNTVAGKTVEGAENVAAAAGI PM EPTEP— GAEPG-AEPGEQE
61  EQANW GGAW SGVNQVSSKTVEGTZNW SSTGLVKKEDLHPDQFEEPAAEE-PAVEATE
61  e q a n w x x x x x x s v n t v a n k t v e g a e t iv a t t g v ik k e d l a p q q p —a a e g e p a a p g s t e
6 1  EQANW GEAW ASVNTVANKTVEGAETIVATTGW KKEDLAPQQP— AAEGEAA IPGSTE
6 1  EQ A N A V SEA W M SV N TV A TK TV EEA EN IW TA G W RK V SLV SSCP--R--------------- PGRQP
6 1  EQANW SEAW ASVNTVATKTVEEAENIAVTSGW RKEDLVKPVP— PQ -D K -A A TEEEG  
5 5  BQ A N A VSEAW TSINTVAVK TVEEAENIAITSGW RKEDLEQPAA—  PQEDK-AAKVQEE
6 1  EQANAVSEAW SSVN TVANK TVEEAENIW TTGW RKEDLEPPAQ— DQEAK---------- EQE
6 1  EQ A N A V SEA W TSV N TV A TK TV EEA EN IW TSG W R K ED LK PSA F--PQ EG E-A A -K ZEE 
6 1  EQANAVSEA W SSVN TVATKTV EEAENIAVTSGW RKEDFKPSAP- -Q Q EG E-A SK EK EE 
6 1  EQANAVSEA W SSV N TV A TK TV EEA EN IA V TSG W RK ED LRPSA P--Q Q EG E-A SK EK EE 
6 1  EQANAVSEAW SSVNTVAAKTVEEAENIAVTSGW RKEDLKPSAP— QQEGE-AAKEKEE 
6 1  EQANAVSGAW ASVNTVATKAVEEVENVALTAGW RKEDLEQPAP— PQEDK-AAKAEEE 
6 1  EQANAVSEAW S S VN TVATKTVEEVENIAVT S  GAVRKEALKQ PV P— SQEDE-AAKAEEQ 
6 1  EQANAVSEAW S SVNTVATKTVEEVENIAVTSGW HKEALKQPVP— SQEDE-AAKAEEQ 
6 1  EQASAVSEAW  S S VNTVATKTVEEAENIAVTSGW RKEDLHQPAP- -  SQ -D E  -AAKVEEE 
6 1  EQ A H A V SEA W TSV N TV A IK TV EEA EN IA ITSG V IRK ED LEQ PA P— SQEDK-AAKAEEE
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Figure 64. Sequence alignment of human and other animal y-synucleins
y-Svnucleins o f  frog, rabbit and rhesus monkey have histidine (H) in location 50 while 
the other animals including humans have glutamine (Q). y-Synucleins o f  both humans 
and animals have a serine (S) in location 51 instead o f a glycine (G) as is the case in a- 
and P-synuclein (Figures 61 and 63). In addition, in location 53. some animals have an 
asparagine (N) instead o f threonine (T). Color code: green are locations o f  possible 
mutations; purple are the amyloidogenic regions; and red are amino acid residues 
different from those o f the human a-synuclein at a given location. In the alignment: the 
star symbol indicates identical residues: the two dots, very similar ones; and one dot, 
moderately similar ones. The alignment was constructed with MUSCLE (Edgar. 2004; 
Me William et al., 2013).
1 5 6
The observations made o f the synuclein m utations in humans and other animals 
are summarized in Table 12. Among the primates, the woolly and spider monkey a- 
synucleins have a threonine at location 53 instead o f  an alanine residue. Long-lived and 
other animal a-synucleins also have a threonine at location 53. p-synucleins have a 
glutamate, aspartate or glutamine residue at location 46. They also have a glutamine at 
location 50 instead o f a histidine. At location 53. they have either an alanine or a 
threonine residue. y-Synucleins have substitutions at locations 50. 51 and 53.
The segments of the a-, (3- and y-synuclein genes that translate into the 
degenerate repeat sequences were identified. The repeat sequences are indicated by the 
purple color and are underlined (Tables 13-15). For a-synuclein. exon two contains the 
first, second and third degenerate repeat sequences. The third exon contains the fourth, 
while the fourth exon contains the fifth, sixth and seventh repeat sequences (Table 13). 
For P-synuclein, the first, second and third repeat sequences are in exon three The fourth 
repeat sequence is in exon four. The fifth and the truncated sixth and seventh repeat 
sequences are in exon three (Table 15).
Table 12. Point mutations in the synucleins
Protein “Locations of select key mutations
A 3 0 P  E46K H50Q G 5 1 D  A 5 3 T
Primate a-synucleins A E H G A
W oolly  and spider monkey a-synucleins A E H G T
Long-lived animal a-synucleins A E H G T
Other animal a-synucleins A E H G T
P-synucleins A E/D/Q Q G A /T
y-synucleins A E T/Q/H S N /T
“Alanine (A): Glutamate (E); Histidine (H): Lysine (K); Asparagine (N); Proline (P); Glutamine (Q): 
Serine (S): Threonine (T)
1 5 7
Table 13. a-Synuclein exons that encode the degenerate repeat sequences
Exon DNA sequence Amino acid
Exon 2 atg gat gta ttc atg aaa gga ctt tea aag gcc aag gag gga gtt 
gtg get get get gag aaa ace aaa cag ggt gtg gca gaa gca gca 





Exon 3 ggc tec aaa ace aag gag gga gtg gtg cat ggt gtg gca aca 
gtg get
41  G SKTKEGVVHGV 
ATVA
Exon4 gag aag ace aaa gag caa gtg aca aat gtt gga gga gca gtg 
gtg acg ggt gtg aca gca gta gcc cag aag aca gtg gag gga 






Table 14. P-Synuclein exons that encode the degenerate repeat sequences
Exon DNA sequence Amino acid sequence
Exon 3 atg gac gtg ttc atg aag ggc ctg tcc atg gcc aag gag ggc 
gtt gtg gca gcc geg gag aaa acc aag cag ggg gtc acc 





Exon 4 gga age aag acc cga gaa ggt gtg gta caa ggt gtg get 
tea gtg get
41 G SKTREGVVQGV 
ASVA
Exon 5 gag aag acc aaa gag caa gtg aca aat gtt gga gga gca 
gtg gtg acg ggt gtg aca gca gta gcc cag aag aca gtg  
gag gga gca ggg age att gca gca gcc act ggc ttt gtc aaa 






Table 15. y-Synuclein exons that encode the degenerate repeat sequences
Exon DNA sequence Amino acid sequence
Exon 1 atg gat gtc ttc aag aag ggc ttc tcc ate gcc aag gag ggc 
gtg gtg ggt geg gtg gaa aag acc aag cag ggg gtg acg 





Exon 2 gga gcc aag acc aag gag aat gtt gta cag age gtg acc 
tea gtg gcc
41 G AKTKENWQSV 
TSVA
Exon 3 gag aag acc aag gag cag gcc aac gcc gtg age gag get 
gtg gtg age age gtc aac act gtg gcc acc aag acc gtg gag 







Among the synucleins, there is variability in size with some proteins containing 
121  residues (mole rat a-synuclein), while others are composed o f 2 1 0  residues 
(mole rat p-synuclein). For the long synucleins, the extra residues are added at the N- 
terminus, (Figures 40 and 42). There are also truncations at either the N- or C-terminus 
or both, as is the case for a-synucleins in long-lived animals (Figure 62). The histidine 
residue at location 50 is only seen for the a-synucleins. This histidine in a-synucleins is 
necessary for binding copper. As already discussed in a previous section, a-synucleins 
have a copper-dependent ferrireductase enzyme activity (Davies et al., 2011). Further, 
a - and p-synuclein have an alanine at position 53 while y-synuclein has a threonine 
which is interesting, as a mutation in a-synuclein to threonine is found in some patients 
with early-onset Parkinson's. Lastly, all three synucleins vary in the number o f  exons 
with p-synuclein having 7. and a -  and y-synuclein having 6  and 5. respectively which 
suggests deletion was involved in the evolution o f  the latter two.
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The synucleins and their related proteins
Our bioinformatics results indicate that the synucleins do not appear to belong to 
a superfamily in animals. However, they share a marginal relationship to four disparate 
proteins which include an endoglucanase enzyme, a CRE-DUR-1 protein, a marsupial 
(Tasmanian Devil) protein and cytochrome c. The similarity between the synucleins and 
the endoglucanase, the CRE-DUR-1 and the cytochrome c proteins is based on the 
presence o f the hexameric KTK(E/Q)GV m otif in their polypeptide sequences. The N- 
terminus o f  the marsupial protein is almost identical to that o f  the synucleins (Figure 
48).
The endoglucanase enzyme from bacterium Acetobacter pom orum  shares 20- 
35% similarity with the human synucleins as indicated in Tables 2-4. The protein 
belongs to a group o f enzymes in bacteria and fungi which are responsible for wood 
decay by breaking the p-l,4-glycosidic bonds in cellulose to generate smaller 
saccharides. A characterized endoglucanase (218 amino acids) from a fungus is 
composed o f  two P-sheet sandwiches and one a-helix (Sandgren et al., 2001), while 
another from bacterium Thermotoga maritime contains a-helices and p-sheets arranged 
into a barrel shape (Pereira et al.. 2010). The synucleins are heat stable at 100°C. 
Interestingly, some endoglucanase enzymes are also thermophiles that are stable at 70°C, 
such as an endoglucanase from the fungus Daldinia eschscholziii (Kam chanatat et al.. 
2008). The endoglucanase from the bacterium Acetobacter pomorum  has not yet been 
characterized. It is possible that the svnuclein-like repeats are interacting with the 
cellulose.
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The second relative o f the synucleins retrieved from the database was the protein 
from the Tasmanian Devil which shares 80%. 65% and 55% similarity with human y-.a- 
and p-synuclein respectively (Tables 2-4). The protein is composed o f  310 amino acid 
residues. The marsupial polypeptide sequence has an alanine (A) at location 30 a 
glutamate (E) at location 46. a glutamine (Q) at location 50, a serine (S) at location 51 
and a threonine (T) at location 53. This pattern is similar to the one observed in the y- 
synucleins (Figure 64). The N-terminus domain o f the marsupial protein may have a 
function similar to that o f  the N-terminus o f y-synucleins.
The CRE-DUR-1 is a large protein composed o f  524 amino acid residues. The 
segment o f the polypeptide that is similar to the synucleins is the stretch between 
residues 356 and 463 and begins with MDV (methionine, aspartate and valine, 
respectively) which is similar to the synucleins (Figure 45). The CRE-DUR-1 protein 
shares 36% similarity with a- and y synucleins, and 32% with the P-synuclein (Tables 2- 
4). The phylogenetic tree (Figure 56) appears to indicate that the CRE-DUR-1 protein is 
the one closest to the ancestor and is also closer to the synucleins than the 
endoglucanase and cytochrome c. The 108 amino acid section of similar residues of 
CRE-DUR-1 appears to correspond to the synuclein N-terminal domain. The CRE- 
DUR-1 has not been characterized and its function in the nematode is not known. 
However, the CRE-DUR-1 shares 27% (e-value =7 x 10'9) sequence identity with the 
late embryogenesis abundant (LEA) proteins. LEA proteins in a nematode Aphelenchus 
avenae have a chaperone-like function (Goyal et al., 2005). They protect other proteins 
in the worm from aggregation induced by desiccation. The proteins are described as
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greatly hydrophilic and unstructured in solution (Goval et al.. 2005). The CRE-DUR-1 
may have a similar function as the LEA-1 proteins.
The fourth protein related to the synucleins is cytochrome c class I from the 
bacterium Thiomicrospira crunogena. Cytochrome c which transports electrons between 
complex III and complex IV o f the electron transport chain in both prokaryotes and 
eukaryotes, belongs to class I cytochromes (Battistuzzi et al.. 2001). The cytochrome c 
from the Thiomicrospira crunogena bacterium is composed of 192 residues and shares 
23%. 22% and 24% sequence similarity with a-. P- and y-synucleins respectively 
(Tables 6 -8 ). The segment o f the protein that is similar to the synuclein N-terminus is 
between residues 15 and 119 (Figure 50). Incidentally, both human cytochrome c and a- 
synuclein associate with the inner membrane o f  the mitochondria (Parihar et al., 2008). 
Interestingly, the aggregated mutant A53T of a-synuclein causes the release o f 
cytochrome c into the cytoplasm at the human mitochondria membrane. This release 
initiates apoptosis, resulting in the death o f the cell (Parihar et al.. 2008). There is no 
significant sequence identity between a-synuclein and the human mitochondrial 
cytochrome c. It appears that mitochondrial cytochrome c and a-synuclein are related to 
the cytochrome c from the Thiomicrospira crunogena which does not have 
mitochondria.
Role of the conserved KTKEGV sequence
The function o f the repeat KTK(E/Q)GV sequences in the synuclein proteins is 
not clear. However, mutation o f the least conserved sixth AVVTGV and the seventh 
KTVEGA repeat sequences o f the human a-synuclein (Figure 40) to the conserved 
KTKEGV m otif showed a decrease in the tendency of the protein to form fibrils (Sode
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et al.. 2007). According to these researchers, the conserved KTKEGV sequences seem to 
maintain the unfolded native state o f  the synuclein proteins and also make them soluble 
in aqueous solution. The mutation A30P is in the second repeat m otif while E46K,
H50Q and the G51D mutations are in the fourth. The A53T mutation is between the 
fourth and fifth repeat sequences (Figure 65). The presence o f the mutations in these 
regions, have been shown to enhance the fibrillation o f a-synuclein (Narkiewicz et al.. 
2014).
The fact that the region containing the repeat sequences is conserved, implies 
that this domain in both the synucleins and their four relatives has a critical role in the 
function of the proteins. My hypothesis is that the synucleins in the vertebrates were 
once functional domains o f  larger ancient proteins. Over time, this N-terminal functional 
region (in higher organisms) became stable enough to exist in the cells independent o f  
the precursor proteins. Because the synucleins have only been identified in vertebrates 
so far, they may not be ancient proteins. In addition, it appears that the main function o f 
the N-terminus o f the synucleins is to provide a binding surface to facilitate protein- 
protein and protein-membrane interactions.
Curiously, the N-terminus o f p-synuclein from mole rat (residues 20-76) contains 
several cysteine residues which normally form stabilizing disulfide bonds in globular 
proteins, but may not happen in this protein (Figure 42). Also, this P-synuclein contains 
in its N-terminus the KTKEGV motifs that maintain it in a unstructured confirmation.
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Figure 65. A schematic indicating locations of point mutations in a-synuclein
The underlined residues are the degenerate eleven amino acid repeat sequences. The 
green color are: A (alanine). E (glutamate). H (histidine) and G (glycine) which can 
undergo point mutations to A30P. E46K. H50Q, G51D and A53T. These point 
mutations are in the second, fourth and between fourth and fifth repeat sequences.
Sites of protein modification
The scan prosite and scan m otif algorithms further confirmed the evolutionary 
relationship between the synucleins and the four disparate proteins by identifying 
functional sites at conserved locations. The algorithms identified sites for 
phosphorylation and N-terminal myristoylation. The N-terminal glycine (G) residues to 
which the myristic fatty acid (CH3(CH2)i2COOH) is added by the enzyme N- 
myristoyltransferase are in conserved locations (Figure 53). The addition o f  a myristic 
acid moiety to the N-terminal glycines o f  a protein increases the hydrophobicity o f  the 
protein. In the case o f synuclein proteins that associate with cell membranes, 
myristoylation would enable them to efficiently bind to cell membranes (W right et al.. 
2010).
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Similarly, the site for phosphorylation by the enzymes casein kinase II and 
tyrosine kinase were identified. Phosphorylation o f a protein occurs when a phosphate 
group (PO33’) is covalently bound to a tyrosine, threonine or serine via an ester bond. 
Phosphory lation is a mechanism by which the function o f  a protein is regulated as it 
moves between the phosphorylated form and the unphosphorylated form (Pearlman et 
al.. 2011). One of the forms is active while the other inactivate. Our results indicate that 
the casein kinase II phosphorylates at the threonine or serine residues in conserved 
locations while phosphorylation by tyrosine kinase is at conserved tyrosine (Y) residues 
(Figure 53). In a-synuclein, depending on the location o f  the serine or threonine residue 
phosphorylated, the modification can either inhibit aggregation or enhance it. For 
example, phosphorylation at serine 129 enhances a-synuclein fibrillation (Lou et al., 
2010; Sato et al., 2011) while phosphorylation at serine 87 and 125 inhibits fibrillation 
(Paleologou et al., 2010; Oueslati et al., 2012).
The synuclein phylogenetic tree
The phylogenetic tree suggests that the proteins cytochrome c and y-synuclein 
are the furthest from the ancestor and p-synuclein is the most ancient (Figure 56). The 
marsupial protein is closer to the y-synuclein and both appear to be more distant from 
the ancestor than the a- and p-synucleins. The protein CRE-DUR-1 is the closest to the 
ancestor. A recent publication reports that y-synuclein could be the ancestor o f  the a- 
and p-synucleins (Yuan and Zhao, 2013). Other phylogenetic algorithms need to be 
employed in order to achieve conclusive results. Interestingly, our results suggest the 
order o f evolution is, P-, a- and y-synuclein. Based on the number o f  exons. P-synuclein
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has seven, a-synuclein has six and y-synuclein has five. Thus gene duplication and 
deletion may have led to the formation o f  the a- and y-synucleins.
Analysis of human and other animal synucleins
When human beings advance in age. they may succumb to various 
neurodegenerative diseases including Parkinson's. The focus of the analysis was on the 
point mutations A30P. E46K. H50Q. G51D and A53T which cause early-onset 
Parkinson's disease in humans (Narkiewicz et al.. 2014). In the sequence alignment o f  
primates, the a-synuclein proteins are the same except for the woolly and spider 
monkeys that have threonine (T) instead o f  alanine at position 53 and a few substitutions 
at some other locations (Figure 59). The alanine (A) in position 30 and the glutamate (E) 
in position 46 are conserved. Among the mutations, A53T has the highest propensity to 
cause aggregation. Investigators observed that the presence o f threonine (T) at location 
53 favors the formation o f a |3-sheet structure which may result in fibrillation (Choubey 
et al., 2 0 1 1 ).
Domestic and wild animal a-synucleins have a threonine residue (T) at location 
53 instead o f alanine (A) (Figure 61). The two amyloidogenic sequences 36-41 and 6 8 - 
78 are intact except for a few glutamate (E) substitutions for glycine (G) at position 6 8  
in some animals (Figure 61). The birds, zebra finch, canary, duck and turkey differ 
significantly from humans at a stretch between residues 113 and 120 (Figure. 61). The 
a-synucleins o f the long-lived animals have a threonine (T) at location 53 and 
truncations at both the N- and the C-termini, resulting in short a-synucleins (124-125 
residues) (Figure 62). The two amyloidogenic sequences (the purple regions), and the
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A30. E46. H50 and G 51 residues are unchanged except for a few substitutions at 
position 6 8  (Figure 62).
The p-synucleins o f wild and domestic animals have the conserved alanine (A) at 
position 30 (Figure 63). Some animals have alanine (A) at location 53, while others have 
threonine (T) or glycine (G). At location 46 some animals have the conserved glutamate 
(Q) while others have aspartate (D) or serine (S). The salmon, zebra and rainbow smelt 
fish have some substitutions in the 36-41 amyloidogenic sequence. The substitutions 
may reduce the tendency o f the region to aggregate. Both humans and animals have 
extensive substitutions in the 68-78 amyloidogenic sequence compared to a-synuclein 
(Figure 63). However, some substitutions, for example, phenylalanine (F) and isoleucine 
(I) do not diminish the hydrophobicity o f  the region (Figure 63). Interestingly, P- 
synucleins have a glutamine residue (Q) at location 50 instead of a histidine (H) (Figure 
63). A group o f researchers discovered two mutations in P-synuclein that may be 
associated with Dementia with Lewy bodies. (Ohtake et al., 2004; Fujita et al., 2010). 
The mutations are valine 70 to methionine (V70M) and proline 123 to histidine 
(P123H). These two mutations make the P-synuclein protein more susceptible to 
fibrillation and also render the synuclein incapable o f preventing a-synuclein fibrillation 
(Fujita et al., 2010). The mutations in P-synuclein are hypothesized to predispose an 
individual to Dementia with Lewy bodies (Ohtake et al., 2004). In transgenic mice, the 
P123H P-synuclein induced a neurodegeneration whose symptoms were axonal swelling 
and memory disorder (Fujita et al.. 2010).
y-Synucleins in both humans and animals have a threonine (T) in location 53 
instead o f an alanine (A) (Fig. 64). In addition, the proteins have a glutamine (Q) instead
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o f a histidine (H ) in location 50 and a serine (S) instead o f a glycine (G) in location 51. 
The leucine (L) residue in the 36-41 amyloidogenic sequence is replaced by either 
isoleucine (1) or methionine (M) residue. The 68-78 sequence is extensively substituted 
by polar residues including asparagine (N). serine (S) and threonine (T) thereby 
reducing protein 's hydrophobicity and propensity to aggregate (Figure 63). The 
disrupted amyloidogenic sequences may explain why y-synuclein proteins do not readily 
aggregate and form fibrils despite the threonine at location 53.
The presence o f a threonine (T) in non-primates seems to suggest that originally 
the synucleins had the threonine residue in that position. Our computational results 
appear to suggest that among the three proteins, P-synuclein is the oldest and evolved to 
contain amino acid sequences to prevent fibril formation, such as the change from 
threonine at location 53 to alanine. a-Synuclein also does not have a threonine at 
position 53. However, interestingly, y-synuclein does have a threonine, but this protein 
is not prone to fibril formation.
O f the three human synucleins, a-synuclein is the largest, leading to an increase 
in the number o f charged residues including glutamate (E) and aspartate (D) in its C- 
terminus. The VI repeat sequence in a-synuclein is prone to aggregation (Figure 62) 
(Kumar et al., 2009). Perhaps its C-terminus has an increased number o f  charged amino 
acid residues in order to counteract the propensity o f the amyloidogenic VI sequence to 
aggregate when the protein is in the cytoplasm. This sequence was most likely 
maintained because a-synuclein needs the VI (5SGAVVTGVTAVA78) repeat region for 
associating with lipid membranes and perhaps to facilitate the assembly o f  multimeric 
forms of the protein.
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Taken altogether, the synuclein proteins appear to have no bona fide superfamilv 
relatives in animals, but share significant sequence similarity with endoglucanase. CRE- 
DUR-1. cytochrome c and the Tasmanian Devil proteins. Each one o f the related 
proteins contains KTK(E/Q)GV repeats which are a unique characteristic o f  the N- 
termini o f the synucleins. The identical sites o f protein modifications in both the 
synuclein and the disparate proteins further suggest an evolutionary relationship between 
the synucleins and the disparate proteins. The analysis o f  the synucleins indicated that 
almost all primates avoided the A30P, E46K, H50Q, G51D and A53T substitutions. 
Elowever. all other animal a-synucleins have the A53T substitution. (3-synucleins have 
the H50Q substitution. Almost all y-synucleins have the H50Q/T, G51S and A53T/N 
substitutions. In conclusion, we also speculate based on conversations with other 
scientists (Ellis and Jessica Bell) that the N-and C-termini o f  the synucleins actually 




CONCLUSIONS AND FUTURE WORK 
CONCLUSIONS
This research project presents original results and theories based on the 
experimental and computational analysis of the synuclein proteins. In our laboratory we 
were able to express and purify a-and p-synuclein and also establish conditions which 
induce them to form fibrils in vitro.
In Chapter III, in collaboration with engineers, we were able to show for the first 
time that low temperature plasma bullets or plume emitted by a plasma pencil can break 
protein fibrils into small fragments which we propose will facilitate their elimination, a- 
Synuclein was used as the protein model. Fragmentation o f the synuclein fibrils began to 
show up at two minutes and the maximum time to achieve extensive breakage was six 
minutes. Other methods including ultrasonication, laser beam irradiation and mechanical 
shaking have been employed to break protein fibrils. However, unlike these methods 
which rely on physical mechanisms, our method is based on the reactive species o f  the 
low temperature plasma. We expect that under plasm a exposure the fibrils undergo 
chemical reactions that compromise their structural as well as chemical integrity.
In Chapter IV, we conducted synuclein inhibition studies in which a 1:2 and 1:4 
ratio o f a-synuclein to (3-synuclein were employed. Under the experimental conditions 
o f the study, our results indicated that some form(s) o f a-synuclein can inhibit fibril 
formation of P-synuclein which is quite surprising. Furthermore, our studies indicated
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that p-svnuclein fibrils can form reasonably rapidly under the same conditions as a- 
synuclein in vitro. Most importantly the results suggested that when two proteins 
capable o f  forming fibrils are incubated together under the same conditions, an 
inhibitory effect can occur. To the best o f  our know ledge, this is the first study o f  a co­
incubation o f two fibril forming proteins under fibrillation promoting conditions.
Because investigators in the past did not conduct a study similar to ours, they did not 
observe this phenomenon. Two different fibril forming proteins in vivo could perhaps 
cancel each other out. although in nature each fibril associated protein occupies distinct 
niches within or outside various tissues in the body. These findings may provide new' 
lines of investigation regarding the design o f inhibitors, as well as facilitate our general 
understanding of the mechanism of fibril formation.
In Chapter V, we isolated a high MW form o f the human p-synuclein protein, 
which is an important step in addressing the controversy over the true native, 
physiological state o f  the synucleins. A computer program K2D3 estimated from the far- 
UV circular dichroism spectra that the p-synuclein complex was 6 8 %  a-helical, 6.7% P- 
sheet and 25.2% random coil. This prediction suggests that our P-synuclein complex is 
predominantly helical in structure as we would predict.
In Chapter VI. a PSI-BLAST search tool retrieved from the database four 
disparate protein sequences that we propose are related to the synucleins: endoglucanase 
enzyme from bacterium Acetobacter pomorum. a CRE-DUR-1 protein from a nematode, 
a putative protein from the Tasmanian Devil and cytochrome c from the bacterium 
Thiomicrospira crunogena, all o f  which had significant sequence similarity to the 
synucleins. Each one o f the retrieved sequences contained KTK(E/Q)GV repeats which
are a unique characteristic of the N-terminal regions o f the synucleins. Surprisingly the 
synucleins seem to be orphan proteins in the vertebrate line. Two other bioinformatics 
search engines, the scan prosite and scan motif, identified sites of myristoylation and 
phosphorylation in the synucleins. These sites are similar to those found for related 
proteins as well. The myristoylation is expected to occur at specific glycine residues in 
the N-terminal regions of the synucleins. Phosphorylation was at specific tyrosine, 
threonine and serine residues which are also in the N-terminal region. An alignment o f 
the synucleins with their related proteins indicated that the glycines and serine/threonine 
residues involved in the protein modification were in conserved locations. The 
conserved sites o f  protein modification further suggest an evolutionary relationship 
between the synucleins and the four disparate proteins.
A phylogenetic tree generated from the three human synucleins and the four 
proteins indicated that the CRE-DUR-1 protein is more closely related to the synucleins 
than the endoglucanase and cytochrome c. The Tasmanian Devil protein shares the same 
ancestor with y-synuclein. The link between the CRE-DUR-1 protein and the ancestor 
protein is the shortest while the longest link is for cytochrome c and y-synuclein. 
According to these links, a - and P-synuclein. which have six and seven exons 
respectively, appear to be evolutionarily older than the y-synuclein, which has five 
exons.
We identified the exons o f the synucleins that contain the degenerate repeat 
sequences. In a-synuclein. the first three degenerate repeats are in exon two, the fourth is 
in exon three, the fifth, sixth and seventh are in exon four. The first three degenerate 
repeats in P-synuclein are in exon three, the fourth is in exon four, the fifth and the small
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segments o f the sixth and seventh repeats are in exon five. In y-synuclein. the first three 
repeats are in exon one. the fourth is in exon two. the fifth, sixth and seventh are in exon 
three. Taken altogether it means that exon two o f  a-synuclein is similar to exon three o f 
P-synuclein and exon one of y-synuclein. Exon three o f  a-synuclein is similar to exons 
four and two of p- and y-synuclein respectively. Similarly, exon four o f a-synuclein is 
similar to exons five and three of P- and y-synuclein respectively.
When a-synucleins o f primates were aligned, we observed that the protein 
sequences are the same except for the woolly and spider monkey, which have a 
threonine residue at location 53 instead o f alanine. The a-synucleins o f  domestic and 
other wild animals, have a threonine residue at location 53. In addition, long-lived 
animals have truncations at both the N - and the C-terminus resulting in a-synucleins 
ranging between 124 and 125 residues. In addition, the alanine at location 30, glutamate 
at location 46, histidine at location 50 and glycine at location 51 are conserved. P- 
synucleins o f some animals have the conserved alanine at location 53, while others have 
a threonine, aspartate or glycine residue. Both human and animal P-synucleins have 
extensive substitutions in the 68GAVVTGVTAVA78 amyloidogenic sequence. The 
alanine at location 30, and the glycine at location 51 are conserved. P-synucleins o f  
some animals have an aspartate or serine residue instead o f  the glutamate at location 46. 
In addition, p-synucleins o f  some animals have a glutamine residue at location 50 
instead o f a histidine, while others have neither a histidine nor a glutamine. Interestingly, 
y-synucleins in both humans and animals carry the A53T mutation. The 68-78 sequence 
is heavily disrupted by substitutions. In humans, the a-synuclein A53T mutation is 
associated with early-onset Parkinson's disease (Wan and Chung. 2012: Oaks et al.,
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2013). y-synucleins. the alanine in location 30 and the glutamate in location 46 are 
conserved, while at location 50. a histidine is substituted w ith a glutamine and at 
location 51. a glycine is substituted with a serine. Seemingly, human y-synucleins carry 
the H50Q and the A53T 'm utations' which have not been reported to be associated with 
Parkinson's disease. These sequences appear to suggest that primates are longer lived 
without the mutations but as these mutations are present in most animals they may be 
functionally less advantageous to primates.
FUTURE WORK 
Application of low temperature plasma on protein fibrils
Although we were successful in breaking protein fibrils into smaller units, the 
nature o f  the damage needs further investigation. Tests need to be conducted to 
determine whether the glial cells can clear the fibril fragments via phagocytosis. It will 
also be o f interest to determine if  the broken fibrils can be eliminated by the ALP or 
UPS systems. Further investigations are additionally necessary to determine whether or 
not the broken fibrils will reassemble, seed the soluble protein molecules to enhance 
fibrillation, or become cytotoxic. Also, the cytotoxicity o f the plasma itself with regard 
to neurons and neuronal cells needs to be examined. The outcome o f such investigations 
will determine the viability o f employment o f cold plasma as a therapy against diseases 
associated with plaques.
Inhibitory effects of a-synuclein on P-synuclein fibrillation
The species and the mechanism by which a-synuclein inhibits P-synuclein 
fibrillation needs further investigation. In addition, the nature of the complex formed 
between a- and P-synuclein during the inhibition process needs to be determined. Future
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investigations may include finding another protein that forms fibrils under the same 
conditions as a-and P-synuclein and then incubate the protein with a-and P-synuclein in 
a 1:1 and 1:4 ratio to further test the hypothesis that two different fibril forming proteins 
will inhibit each other.
Isolation of a multimeric p* and y-synuclein
A repeat o f  the expression and isolation o f  the p-synuclein folded multimeric 
protein is necessary in order to determine its biophysical properties including its stability 
at different pH. concentrations and temperature ranges. A well calibrated gel-filtration 
column using commercially available gel-filtration protein standards will be necessary in 
order to obtain an accurate estimate o f the size o f  the multimeric form o f the P- 
synuclein. The resin should be changed from G-75 to G-100 and G-200. A G-100 or 200 
column can, for example, separate a 2000 kDa protein molecule from a 56 kDa one, 
while the G-75 elutes both molecules around the same fraction. Thus, the putative P- 
synuclein tetramer (56 kDa) and the putative glutamic dehydrogenase hexam er (333.6 
kDa) would elute to the same location when a G-75 column is used. Also, a monomeric 
protein standard with a true 56 kDa MW will be critical for estimating the size o f  the 
multimeric form o f the P-synuclein.
For protein expression, other cell lines can also be used such as Chinese Hamster 
ovary cells and Baculovirus insect cells which may provide a more conducive 
environment close to that o f a neuron, for forming and stabilizing the tetramer. 
Substances including glycerol and n-octyl-p-D-glucopyranoside may be used to stabilize 
the tetramer. A higher temperature (30°C) during anion exchange and gel-filtration 
purification process may increase the hydrophobic effect. Future work also includes the
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formation o f w ell-diffracting crystals o f the p-synuclein complex for X-ray 
crystallography studies to determine its 3D structure. In order to make a complete study 
o f the synucleins. it is necessary to express, isolate and characterize the folded 
multimeric form o f y-synuclein. It w ill also be necessary to see if  hetero-complexes can 
be formed between the synucleins.
Previous experiments have shown that a-and P-synuclein interact with 
polyunsaturated fatty acids in vitro (Israeli and Sharon, 2009). M olecular modelling 
techniques can be employed to investigate the regions by which, for example, a- 
synuclein binds its protein ligands. The polyunsaturated fatty acids including 
docosahexaenoic acid and arachidonic acid, which are abundant in neuronal membranes, 
can be used as model ligands for the synuclein (Rapoport, 2008; De Franceschi et al., 
2011). Besides being associated w ith amyloidogenesis, the other possible roles o f  the 
36GVLYVG4iand 68GAVVTGVTAVA78 regions need further investigation using 
molecular modelling techniques. These regions may play a role in bringing together 
monomers to form the natural multimeric forms o f  the synucleins, which may confer the 
normal physiological function.
Analysis of the genes of centenarians and supercentenarians
Analysis o f the genes o f  individuals who live to be 100 years and beyond w ill 
shed light on what keeps them healthy, while others may succumb to neurodegenerative 
diseases. From our studies, we have identified that exon two of human a-synuclein 
contains the repeat sequences w'here the mutations A30P, E46K, H50Q. G51D and A53T 
can occur. One could examine and compare exons tw o and three o f a supercentenarian (a 
person who lives over 110 years o f  age) w ith that o f an individual with Parkinson's
1 7 6
disease, since these mutations occur in those regions o f the y-synuclein gene. It will also 
be interesting to compare the sequences o f chaperones and protein clearance systems 
between patients with Parkinson's and supercentenarians as further examples.
1 7 7
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APPENDIX A
CALIBRATION OF G-75 SEPHADEX SIZE EXCLUSION COLUMN WITH 
PROTEIN STANDARDS BLUE DEXTRAN, OVALBUMIN, ALBUMIN AND
RIBONUCLEASE
0.6
blue dextran 2000 kDa Chymotrx psmojKn 2 1.2 kDa
0.5
0 .4





0 10 20 30 40 5 0
Fraction number (mis)
Figure A. Calibration of the G-75 size exclusion column.
Absorbance o f the protein standards were determined by UV spectrophotometer at 280 
nm. Absorbance on the Y-axis was plotted against fractions on the X-axis. The volume 
o f each fraction is 5 mis. The void volume o f our column is 105. The blue dextran elutes 
at fraction 2 1 .The shoulder molecules (red circles) are dim er species o f  the albumin 
(61.7 kDa) and ovalbumin (48.5 kDa).The dimers species under conditions o f  our 
column elute in the void volume. The G-75 column cannot separate the blue dextran 
from albumin since they elute to the same fraction 2 0 .
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APPENDIX B
SITES FOR PROTEIN MODIFICATION IN THE SYNUCLEINS
Protein M yristoylation C asein  k inase  
p h osp h ory la tion
T yrosine k in ase  
phosph orylation









CRE-DUR-i 176-181 GCa\ SO 39-42 TgaE 410-417 KeaaEaaY
401-406 GAaeGY 58-61 TqtD
412-417 GAeaAY 68-71 SaeE
423-428 GActAV 334-337 TsIE
466-471 GGaeAA 426-429 TavE
452-455 SmhD
459-462 SagD
Marsupial 14-19 GVveAV 54-57 SvaE 32-39 K tkEevm Y
24-5-30 GVteAA 81-84 TveE
261-266 GlmsGA 148-151 SprF
220-223 Spre
Cvtochrome c 21-26 GAIIAA 45-48 StsE














6-Svnuclein 7-12 Gl.sm A K 54-57 SvaE 32-39 KtkEavlY





y-Svnuclein 14-19 GVvaAV 54-57 SvaE 32-39 KtkEgvmY
25-30 GVteAA 81-84 TveE
124-127 SggD
Table 1. Protein Modification Sites.
Myristic acid is added to specific conserved glycines in both synucleins and the 
disparate proteins. Phosphate groups are also added to specific conserved threonine, 
serine, or tyrosine residues to both the synucleins and the disparate proteins.
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